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Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor 
that plays an important role in atherosclerosis development. The binding and 
internalisation of oxidized low-density lipoprotein (Ox-LDL) via LOX-1 induces 
endothelial dysfunction, leukocyte recruitment, foam cell formation, and thus 
atherosclerotic plaque development. Therefore, inhibiting the LOX-1/Ox-LDL interaction 
would be an attractive way to prevent and fight against this cardiovascular disease. 
However, the recognition mode of LOX-1 to Ox-LDL is still unclear. A trisaccharide was 
previously shown to inhibit LOX-1 binding to Ox-LDL in cells and mice. This thesis 
presents an improved synthetic strategy towards an analogue of the lead trisaccharide, 
and an approach to increase its binding affinity by attaching the trisaccharide units to a 
polymer scaffold to make multivalent carbohydrate structures. The -selectivity of 
glycosylation reactions was significantly improved by the use of a thiophenyl glycoside 
having a 4-methoxybenzoyl group at the O-4 position, potentially due to the remote 
protecting group participation. Moreover, -manno- and -galacotopyranoside bearing 
a 4-methoxycarbonylphenyl group were prepared and converted to the corresponding 
hydrazide for use in glycopolymer dynamic combinatorial libraries. Using the same 
strategy, the trisaccharide epitopes were successfully attached to a polymer scaffold.  
Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-intergrin (DC-
SIGN) is a C-type lectin receptor that is implicated in several viral infections, e.g., HIV 
and Ebola viruses. This lectin and its related receptor DC-SIGNR bind to high-mannose 
glycan structures. However, these two receptors still have distinct functions and 
specificities for different glycans. More structural and functional data of DC-SIGN and 
DC-SIGNR still awaits investigations. This thesis outlines successful synthetic routes to 
azide-appended mannose epitopes in form of mono- and disaccharides and a newly 
established and efficient method to prepare dense and compact mannose-capped 
quantum dots (i.e., mono-Man-QDs and di-Man-QDs) to be used as multivalent probes 
for carbohydrate-binding proteins, e.g., DC-SIGN and DC-SIGNR via FRET (Förster 
resonance energy transfer) technique. The interactions between the synthetic Man-
QDs with DC-SIGN and DC-SIGNR were for the first time investigated by FRET. The 
results showed that the mannose-capped QDs exhibited higher binding affinities to DC-
SIGN than its related receptor DC-SIGNR. This finding was confirmed by viral inhibition 
assays, indicating that the tested mono-Man QDs specifically inhibited DC-SIGN- but 
not DC-SIGNR-mediated pseudo-Ebola viral entry of target cells.  
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1.1 Cell surface carbohydrate-protein interactions 
Mammalian cell surfaces are covered with a glycan-rich layer, referred to as glycocalyx 
(Figure 1-1), which comprises glycans of glycoproteins or glycolipids.1 Cell surface 
glycans form complex and highly branched structures, as their monosaccharide units 
can form glycosidic linkages via hydroxyl groups at different positions on the sugar ring. 
The broad range of structures can also arise from different types of glycosidic linkages 




 An electron microscopic image of glycocalyx on the surface of a 
coronary artery, figure reproduced from reference 1.  
The sugar-based information on cells can be decoded by carbohydrate binding proteins, 
e.g., lectins, which recognise specific carbohydrate structures. These protein-
carbohydrate interactions play crucial roles in many important biological process, e.g., 
fertilisation,2,3 inflammation,4 signal transduction.5 On the other hand, carbohydrate 
recognition in biological system is also associated with various pathologic conditions 
and diseases, e.g., inflammation-associated cancer,6 cancer metastasis,7,8 viral and 
bacterial infections.9 Several pathogenic bacteria and viruses exploit specific glycan 
structures to adhere to and infect host cells (Figure 1-2). For instance, Staphylococcus 
aureus specifically bind to sialyl-Lewisx structures, influenza virus recognises sialic acid 
residues of glycoproteins and bacterial toxins from Vibrio cholera bind selectively to 







 Cell surfaces are decorated with different carbohydrate structures, 
which were exploited by several pathogens for the cell entry, figure reproduced 
from reference 9. 
Generally, interactions between proteins and carbohydrates can occur through different 
types of interactions, e.g., hydrogen bonds (H-bonds), hydrophobic stacking, 
electrostatic interactions and interactions with water and calcium ions.12 Hydroxyl 
groups on carbohydrates can facilitate the formation of H-bonds with polar moieties of 
proteins that are considered the most important interaction of protein with 
carbohydrates. Also, water-mediated interactions play an important role in protein-
carbohydrate complexation. Water molecules often facilitate the interactions between 
sugar hydroxyl groups and amino acid residues in the protein binding site. One 
example of protein-carbohydrate complex that exemplifies the hydrogen bond network 
is the trimannose binding site of Concanavalin A (Con A) in complex with trisaccharide 






 A schematic representation of the hydrogen bond network 
established between the extended binding site of Con A and the bound 
mannotriose Man--1,3-(Man--1,6)-Man (in red). Hydrogen bonds are 
represented as black dotted lines, reproduced from reference 13, model based on 
X-ray crystal structure. 
Hydrophobic stacking can also take part in protein-carbohydrate interactions. Although 
carbohydrates are hydrophilic molecules, they also possess hydrophobic faces (and 
 faces) of the sugar ring, exhibiting C–H patches. The hydrophobic faces of the 
carbohydrates can interact with electron-rich aromatic side chains of proteins (e.g., 
tryptophan, phenylalanine, tyrosine), contributing to hydrophobic CH− interactions 




 Hydrophobic stacking between maltose (in red) and tryptophan and 
tyrosine residues on maltodextrin-binding protein, redrawn from reference 14, 
model based on X-ray crystal structure.  
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Other groups present on the sugar scaffold, e.g., the methyl moiety of acetamido 
groups, can be involved in non-polar contacts with the interacting partners.16 Moreover, 
aromatic aglycones (i.e., non-sugar moieties) introduced to carbohydrates have been 
reported to exhibit a higher affinity than glycosides without such hydrophobic 
substituent as a result of additional hydrophobic effects and/or - interactions.17 Some 
sugars or modified sugars (e.g., sialic acids, glucosamines, phosphorylated and 
sulfated sugars) are positively or negatively charged, and can interact with charged 
residues on lectins through ionic electrostatic interactions.18 
Calcium ions (Ca2+) are essential for the formation of lectin-carbohydrate complexes, 
either by direct co-ordination with the carbohydrate itself or maintaining the geometry of 
the binding site. Such an interaction is found in lectins belonging to the C-type family, 
which are Ca2+-dependent upon binding to their carbohydrate ligands. For example, the 
carbohydrate recognition domain of E-selectin coordinates with a calcium ion and 
partakes in multiple H-bonds with the amino acid residues (Figure 1-5).19 Dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), a C-type 
lectin, also requires calcium ions for carbohydrate binding. The structure of this type of 




 The binding site of E-selectin in complex with sLe
x
 (Nue5Ac2-
3Gal1-4(Fuc1-3)GlcNAc-O(CH2)8COOMe, in red), showing the amino acid 
residues involved in coordinating the calcium ion and binding the trisaccharide, 
reproduced from reference 20, model based on X-ray crystal structure. 
1.1 Multivalency 
Individual protein-carbohydrate interactions are typically weak with typical dissociation 
constant in the mM range. The binding is enthalpy-driven and via the contribution of 
multiple hydrogen bonding and hydrophobic interactions. Water-mediated interactions 
can influence the binding thermodynamics comprising the entropic gain of displacing 
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highly ordered water molecules and the enthalpy decrease of breaking water-protein H-
bonds. However, this process is counteracted by unfavorable entropy which may result 
from reduced flexibility of carbohydrates.21  
Nature has therefore means to enhance the binding affinity involving multivalency, i.e., 
the use of multiple copies of binding epitopes to promote clustering events.22 
Advantages of multivalent binding are not only for having a greater contact between the 
surfaces but also magnifying the overall binding affinity. The multivalent effect was 
originally observed by Lee and Lee and termed the “glycoside cluster effect”, wherein 
the relatively small di- and trivalent cluster glycosides provided almost an exponential 
enhancement of the binding potency to the corresponding lectin.23  
According to Bertozzi and Kiessling,24 this enhanced binding could occur through 
several possible mechanisms (Figure 1-6), including:  
a) Chelate effect (chelation) involves the simultaneous binding of a multivalent 
ligand to a multivalent receptor. An increase in binding affinity can occur when 
the carbohydrate ligand spacing matches the inter-binding-site distances.  
b) Receptor clustering induced by the multivalent ligands enhances the binding 
affinity by increasing proximity of the receptors.  
c) Subsite binding describes the occupation of the carbohydrate ligand to the 
primary site and the secondary site of the same receptor. 
d) Statistical effects result from the increased probability of rebinding by a high 
local concentration of carbohydrate epitopes. 
e) Steric stabilisation can be explained by steric hindrance of a bulky ligand that 





Figure 1-6. Possible modes of multivalent ligand binding for an increase in the 
binding affinity: a) chelate effect; b) receptor cluster; c) subsite binding; d) 
statistical effects; e) steric stabilisation.  
Multivalency is involved in many biological processes, such as cellular adhesion, viral 
entry, and host-pathogen interactions. Some bacterial toxins bind and gain entry to 
cells by the use of multivalent interactions. A typical example is Shiga toxin, which is 
produced by Shigella dysenteriae. Infection of this toxin can cause diarrhea, 
hemorrhagic colitis or hemolytic uremic syndrome. Shiga toxin comprises two subunits; 
a toxic A subunit and a pentameric B subunit which delivers the A subunit into the host 
cell. The recognition of globotriaosylceramide (Gb3) glycolipids on the host cell surface 
by the B subunit permits the internalisation of the A-subunit by receptor-mediated 
endocytosis.25 Each of the individual B subunits contains three binding sites. The 
organization of the B subunits in a pentameric form provides a total of 15 carbohydrate 
binding sites, which allows multivalent interactions with the Gb3 and thus increases the 
binding avidity.26  
Also, several lectin receptors, e.g., DC-SIGN, occur as a tetramer and form clusters on 




1.2 Glycomimetics and multivalent glycoconjugates 
The involvement of carbohydrate-protein interactions, as well as their multivalency, in 
numerous biological and pathological processes, directed research into the rational 
design and synthesis of glycomimetics and multivalent glycoconjugates to understand 
and mediate such interactions. Many different glycomimetics (molecules that mimic the 
key bioactive structural motifs of carbohydrates) have been developed as probes or 
inhibitors, which may be beneficial for treating diseases, e.g., inflammatory diseases, 
viral and bacterial infections. Furthermore, the attachment of glycomimetics onto 
multivalent scaffolds, forming multivalent glycoconjugates, could augment their affinity 
to target proteins. Various multivalent scaffolds have been developed to present 
multiple copies of carbohydrate ligands. Examples of the multivalent scaffolds include 
peptides, lipids, polymers, nanoparticles, clyclodrextrins, calixarenes, fullerenes, 
dendrimers, liposomes, viruses (Figure 1-7).29  
 
Figure 1-7. Selected multivalent carbohydrate structures using different scaffolds. 
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In the following, selected carbohydrate-based therapeutics for lectin targeting (e.g., 
selectins and DC-SIGN) will be discussed. 
Selectins, a family of three adhesion molecules (i.e., E-selectin, L-selectin and P-
selectin), mediate the initial steps of the inflammatory response, i.e., the tethering and 
rolling of leukocytes on endothelial cells. These adhesion molecules contribute to vaso-
occlusive crisis (VOC) of sickle cell disease patients.30 VOC is caused by the 
obstruction of capillaries by sickle-shaped erythrocytes, leukocytes and platelets 
leading to reduced blood flow, ischemia, and tissue damage. These adhesion 
processes were mediated by adhesive molecules, i.e., selectins. Inhibiting these 
selectins would therefore be beneficial for preventing or reversing VOC. For instance, 
rivipansel (also called GMI-1070; compound 1, Figure 1-8) have been shown to be a 
potent pan-selectin antagonist and could reverse vaso-occlusion in mice.31 This 
compound is currently in Phase III clinical trial for sickle cell disease. This antagonist 
was rationally designed to mimic the biologically active conformation of the sialyl-
Lewisx (sLex, compound 2) carbohydrate core in the binding domain of E-selectin. NMR 
methods had shown close contacts of the asterisked atoms (Figure 1-8) with the 
protein.32,33 Another important feature incorporated in the structure was an extended 
sulfated domain, which was required for binding to L- and P-selectins.31  
 




) mimic GMI-1070 (1) and 






Several glycomimetics and multivalent ligands have been developed to target DC-
SIGN, which is a C-type lectin involved in the recognition of viruses, such as human 
immunodeficiency virus type 1 (HIV-1) and Ebola virus.34 An approach to design high 
affinity ligands for DC-SIGN is to mimic the two or three determinant mannose residues 
of the oligomannoside (Man)9(GlcNAc)2 natural ligand (3, Figure 1-9).
35 A linear 
trimannose analogue (4) exhibited anti-HIV activity in a cell-based assay.36 The 
presentation of this linear trimannoside mimic in a tetravalent glycoclusters (5) also 
enhanced the binding properties and provided more efficient inhibition of HIV trans-
infection of T-cells both in cellular and human cervical explant models.36,37 The same 
trimannoside glycomimetic was conjugated to BoltornTM dendrimer to form a 
glycodendrimer (6) containing multiple copies of the synthetic epitopes. The pseudo-
mannosylated glycodendrimers effectively inhibited DC-SIGN-mediated Ebola or HIV 
viral infections.38,39  
Furthermore, as Man-1,2-Man disaccharide was the minimal carbohydrate epitope for 
DC-SIGN recognition, the Man-1,2-Man mimic (7, Figure 1-10) containing a 
cyclohexane-based aglycone showed anti-Ebola viral activity in vitro.40 Further DC-
SIGN inhibitors development by Varga et al. led to the bis-benzylamide (8), which binds 
DC-SIGN with an improved selectivity.41 They also demonstrated that a hexavalent bis-
benzamide pseudo-disaccharide dendrimer (9) could inhibit HIV transinfection of T-
cells, as well as DC-SIGN mediated uptake of Dengue virus.42 Recently, Ordanini et al. 
showed that trimers of the same bis-benzamide pseudo-disaccharide linked by a rod-
like spacer (10) even more potentially block HIV transinfection, possibly because of 





Figure 1-9. Structure of: Man9 (3); DC-SIGN inhibitors: a trimannoside analogue 4; 




Figure 1-10. DC-SIGN inhibitors: a disaccharide analogue 7 with a cyclohexane-
based aglycone; a disaccharide analogue 8 with a bis-benzylamide; a pseudo-
disaccharide dendrimer 9; a pseudo-disaccharide linked by a rod-like spacer 10. 
1.3 Cell surface receptors: lectins 
Cell surface receptors are responsible for binding of extracellular ligands and induction 
of signal transduction pathways. Among various types of cell surface receptors, lectins 
are of particular interest because of the ability to bind to specific carbohydrates, their 
important roles in cell-to-cell communication and their involvement in diseases. Lectins 
are classified according to the domain architecture and folding patterns of their 
carbohydrate recognition domains (CRDs) into different types, e.g., C-type, I-type, P-








 Examples of different types of lectins and their ligands.  























L-type (ERGIC-53, VIP36) ManxGlcNAc2 
Galectins galactosides 
Calnexin, calreticulin Glc1Man9GlcNAc2 
However, some types of lectins, e.g., L-type lectins, C-type lectins, calnexin, and 
calreticulin, share a similar Ca2+ dependent binding property. In other words, not only 
C-type lectins require Ca2+ for ligand binding. In this section, C-type lectins and C-type 
lectin like receptors will be briefly outlined. 
C-types lectins have the ability to recognise carbohydrate epitopes in a Ca2+ dependent 
manner through their carbohydrate recognition domains (CRDs). These lectins have a 
C-type lectin fold (Figure 1-11) which is characterised by two-stranded antiparallel -
sheets formed by a conserved series of amino acids connected by two -helices and a 
three-stranded antiparallel -sheet.45 The CRD has two highly conserved amino acids 
for disulfide bonds and up to four sites for calcium binding. Examples of these C-type 
lectins include asialoglycoprotein receptor, selectins, rat serum mannose-binding 






 Carbohydrate binding domain of DC-SIGN having a prototype C-
type lectin fold, figure reproduced from reference 45. 
Several proteins (e.g., natural killer (NK) cell receptors) have a C-type lectin fold but 
are not known to bind carbohydrates due to the lack of some or all amino acids 
responsible for Ca2+ and/or glycan interactions. They contain a C-type lectin-like 
domain (CTLD) which is homologous to the C-type lectin CRDs of C-type lectins by 
sharing the same fold.46  
In this thesis, two main families of receptor will be explored: one is lectin-like oxidized 
low density lipoprotein receptor 1 (LOX-1) which is implicated in atherosclerosis and 
the other is DC-SIGN which is involved in recognition of viruses via the immune system. 
LOX-1 functions with a CTLD as a scavenger receptor, while DC-SIGN is a C-type 
lectin that acts as a pattern recognition receptor (PRR). 
1.4 LOX-1 and its implication in atherosclerosis 
1.4.1 Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease, characterised by the accumulation 
of cholesterol-rich lipids within blood vessel walls. Various risk factors can provoke 
atherosclerosis including inflammation, smoking, dyslipidemia, hypertension, diabetes 
mellitus, and genetic factors.47 It has been hypothesised that early atherosclerotic 
lesions are caused by endothelial dysfunction which often results from oxidized low 




1.4.2 Prevention and treatment of atherosclerosis 
Life style improvements, such as smoking cessation, exercise, and low fat diet 
consumption, are important for the primary prevention of atherosclerosis. Low dose of 
aspirin has also been used in the secondary prevention of atherosclerosis in patients 
with type 2 diabetes mellitus.49 Aspirin can prevent blood clots and platelet aggregation 
by inhibiting cyclooxygenase (COX), which in turn blocks the formation of thromboxane 
A2, reducing platelet aggregation. Statins are one drug choice that can be used to 
reduce cholesterol levels and retard the progression of atherosclerotic plaques by 
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Statins  
inhibit the rate limiting step in cholesterol synthesis, lowering cholesterol in LDL 
particles.50 However, patients treated with statins still retained significant residual 
risk of cardiovascular disease and even receiving high dose medication, more than 20% 
of patients have the recurrent disease.51 Furthermore, atherosclerosis can be treated 
by surgical techniques such as balloon dilation, angioplasty with stenting, and bypass 
operation. Nonetheless, more effective prevention and treatment of atherosclerosis are 
still required. Exploring new biological targets either for reducing LDL or inhibiting the 
binding of OxLDL to receptors, i.e., LOX-1, would be one of the best strategies to fight 
against this multifactor cardiovascular disease.  
1.4.3 Roles of LOX-1 in atherosclerosis 
LOX-1 plays a critical role in the initiation and development of atherosclerosis, notably 
in endothelial dysfunction.52 Under normal conditions, the expression of LOX-1 is low.  
However, the upregulation of LOX-1 is induced by several processes, both in vivo and 
in vitro, which are related to atherosclerosis including hypertension, diabetes mellitus 
and dyslipidemia.53 Several studies showed the augmented expression of LOX-1  
around the atherosclerotic lesion in hypercholesterolemic rabbits54 and in human 
carotid arteries.55 Hayashida et al. reported that soluble LOX-1 (sLOX-1) in serum is 
increased in acute coronary syndrome.56 Moreover, it was found that the deletion of the 
LOX-1 gene can reduce the formation of atherosclerotic plaques in LDL-receptor 
deficient mice.57 These findings showed the link between LOX-1 and atherosclerosis 
progression. Thus, LOX-1 would be one of the attractive targets for cardiovascular 
disease therapy.  
LOX-1 is classified as a scavenger receptor which is a group of proteins that identify 
and remove unwanted entities (e.g., apoptotic cells, Ox-LDLs). The roles of LOX-1 
include binding, internalisation, formation of foam cells, and degradation of OxLDL.58 
LDL particles enter the intima layer of the artery wall and undergo oxidation to form 
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OxLDL (Figure 1-12). The binding of OxLDL to LOX-1 promotes the expression of 
adhesion molecules and leads to endothelial cell dysfunction and the recruitment of 
monocytes into the arterial blood cell wall. Monocytes are differentiated to 
macrophages and take up OxLDL via LOX-1, leading to the formation of foam cells and 
plaques, which are vulnerable to rupture and can lead to thrombosis and myocardial 
infarction.59,60 The recognition of OxLDL by LOX-1 also mediates pro-atherogenic 
cellular responses many of which can induce endothelial dysfunction including a 
reduction of nitric oxide (NO) release, increased production of reactive oxygen species 
(ROS), secretion of monocyte chemoattractant protein-1 (MCP-1), expression of matrix 





 The roles of LOX-1 in atherosclerosis. Low density lipoprotein (LDL) 
particles diffuse into the arterial intima, followed by the conversion of LDL to 
oxidized LDL. The recognition of OxLDL by LOX-1 induces several effects 
including lipid uptake and formation of foam cells and atherosclerotic plaques, 
figure reproduced from reference 59. 
High levels of soluble forms of membrane proteins secreting into the blood stream can 
reflect abnormally expressed proteins in the presence of some disease states. LOX-1 
also exists in a soluble form (sLOX-1) and may be used as a prognostic biomarker for 
acute coronary syndrome.56,62  
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1.4.4 Identification and structure of LOX-1  
LOX-1 was originally identified in 1997 by Sawamura et al. as a receptor for OxLDL in 
endothelial cells.52 Subsequently, this protein was also detected in macrophages,63 
platelets,64 smooth muscle cells, monocytes, and cardiac fibroblasts.65 LOX-1 is a type 
II membrane glycoprotein, which belongs to the C-type lectin-like protein superfamily. 
This receptor does not share structural homology with any others scavenger receptors 
but it is likely to resemble natural killer (NK) cell receptors, e.g., CD94 (KLRD1) and 
NKR-P1 (KLRB1) because they possess a C-type lectin-like domain (CTLD).52 LOX-1 
comprises 4 domains (Figure 1-13): a short cytoplasmic N-terminal domain, a single 
transmembrane domain (TMD), an extracellular connecting neck domain, and a C-
terminal C-type lectin like domain.59 Chen and colleagues have demonstrated that the 
CTLD is essential and conserved for ligand binding of LOX-1.66,67 
 
Figure 1-13. a) Schematic representation of human LOX-1 in a dimeric form. Each 
individual protein contains 4 different domains: a short cytoplasmic N-terminal 
domain, a single transmembrane domain, a neck domain, and a C-terminal C-type 
lectin-like domain (CTLD); b) LOX-1 in dimeric form upon the binding to ligands, 
e.g., Ox-LDL. 
The X-ray crystal structure of LOX-1 has revealed to be a heart-shaped homodimer 






 X-ray crystal structure of human LOX-1 ligand CTLD binding domain 
in: a) side view and b) top view. The central hydrophobic tunnel is outlined by 
dotted lines, figure reproduced from reference 68. 
On the top of the CTLD dimer of LOX-1, there is a linear arrangement of positively 
charged residues, spanning over the dimer surface, called basic spine which is 
responsible for the ligand binding.68,69 Studies also showed that the central hydrophobic 
tunnel extending through the entire LOX-1 molecule is essential for Ox-LDL recognition 
and binding.70 However, the components of Ox-LDL that are recognised by LOX-1 are 
still unknown. 
1.4.5 LOX-1 ligands  
Similar to other scavenger receptors, LOX-1 does not bind only to OxLDL, but also to 
various other ligands. A previous study reported that LOX-1 recognises other forms of 
modified lipoproteins such as hypochlorite-modified high density lipoprotein (HDL) in 
human umbilical venous endothelial cells (HUVECs).71 HDL can be modified by 
hypochlorous acid (HOCl) and hypochlorite (OCl-), which are oxidants produced by the 
myeloperoxidase-H2O2-chloride system of activated phagocytes, forming an 
atherogenic lipoprotein particle.   
Jono and co-workers have shown that advanced glycation end-products (AGEs), 
formed by the non-enzymatic reaction of sugars with free amino groups on proteins, 
exhibit binding activity to LOX-1 and serves as a ligand for LOX-1.72 
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Cellular ligands, e.g., aged/apoptotic cells, activated platelets, and bacteria can also be 
recognised by LOX-1. There is evidence that LOX-1 could bind to aged red blood cells 
and apoptotic cells in bovine aortic endothelial cells (BAE) and Chinese hamster ovary 
(CHO) cells expressing bovine LOX-1. Due to the fact that these interactions can be 
inhibited by phosphatidylserine (PS) liposomes, it was proposed that PS was the ligand 
recognised by LOX-1 on surface of the apoptotic cell.73,74 
In addition, activated platelets can also bind to LOX-1.64 The binding activities of 
aged/apoptotic cells and activated platelets support the role of LOX-1 in the process of 
phagocytosis and the induction of endothelial dysfunction. It has been reported that 
LOX-1 can serve as a receptor for Gram-positive and Gram-negative bacteria including 
Staphylococcus aureus and E. coli in both cultured vascular endothelial cells and 
Chinese hamster ovary-K1 (CHO-K1) cells stably expressing LOX-1.75  
C-reactive protein (CRP), an acute phase protein expressed by hepatocytes in 
response to inflammation and tissue damage, has been shown to be recognised by 
LOX-1 in cells expressing LOX-1.76 Another study also showed that LOX-1 binds to 
CPR and the ligand-receptor interaction promotes endothelial inflammation.77  
Heat shock proteins (HSPs) were originally discovered as molecular chaperones that 
interfere in inflammation and protect proteins from environmental stress. Recently, 
evidence has indicated that HSPs are ligands for LOX-1. The receptor could bind and 
internalise HSP60 and HSP70 in dendritic cells.78,79  
Moriwaki and colleagues have suggested that LOX-1 recognises the protein moiety of 
OxLDL and the lipid part of the ligand is unlikely to be important for the binding 
activity.80 However which part of the major ligand OxLDL binds to LOX-1 remains 
obscure as no conclusion can be drawn from the published cystal structure.  
To identify whether the carbohydrate or protein moieties of OxLDL is more important 
for being recognised by LOX-1, Dr. K. Lacey and Dr. S. Ponnambalam (School of 
Molecular and Cellular Biology, University of Leeds), our collaborators, digested OxLDL 
particles with either protein kinase K or N-glycosidase F (also known as PNGase F) 
and endoglycosidase H (Endo H).81 Their results revealed that only removal of the 
carbohydrate part showed significant reduction in binding to LOX-1 expressing cells 
(Figure 1-15). This observation thus raised a question: does a carbohydrate compound 
bind to LOX-1 and inhibit the Ox-LDL/LOX-1 interaction? As a consequence, a glycan 






 The percentage of LOX-1 transfected cells binding to labelled 
OxLDL which depends on interaction with protein moieties (A) or sugar moieties 
(B), figure reproduced from K. Lacey‟s Ph.D. thesis University of Leeds 2012, 
reference 81. LDL, Low-density lipoprotein; OxLDL, Oxidized low-density 
lipoprotein; PNGaseF, N-glycosidase F; Endo H, endoglycosidase H. 
1.4.6 LOX-1 inhibitors  
In general, there are two ways to inhibit the activity and function of LOX-1 that are 1) 
blocking LOX-1 from binding to OxLDL and 2) suppressing LOX-1 expression. 
Sawamura and co-workers identified procyanidins, polyphenolic compounds 
abundantly found in apples and red wine, as potent inhibitors for LOX-1.82 A total of 
472 food extract samples were tested to identify materials that had inhibitory effect for 
LOX-1 using an enzyme-linked immunosorbent assay (ELISA) and 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled OxLDL uptake assay. 
Their results indicated that procyanidins are potent inhibitors of LOX-1. Purified 
procyanidins in form of a dimer, a trimer, and a tetramer could also inhibit OxLDL 
uptake (Figure 1-16), whereas monomeric epicatechin (11, Figure 1-17) did not show 
an inhibitory effect. The chemical structures of the trimer procyanidin isomers (12 and 
13) used in their study are present in Figure 1-17. Moreover, the chronic administration 
of oligomeric procyanidins in stroke-prone spontaneously hypertensive rats (SHR-SP) 






 The result of different isomers of procyanidins in inhibiting OxLDL 
binding to LOX-1 expressing cells, figure reproduced from reference 82. 
 
 
Figure 1-17. Chemical structures of epicatechin 11 and the trimer procyanidin 
isomers used for the binding assay (12 and 13).  
There is also evidence showing that polyinosinic acid (i.e., a homopolymer of inosine 
which is a nucleotide that is composed of hypoxanthine and ribose) and carrageenans 
(i.e., a class of sulfated polysaccharides), significantly reduced OxLDL binding to LOX-
1 by 62% and 60%, respectively in Chinese hamster ovary K1 (CHO-K1) cells stably 
expressing LOX-1.80 These findings demonstrate that polyinosinic acid and 
carrageenan are chemical inhibitors of LOX-1.  
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On the other hand, some polyphenolic antioxidants and drugs have shown to exert 
inhibitory effects on LOX-1 expression. Lee and co-workers have reported that ellagic 
acid (14, Figure 1-18), present in numerous fruits and vegetables, inhibits OxLDL-
mediated LOX-1 expression, ROS production, and inflammation in human endothelial 
cells.83 Likewise, epigallocatechin-3-gallate (EGCG, 15), the most abundant antioxidant 
found in green tea, has been shown to inhibit OxLDL-induced LOX-1-mediated 
signaling pathway. This antioxidant compound is involved in the anti-atherosclerotic 
processes by inhibiting NADPH oxidase and consequent ROS-enhanced LOX-1 
expression (Figure 1-12).84 Moreover, mulberry (Morus Alba L., family Moraceae) leaf 
aqueous fractions have proved to reduce oxidative modification of LDL by inhibiting 
TNF-- induced-NF-B activation and LOX-1 expression in vascular endothelial cells.85 
 
Figure 1-18. Chemical structures of: ellagic acid (14) and EGCG (15).
 
Furthermore, several drugs with antioxidant effects, e.g., simvastatin (16, Figure 1-19) 
atorvastatin (17), aspirin (18), gliclazide (19) have been shown to inhibit OxLDL-
mediated LOX-1 expression in endothelial cells. It is known that OxLDL upregulates the 
expression of LOX-1 and endothelial nitric oxide synthase (eNOS) in human coronary 
artery endothelial cells (HCAECs).86,87 Pre-treatment of such cells with simvastatin or 
atorvastatin showed the reduction on OxLDL-induced up-regulation of LOX-1 and 
down-regulation of eNOS. These results suggest that besides acting as HMG-CoA 
inhibitors, statins have an additional advantage on LOX-1 activity.88 Moreover, the 
inhibitory effect of aspirin, an anti-platelet drug, on LOX-1 expression has been studied 
in HCAECs. The results indicate that aspirin suppressed OxLDL-mediated LOX-1 
expression.89 Another example of a drug with antioxidant effect against LOX-1 is an 
oral anti-diabetic drug, gliclazide.90 The incubation of human aortic endothelial cells 
(HAECs) with OxLDL showed an increase in LOX-1 expression, and induced apoptosis. 




Figure 1-19. Chemical structures of: simvastatin (16), atorvastatin (17), aspirin (18), 
and gliclazide (19). 
Biocca and colleagues reported that lovastatin disrupted LOX-1 receptor cluster 
distribution in plasma membranes, disturbing LOX-1 function.91 They further 
demonstrated that statins could inhibit LOX-1 from binding to Ox-LDL by direct 
interaction with the CTLD of LOX-1 in a cell-based assay.92  
A synthetic phospholipid-based compound called PLAzPC (20, Figure 1-20) developed 
by Falconi et al. was shown to fill the hydrophobic tunnel in the LOX-1 CTLD dimer 
surface and is also stabilised by electrostatic interactions with water and other 
residues.93 Cell-base assays showed that this modified phospholipid could inhibit Ox-
LDL from binding to LOX-1 in COS fibroblasts transiently transfected with full length 
human LOX-1. Their finding could lead to the development of selective inhibitors for 
LOX-1. 
 
Figure 1-20. Chemical structure of a potential inhibitor of LOX-1 called PLAzPC. 
More recently, Thakkar et al. has identified two small molecules (21 and 22, Figure 1-
21) as inhibitors of LOX-1. Using cell-based assays, these compounds significantly 
decreased the uptake of ox-LDL by human endothelial cells (HUVECs). It should be 
noted that compound 22 was also confirmed the efficacy in HUVECs as well as in CHO 
cells expressing LOX-1. Moreover, both small molecules reduced the LOX-1 
transcription and the downstream effects like MAPKs activation as well as the 
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expression of adhesion molecules on endothelial cells and subsequent monocyte 
adhesion.94  
 
Figure 1-21. Chemical structures of potential small molecule inhibitors of LOX-1. 
1.4.7 Previous studies on LOX-1 ligand bindings  
This section briefly describes the studies on LOX-1 ligand bindings which were 
previously performed by Dr. K. Lacey (Dr. S. Ponnambalam, School of Molecular and 
Cellular Biology, University of Leeds).81  
As previously mentioned, Dr. K. Lacey demonstrated that the carbohydrate portion of 
Ox-LDL was important for LOX-1 binding than the protein composition. Further, soluble 
recombinant LOX-1 (sLOX-1) was used to screen against a carbohydrate array of more 
than 300 natural occurring and synthetic sugars in the presence of calcium ions.* 
Bound sLOX-1 was detected by fluorescent-labelled anti-HexaHis monoclonal 
antibody. The glycan array revealed two sugars molecules, GalNAc1-3Gal (23) and 
Gal1-3(Gal1-4)Gal1-4GlcNAc (24), that were capable of binding to LOX-1 (Figure 
1-22). These findings supported the hypothesis that carbohydrate molecules are 
involved in the interaction between OxLDL and LOX-1.  
                                               
* Recombinant LOX-1 was produced by Dr. R.Vohra, University of Leeds, U.K. and the glycan 







 Glycan array data of extracellular LOX-1 showing the two 
carbohydrate structures that could bind to LOX-1, K. Lacey‟s Ph.D. thesis 
University of Leeds 2012, reference 81.  
A hypothesis was then formulated that a specific carbohydrate structure would inhibit 
the binding of OxLDL to LOX-1, leading to a reduced accumulation of lipids in cells 
expressing LOX-1. To test this hypothesis, three different synthetic oligosaccharides 
23-25 (Figure 1-23) were synthesised† and tested for their ability to inhibit OxLDL 
binding to LOX-1 expressed on immortalised epithelial (HeLa) cells. The biological 
testings of the carbohydrates were performed by Dr. K. Lacey (Figure 1-24). The DiI-
labelled-OxLDL uptake assay showed that disaccharide 23 was unable to block the Ox-
LDL-LOX-1 interaction but tetrasaccharide 24 almost completely blocked the OxLDL 
binding at 10 mM. Surprisingly, a more simple carbohydrate structure 25, which is an 
intermediate for the synthesis of tetrasaccharide 24 showed an improved inhibitory 
effect.  
                                               
†  Carbohydrate compounds were synthesised by Dr. P. Mandal, a former postdoc in the 










 The tests of various carbohydrates in inhibiting OxLDL binding to 
LOX-1 expressing cells. (S2 = disaccharide 23; S3 = trisaccharide 25; S4 = 
tetrasaccharide 24), figure reproduced from K. Lacey‟s Ph.D. thesis University of 
Leeds 2012, reference 81. 
Trisaccharide 25 was used for further tests in an animal model because of its high 
specificity to LOX-1, relative to another scavenger receptor (CD 36).81 Apolipoprotein E 
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(Apo-E)-deficient mice fed a fat-rich diet were used as an animal model of 
atherosclerosis.  In the absence of Apo-E, lipoprotein remnants are not transported to 
the liver and the mice develop hypercholesterolemia, which leads to atherosclerotic 
lesions after 10-12 weeks on a fat-rich diet. The results showed that trisaccharide 25 
can reduce the formation of atherosclerotic plaques in the mouse aorta in comparison 





 The effect of trisaccharide 25 (sugar 3) on plaque formation in 
ApoE-deficient transgenic mice. Control (saline), 0.1 mM and 1 mM of trisaccharide 
25 administration was evaluated in ApoE-deficient mice after 10 weeks on a 
cholesterol- and fat-rich diet, figure reproduced from K. Lacey‟s Ph.D. thesis 
University of Leeds 2012, reference 81. 
Therefore, trisaccharide 25 could serve as a starting point for the development of a 
more potent inhibitor of LOX-1. A potential strategy for the enhancement of the binding 
affinity and inhibitory effect is to synthesise a trisaccharide analogue and present the 






1.5 DC-SIGN and its implication in viral infection 
DC-SIGN (Dendritic cell-specific Intercellular adhesion molecule-3-grabbing non-
integrin; also known as CD209) was originally cloned and identified from human 
placenta as a receptor for the HIV envelope glycoprotein gp120 by Curtis et al.95 and 
was discovered later as an intercellular adhesion molecule (ICAM-3) receptor that 
supports DC-mediated T-cell clustering by Geijtenbeek et al.34,96,97 DC-SIGN and the 
related receptor DC-SIGNR (also known as L-SIGN, Liver/lymph node-specific ICAM-3 
grabbing non-integrin or CD209L) share 73% identity at nucleic acid level27 and 77% at 
amino acid level with DC-SIGN.98 The two receptors are trans-membrane proteins that 
belong to C-type calcium-dependent lectin family. They involved in the innate immune 
system by acting as cell adhesion and pathogen recognition receptors of various 
pathogens through pattern recognition process. These receptors thus were classified to 
be in a group of receptors called pattern recognition receptors (PRRs), which recognise 
pathogen-associated molecular patterns (PAMPs) by binding to conserved motifs 
present on pathogens and also have the ability to bind to endogenous stress signals 
called damage-associated molecular patterns (DAMPs). These interactions result in the 
triggering of signals associated with immune response.  
This section outlines the similarities and differences of DC-SIGN and its homologue 
DC-SIGNR, notably on their structural and functional aspects. 
1.5.1 Structures of DC-SIGN and DC-SIGNR  
DC-SIGN and DC-SIGNR share similar overall structural organisation, comprising four 
domains: an N-terminal cytoplasmic domain, a trans-membrane domain, a tandem-
repeat neck domain and a carbohydrate recognition domain (CRD) (Figure 1-26). 
Despite their structural similarity, biochemical and structural investigations revealed 
that they exhibit distinct binding properties and different physiological functions,96,99 





Figure 1-26. a) Schematic representation of the structures of DC-SIGN and DC-
SIGNR; b) Arrangement of DC-SIGN and DC-SIGNR in a tetramer through the 
tandem-neck domains. 
1.5.1.1 Extracellular region 
The extra-cellular region of DC-SIGN and DC-SIGNR comprises the CRD and neck 
domains. As a single CRD interacts with low affinity to carbohydrate ligands, homo-
oligomerisation into a tetramer through the -helical neck regions is essential to 
provide a high affinity for ligand binding through multivalency.100 Moreover, DC-SIGN 
tetramers can organise into nanoclusters, which can further increase the multivalent 
binding effect.27  
A remarkable difference of DC-SIGN and DC-SIGNR is found in the neck region. The 
neck region of DC-SIGN always consists of seven complete and one incomplete 23-
residue tandem repeats, whereas that of DC-SIGNR varies from three to nine 
repeats.101 The variation of the length is thought to affect how CRDs are projected from 
the plasma membrane and therefore influencing ligand-binding properties. Feinberg et 
al. demonstrated that differences in oligomeric states of DC-SIGN and DC-SIGNR are 
caused by the number of repeats in the neck domain.102 They found that the lack of two 
repeats resulted in partial dissociation of the final tetramer, while the absence of more 
than five repeats leads to a reduced overall stability of the protein (Figure 1-27). The 
authors also showed that the neck and CRDs of DC-SIGN and DC-SIGNR are 
independently folded domains and the portion of the neck protein adjacent to the CRD 
is sufficient to mediate the formation of the dimers, whereas regions near the N-
terminus are needed to stabilise the tetramers.102  Yu et al. also suggested that the 
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neck domains and the CRDs of DC-SIGN and DC-SIGNR are independent.100 The 
neck portions could assemble as tetramers in the absence of the CRDs and function 




 A) Neck sequences of DC-SIGN and DC-SIGNR; B) Effects of neck 
sequences on oligomerisation of DC-SIGN and DC-SIGNR, figure adapted from 
reference 102.  
Crystal structures of neck domain of DC-SIGNR confirmed a series of four-helical 
bundles, linked by short, non-helical linkers containing the conserved proline residues 
(Figure 1-28a).28 A model of an extracellular domain of DC-SIGNR with 8 repeats of the 
neck domains was generated (Figure 1-28b),28 displaying a tetramerisation domain 
supporting the neck in which four polypeptides interact extensively throughout their 
length, giving a rigid tetrameric structure. The authors also commented on the 
differences of the extracellular domains (ECDs) of DC-SIGNR and DC-SIGN by 
comparing the structural analysis of DC-SIGN neck domain, which were reported by 
31 
  
Tabarani and co-workers.103 The neck region adjacent to the CDRs of DC-SIGNR was 
thought to slightly splay apart of the final neck repeat, placing the CRDs to the side of, 
rather than at the ends of, the helices compared with DC-SIGN. However, more details 




 a) Structure of the DC-SIGNR four-bundle of 23-amino acid repeat 
motifs which are connected through a short non-helical segments, i.e., a proline 
residue (Pro); b) Model of much of the extracellular domain of DC-SIGNR, 
including neck repeats 2 to 8 and the CRD, figure reproduced from reference 28.  
The Ca2+ dependent CRDs of DC-SIGN and DC-SIGNR, located at the C-terminus of 
the proteins, are projected from the membrane surface by neck domains. CRDs of DC-
SIGN and DC-SIGNR play an essential roles in the ligand recognition by specifically 
bind high mannose glycan structures.45,100 The CRDs of DC-SIGN and DC-SIGNR bind 
Man9GlcNAc2 oligosaccharide 130- and 17-fold more tightly than mannose, and affinity 
for a glycopeptide bearing two such oligosaccharides is increased by a further factor of 
5- to 25-fold.104 The CRDs of DC-SIGN are thought to have a flexible arrangement, 
which is required for optimal adaptation upon binding to carbohydrate ligands.105  
Crystal structures of CRDs of DC-SIGN and DC-SIGNR in complex with a 
pentasaccharide, in combination with binding studies, showed that they selectively 
recognise high mannose oligosaccharides (Figure 1-29A&B).45 The CRD in DC-SIGN 
adopts a typical long-form C-type lectin fold and selectively recognises high mannose 
glycans by ligation to bound Ca2+ site conserved in C-type lectin family. The CRD of 
DC-SIGN has two Ca2+ binding sites: one is important for the CRD conformation and 
the other is for direct ligation with carbohydrate ligands.  
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The CRDs of DC-SIGN and DC-SIGNR bind the central mannose residue (Man2) 
through equatorial 3-OH and 4-OH groups coordinating with the Ca2+ site, and the 
hydrogen bond network between distinct sugar residues of the ligand and the amino 
acid residues in the protein. The terminal GlcNAc (GlcNAc1) residues also form a 
number of contacts with DC-SIGN and DC-SIGNR. However, in the DC-SIGN complex, 




 Interactions of DC-SIGN and DC-SIGNR with GlcNAc2Man3 A) 
Interactions of the 1-3-linked branch with DC-SIGNR. Only important sugars are 
shown. Ca
2+ 
coordination is shown by solid black lines and hydrogen bonds as 
dashed lines; B) Interactions of the 1-3-linked branch with DC-SIGN. The terminal 
GlcNAc1 forms a cross link by forming the typical C-type lectin interactions with the 
principal Ca
2+
 (grey) are shown, figure reproduced from reference 45.  
Moreover, Guo and colleagues performed glycan array analysis to show that DC-SIGN 
and DC-SIGNR have different ligand-binding properties (Figure 1-30).99 Both receptors 
recognise N-linked high-mannose structures, among which Man9GlcAsn glycopeptide 
had a highest binding affinity. DC-SIGN recognises a broader set of ligands than DC-
SIGNR; that is DC-SIGN but not DC-SIGNR binds to a selected set of fucosylated 







 Glycan array probed with fluorocein-labelled DC-SIGN and DC-
SIGNR. a) DC-SIGN binds to fucose- and mannose-containing glycans; b) DC-
SIGNR binds to mannose-containing glycans, figure reproduced from reference 99. 
Guo et al. also investigated the ability of DC-SIGN to bind fucosylated ligands and a 
high mannose glycan (Figure 1-31).99 In the case of a high mannose glycan binding, 
the 1,3-linked mannose residue interacts with the primary Ca2+ binding site of the DC-
SIGN CRD and the 1,6-linked mannose residue fills in the secondary binding site. 
Interestingly, the primary binding site of DC-SIGN may not be necessary to bind to the 
terminal mannose residues of the ligand.  However, Man-1,2-Man, which is unusually 
found in high mannose glycan structures, is in contact with the DC-SIGN CRD. On the 
other hand, DC-SIGN binds to fucose-containing glycans (e.g., Lex tetrasaccharide); a 
fucose residue interacts with the DC-SIGN primary binding site in a different geometry 
compared to the mannose residues bound to the protein. The branched 
oligosaccharides with terminal fucose residues are oriented with the central GlcNAc 
residue pointing away from the protein while the terminal galactose residue making 






 DC-SIGN in complex with: a) Man4 structure and b) Le
x
 





is shown by black lines, hydrogen bonds as dashed lines, figure reproduced from 
reference 105. 
Furthermore, structural characteristics of the interaction of the DC-SIGN and DC-
SIGNR with oligosaccharides containing mannose or Lewisx by NMR methods show 
that in certain cases crystallography may reveal only one of multiple modes of ligand 
binding.96,106 More details on the binding of DC-SIGN CRD to their relevant ligands still 
await investigation.  
1.5.1.2 Trans-membrane and cytoplasmic domains 
Trans-membrane domains of DC-SIGN and DC-SIGNR contain approximately 18 and 
22 amino acids that anchor the proteins to the cytoplasmic membrane.27 
The cytoplasmic N-terminal region of DC-SIGN and DC-SIGNR contains several 
internalisation motifs: DC-SIGN contains a di-leucine (LL) motif, a triacidic (EEE) 
cluster, an incomplete immunoreceptor tyrosine-based activation motif (ITAM), 
whereas the related receptor DC-SIGNR contains an LL motif and an EEE cluster, but 
no tyrosine motif.107-109  
1.5.1.3 Tissue distribution of DC-SIGN and DC-SIGNR 
DC-SIGN and DC-SIGNR are expressed in different tissues. DC-SIGN is expressed on 
the surface of dendritic cells, macrophages and placenta, whereas DC-SIGNR is 
present on sinusoidal endothelial cells in the liver and on endothelial cells in lymph 




1.5.2 Functions of DC-SIGN and DC-SIGNR  
Comparison of DC-SIGN and DC-SIGNR showed that they have different ligand 
binding properties and physiologic functions.99 The natural ligands of DC-SIGN are 
high-mannose glycans and fucose-Lewis type determinants.96,99,112  DC-SIGNR has a 
more restricted set of ligands recognising only high-mannose oligosaccharides but not 
fucose-containing oligosaccharides. Both C-type lectins play essential roles in the 
immune system; they share the ability to bind to ICAM-3 (the endogenous adhesion 
molecule of T-cells) and enhance several pathogens infection of T-cells and other cells 
of the immune system.97,101 Both receptors functions as cell adhesion receptor by 
recognising glycoproteins on HIV, Ebola virus, hepatitis C virus (HCV), Dengue virus 
and many other pathogens.34,103,113-115 However, only DC-SIGNR can recognise the 
West Nile Virus (WNV) and facilitates infection.116 Moreover, DC-SIGN binds to ICAM-2 
and facilitates the rolling and trans-endothelial migration of DCs.28 Besides having a 
function in the role of adhesion receptor and DC-T-cell interaction, DC-SIGN has also 
been shown to mediate endocytosis, trafficking as a recycling receptor and releasing 
ligand at endosomal pH, whereas DC-SIGNR only acts as an adhesion receptor and 
does not release ligand at low pH or mediate endocytosis.99,107,108,117 However, the 
roles and mechanism of DC-SIGN and DC-SIGNR in pathogen recognition and uptake 
are still unclear.  
DC-SIGN was utilised by several pathogens for host cell entry. One of the most studied 
and currently accepted models of DC-SIGN-mediated pathogen infection is the case of 
HIV infection, which is briefly discussed in Section 1.5.3. 
1.5.3 The roles of DC-SIGN and DC-SIGNR in viral infections 
The first step of viral entry is the attachment of the virus to the host cell surface. In the 
case of human immunodeficiency virus type 1 (HIV-1), which is the most widespread 
type, the interaction of gp120 viral envelop with CD4+ target cells is important for this 
process, permitting fusion of the virus to the host cell membrane and transfer of the 
viral genome to the target cells. Apart from CD4, other HIV-1 co-receptors (e.g., 
CXCR4, CCR5, Figure 1-32) also mediate the viral entry and productive infection.118 
Although CD4+ T-cells are major targets that are infected by HIV-1 viruses,119 
accumulating evidence showed that dendritic cells (DCs) are among the first cell types 
confronted by HIV-1. DCs are antigen presenting cells that express various PPRs, e.g., 
DC-SIGN which is involved in antigen capture and internalisation. DC-SIGN functions 
in HIV infection can be summarised as follows: 1) DC-SIGN acts as an antigen uptake 
receptor to recognise HIV-1 viral envelope protein gp120, allowing immature DCs to 
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capture pathogens and migrate to lymphoid tissues to present the antigen to T-cell 2) 
DC-SIGN enables cell-cell interactions by binding to receptors on CD4+ T-cells creating 
infectious synapse.  
The dual functions of DC-SIGN enhance HIV-1 infection of T-cells and contribute to 
trans- and cis-infection pathways (Figure 1-32).120,121 Trans-infection  direct infection 
of HIV into CD4+ T-cells across the infectious synapse (pathway a) or DC-SIGN 
mediated capture of HIV which cycles through the DC creating exosomes bearing HIV 
which infect CD4+ T-cells (pathway b). Cis-infection  virus becomes integrated into DC 
genome and new virus particles are released to infect CD4+ T-cells (pathway c).  
All functional data of DC-SIGN were obtained from in vitro studies, nevertheless, the 








 The roles of DC-SIGN in HIV-1 infection and transmission: trans-
infection mediated by DCs can occur by two pathways (a,b) and cis-infection 
mediated by DCs involves one pathway (c), figure reproduced from reference 121.  
DC-SIGNR functions as an HIV-receptor in trans-infection, but in this case it is 
expressed on the surface of endothelial cells in the liver lymph node sinuses, and 
placental villi but not on DCs. Boily-Larouche et al. also demonstrated that DC-SIGNR 
might be essential for mother-to-child transmission of HIV-1.122  
Ebola virus exploits DC-SIGN and DC-SIGNR in trans- and cis-infection and transmits 
the captured infective particles to susceptible cells.123  
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A better understanding of DC-SIGN and DC-SIGNR activities in viral infection and 
protein-ligands interactions would give an insight into the basis of structural information 
for the development of probes or therapeutic agents.  
1.6 Project objectives 
1.6.1 LOX-1 
1.6.1.1 Synthesis of a monovalent carbohydrate-based inhibitor for 
LOX-1 
As described in Section 1.4.7, lead compound 25 was previously synthesised and 
identified as an inhibitor of LOX-1 (Figure 1-33). One of the main objectives of this 
thesis is to synthesise analogous compounds 26 and 27 by replacing a methoxy group 
of the lead trisaccharide with an amine or a methoxycarbonyl group. These lead 
trisaccharide derivatives would be used to construct multivalent carbohydrate 
structures, which were anticipated to have an increased binding affinity to LOX-1. 
 
 
Figure 1-33. Lead compound 25 and its analogous compounds 26 and 27. 
1.6.1.2 Simplification of the lead compound structure and optimisation 
of the glycosylation reactions 
The central galactose residue of the lead compound was chosen to be replaced with 
1,2-cis-cyclohexanediol to form compound 28 (Figure 1-34). This simplified compound 
would allow determining of the significance of central galactose residue for the binding 
activity with LOX-1.  
Replacing the central sugar with 1,2-cis-cyclohexanediol would not only allow the 
production of a simplified analogue 28 of the lead compound 25, but also the 




Figure 1-34. Designed sugar derivative 28.   
1.6.1.3 Synthesis of multivalent carbohydrate structures  
Since the individual binding interaction of the lead trisaccharide and LOX-1 was 
relatively weak, attaching carbohydrate compounds to a multivalent scaffold could be a 
way to increase the binding affinity to LOX-1. To achieve this aim, a trisaccharide 
analogue containing a reactive hydrazide group would be synthesised and used to 
attach to a polymer bearing aldehyde functions (Figure 1-35).124 
 
Figure 1-35. Cartoon representation of a trisaccharide analogue containing a 




1.6.1.4 Evaluation for the inhibitory effects   
Synthesised trisaccharide analogues would be evaluated for their inhibitory effects in 
cells expressing LOX-1. This should ultimately provide an effective novel inhibitor for 
LOX-1. 
1.6.2 DC-SIGN and its related receptor DC-SIGNR 
1.6.2.1 Synthesis of a monomannoside-bearing multivalent probe  
Azido-mannopyranoside 29 (Figure 1-36) was to be synthesised and conjugated to 
quantum dots by strain-promoted alkyne-azide cycloaddition, to form a 
monomannoside-bearing multivalent probe 30. This monomannosylated-probe would 
be used to investigate the differences in multivalent binding by the closely related 
receptors DC-SIGN and DC-SIGNR, employing Förster resonance energy transfer 
(FRET) technique. 
.  
Figure 1-36. Target azido-mannopyranoside 29 and schematic representation of 
mono-mannoside bearing quantum-dots 30; QD = quantum dots. 
1.6.2.2 Synthesis of a dimannoside-bearing multivalent probe  
As Man1-2Man dimannoside was expected to be of improved binding affinity, azido-
mannopyranoside 31 (Figure 1-37) was to be prepared and attached to quantum dots, 




Figure 1-37. Target azido-mannopyranoside 31 and schematic representation of 




Chapter 2: Synthesis of a monovalent 
























As discussed in Section 1.4.7, lead trisaccharide 25 (Figure 2-1), which was 
synthesised in the Turnbull research group by Dr. P. Mandal, has been previously 
identified as an inhibitor of LOX-1 because it could inhibit LOX-1-oxLDL binding to cells 
and reduce atherosclerosis in mice.81 However, the binding affinity between the 
trisaccharide and LOX-1 was relatively weak; constructing multivalent carbohydrate 
structures would be a way to enhance the binding affinity of this interaction. 
 
Figure 2-1. Chemical structure of lead trisaccharide 25, which was identified as an 
inhibitor of LOX-1.  
2.2 Aims and objectives 
The objective of this chapter was to synthesise a lead compound analogue, containing 
an aromatic nitro group at one end. This nitro group was to be reduced to an amine for 
attachment to a polymer scaffold to make a glycopolymer bearing multiple copies of 
trisaccharide analogues.   
2.3 Synthesis of a trisaccharide analogue containing an aromatic 
amine group 
2.3.1 Synthesis of a glycosyl acceptor  
The first step in the synthesis was the removal of the anomeric acetyl group from 
galactose pentaacetate 33 to form a hemiacetal (Scheme 2-1).  Treatment of the 
alcohol with trichloroacetonitrile and a base gave -anomeric trichloroacetimidate 34, 
which has the ability to act as a glycosyl donor under mild acidic conditions such as 
provided by a Lewis acid.  Formation of the - or -trichloroacetimidate depends on the 
type of base used to deprotonate the free hydroxyl group.  With a weak base, 
mutarotation occurs faster than the nucleophilic attack; therefore the -alcohol reacts 
preferentially.  With a strong base, such as DBU, the product can anomerise therefore 
the -anomeric trichloroacetimidate is preferred because it is more thermodynamically 
stable than the -form. -Trichloroacetimidate 34 was reacted with 4-nitrophenol, in the 
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presence of BF3OEt2, to give -galactopyranoside 35, which was deacetylated by 
treatment with potassium carbonate in anhydrous MeOH to yield galactopyranoside 36. 
 
Scheme 2-1. Synthetic route to 4-nitrophenyl galactopyranoside 36. 
Although, the same galactosyl donor was to be used twice to glycosylate the central 
galactose residue, it was necessary to perform one glycosylation reaction at a time. A 
previous attempt was made by Dr. P. Mandal to attach the same galactosyl donor at 
the O-3 and O-4 positions simultaneously, but the glycosylation did not work. It was 
assumed that if the two sugars were attached at the same time, the less hindered 
equatorial position would be glycosylated in preference to the axial position. Hence, it 
would become more difficult to react the axial alcohol with the galactosyl donor to form 
the target trisaccharide (Scheme 2-2a). A way to avoid this problem was to first of all 
selectively protect the O-3 equatorial position and then attach the first sugar onto the 
O-4 axial position. Thereafter, a selective deprotection to reveal the O-3 hydroxyl group 
would allow attachment to the next sugar residue, producing the target trisaccharide 




Scheme 2-2. The necessity of protecting group arrangements for the synthesis of 
the target trisaccharide analogue. 
A benzylidene acetal was employed to selectively protect both O-4 and O-6 positions of 
galactopyranoside 36 by the reaction with benzaldehyde dimethylacetal and camphor 
sulfonic acid (CSA) (Scheme 2-3).  The reaction was selective for the O-4, O-6 
positions because formation of a compound containing a six-membered ring is 
thermodynamically preferred. 4,6-O-Benzylidene protected galactopyranoside 37 was 
treated with dibutyl tin oxide in MeOH at 90 °C and subsequently reacted with allyl 
bromide in the presence of cesium fluoride and tetrabutylammonium iodide (TBAI) at 
90 °C, followed by acetyl protection using acetic anhydride and 4-
dimethyaminopyridine (DMAP) in pyridine. The aim of this three-step synthesis was to 
selectively introduce an allyl group at the O-3 position of compound 37. However, this 
process was not regiostereoselective, furnishing a mixture of three different 
compounds (38a, 38b and 38c). Compounds 38b and 38c were inseparable by flash 





Scheme 2-3. Synthetic route to compounds 38a, 38b, and 38c. 
A mixture of compounds 38b and 38c was obtained in a ratio of 3:2, which was 
determined by integration of anomeric signals in 1H NMR spectrum. The total of 4.84 g 
of the product mixture was obtained, which contained 6.15 mmol of 38b (calculated 
from a relative mass of 472.25). The product mixture was subjected to reduction with 
sodium cyanoborohydride under acidic conditions (Scheme 2-4). After the ring-opening 
reaction, a pure galactopyranoside 39 was successfully isolated in a yield of 80%, 
which was calculated from 6.15 mmol of 38b as starting material. This process 
selectively revealed a free hydroxyl group at the O-4 position on galactopyranoside 39, 




Scheme 2-4. Synthetic route to galactopyranoside 39, which would be used as a 
glycosyl acceptor for further glycosylation reactions. N.B. Starting material contains 
60% of 38b and 40% of 38c. Yield was calculated based on the amount of 38b 
present in the starting material.  
2.3.2 Synthesis of a glycosyl donor 
Reaction of galactose pentacetate 33 with thiophenol in the presence of Lewis acid 
(BF3OEt2) yielded -galactopyranoside 40 (Scheme 2-5). The -galactopyranoside 
was formed preferentially as a result of the neighbouring group participation by the 
acetate protecting group at the O-2 position which could stabilise the intermediate by 
forming a cyclic oxacarbenium ion. Fully-benzylated glycosyl donor 41 was obtained by 
removal of the acetate protecting groups, followed by benzylation using benzyl bromide 
and sodium hydride.  
 
Scheme 2-5. Synthetic route to glycosyl donor 41. 
2.3.3 Glycosylation reactions 
The glycosylation reaction was performed by coupling glycosyl acceptor 39 and 
glycosyl donor 41 using N-iodosuccinimide (NIS) and 
trimethylsilyltrifluoromethanesulfonate (TMSOTf) as a promoter system, producing 
disaccharide 42 (Scheme 2-6). It shoud be noted that this glycosylation provided both 
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- and -galactopyrananosides. However, the -anomer could be isolated by flash 
column chromatography.  
The allyl group at the O-3 position was then removed with PdCl2 in MeOH to reveal a 
free hydroxyl group on disaccharide 43, which was used as a glycosyl acceptor for the 
next reaction. Subsequent glycosylation of disaccharide 43 with glycosyl donor 41 
under the same conditions as described above, followed by removal of protecting 
groups, afforded trisaccharide 44 in a low yield. Liquid chromatography-mass 
spectrometry (LC-MS) and high resolution mass spectrometry (HRMS) showed a mass 
to charge ratio (m/z) corresponding to the desired trisaccharide 44.  
 
Scheme 2-6. Synthetic route to deprotected trisaccharide 44. 
1H NMR spectrum of fully-deprotected trisaccharide 44 showed three possible 
compounds present in the mixture, which could be the trisaccharide with different 
configurations of glycosidic linkages, i.e.,  or  or  (Figure 2-2). The major 
compound was the desired product bearing two -linkages and a -linkage according 
to the coupling constants of the three anomeric proton NMR signals (4.1 Hz, 3.7 Hz, 
and 7.3 Hz). However, on the account of the small amount of product obtained, this 
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sample was not amenable to 13C NMR spectroscopic analysis. Thus, there was a need 




H NMR spectrum of trisaccharide 44 (500 MHz, D2O). Highlighted in 
red shows peaks corresponding to minor compounds presented in the sample.  
2.4 A model study for derivatising an aromatic amine glycoside 
Fully-deprotected trisaccharide 44 was to be further derivatised and used to attach to a 
multivalent scaffold to make multivalent carbohydrates. A model study for derivatising 
an aromatic amine glycoside was therefore conducted using a monosaccharide version 
of the target trisaccharide. 4-Nitrophenyl galactopyranoside 36, an intermediate in the 
synthesis, was reduced by hydrogenation to give the corresponding amine 45 (Scheme 
2-7). Dimethyl squarate 46 was successfully introduced on to the reactive amine group 
in a good yield. The reaction of the galactopyranoside 47 with hydrazine monohydrate 
was attempted but gave undesired product with impurities instead of hydrazide 48. This 
might be because either hydrazine was too reactive and could result in dimer formation 
or it also could cleave the initial amide group of dimethyl squarate. It was thus 
impractical to employ ester squarate as a linker to join 4-aminophenyl 





Scheme 2-7. Attempted synthesis of galactopyranoside 48. 
An alternative approach was to synthesise a trisaccharide containing other 
functionalities, e.g., aromatic ester 27 (Figure 2-3), which would be more practical 
because only a one-step derivatisation to a hydrazide was required. Moreover, 
trisaccharide 27 has the same aglycone structure present in the sugar compounds 
previously attached to the multivalent polymer scaffolds.125 The detailed synthesis of 
trisaccharide 27 is further discussed in Chapter 4. 
 









The synthesis of 4-aminophenyl trisaccharide resulted in a relatively low yield and -
selectivity. The development of an improved synthesis of the lead trisaccharide 
derivatives was therefore necessary. The two key challenges to augment the overall 
yield were 1) improving the regioselectivity of the protecting group chemistry and 2) 
increasing the -selectivity of glycosylation reactions (Scheme 2-8). Furthermore, a 
model derivatisation system to link 4-aminophenyl monosaccharide with a squarate 
ester was unsuccessful. The linkage of trisaccharide through a squarate ester was 
therefore impractical. Another possibility was to alter the aromatic amine to an aromatic 





Scheme 2-8. Entire synthesis of 4-aminophenyl galactopyranoside 44 with two key 
challenges to be improved: 1) the regioselectivity of the protecting group (blue box) 
and 2) the -selectivity of glycosylation (red box).  
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Chapter 3: Optimisation of the 
glycosylation reaction and 
replacement of the central galactose 





















Before attempting to improve both stereoselectivity and regioselectivity of the 
trisaccharide synthesis, the coupling chemistry on a model system using cyclic diols 
was evaluated. One of the objectives of this evaluation was to simplify the molecular 
structure of the lead compound by replacing the central sugar residue with a non-sugar 
residue (i.e., 1,2-cis-cyclohexanediol). The other, which could be done at the same 
time, was to use this simplified system as a means to optimise the glycosylation 
reaction using two different types of glycosyl donors.  
3.2 Glycosylation reaction in general 
In general, a glycosylation involves a reaction between a glycosyl acceptor and a 
glycosyl donor in the presence of a promoter, establishing a glycosidic linkage 
(Scheme 3-1). Upon activation, the promoter assists the departure of the leaving group 
at the anomeric centre of the donor and forms a glycosyl cation, which is further 
stabilised by resonance with the endocyclic oxygen and thus forms an oxacarbenium 
ion. Nucleophilic attack of a glycosyl acceptor is possible from either the top or the 
bottom face of the sugar, enabling the production of a -glycoside and an -glycoside, 
respectively.  
 
Scheme 3-1. General mechanism of a glycosylation reaction. 
3.3 Optimisation of the glycosylation reaction using 1,2-cis-
cyclohexanediol 
In the initial synthesis (cf. Section 2.3.1, Scheme 2-6), on activation of the fully-
benzylated glycosyl donor 41 with NIS/TMSOTf, the disaccharide 42 was formed as an 
anomeric mixture. Because in the lead compound 25 (Figure 3-1), two galactose 
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residues were bonded by -linkages, controlling -selectivity of glycosylation reaction 
is required to increase the overall of yield of the synthesis.  
 
Figure 3-1. Chemical structure of lead compound 25. 
To investigate if it would be possible to achieve higher -selectivity, glycosylation 
reactions of 1,2-cis-cyclohexanediol 49 (1 equiv.) with fully-benzylated glycosyl donor 
41 (2.6 equiv.) was performed attempting to attach both galactopyranosyl groups in 
one-pot (Table 3-1). After each attempt, the crude product mixture was purified by 
either flash column chromatography (silica; hexaneEtOAc; Table 3-1, entries 1-3) or 
size exclusion chromatography (SX-1 Bio-Beads, toluene; Table 3-1, entry 4). 
Following purification, a hydrogenolysis of the benzyl ether protecting groups was 
necessary to avoid the overlapping 1H NMR signals of the protecting groups and the 
sugar ring protons, notably the anomeric protons. Thus, the isolated yields present in 
the Table 3-1 correspond to the debenzylated products. It should be noted that these 
glycosylation reactions gave a mixture of anomers. The / ratios were determined by 
integration of anomeric signals in 1H NMR spectra. The NIS/TMSOTf-promoted 
glycosylation reaction in DCM returned mostly unreacted glycosyl donor and the 
stereoselectivity was poor with / ratio of 1:3 (Table 3-1, entry 1). Ethereal solvents 
has been reported to enhance the -selectivity by a participating electron donating 
effect which stabilises oxacarbenium ion intermediate, favouring the nucleophilic attack 
from the -face of the sugar.126 Consequently, another two glycosylation reactions 
were attempted in diethyl ether. However, they still resulted in low reactivity (Table 3-1, 
entries 2-3).  It is also noteworthy that the use of 1-benzenesulfinyl 
piperidine/trifluoromethanesulfonic anhydride/2,4,6-tri-tert-butylpyrimidine 
(BSP/Tf2O/TTBP) as a promoter system led to a higher yield and less unreacted donor 
remained, when compared with NIS/TMSOTf system. The BSP/Tf2O/TTBP-activated-
glycosylation in DCM afforded pseudo-trisaccharide 51 in a relatively better yield 
compared to the glycosylation using the same promoter system in diethyl ether (Table 
3-1, entry 4). 
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Table 3-1. Glycosylation of 1,2-cis-cyclohexanediol 49 with perbenzylated glycosyl 
donor 41, giving pseudo-trisaccharides 50-51. 
 







1 NIS/TMSOTf DCM  1:3 29% 
2 NIS/TMSOTf Diethyl 
ether 
 - Trace 
3 BSP/TTBP/Tf2O Diethyl 
ether 
 - Trace 
4 BSP/TTBP/Tf2O 
 
DCM  2:1 87% 
*/ ratio was determined by integration of anomeric signals in the 
1
H NMR spectrum of 
the reaction mixture purified by flash column chromatography (entries 1-3) or size 
exclusion chromatography (entry 4).                                                  
**Isolated yields of debenzylated products 51. 
From the above results, the BSP/Tf2O/TTBP-promoted glycosylation reaction of 1,2-cis-
cyclohexanediol with fully-benzylated donor 41 provided an improved yield and 
reasonable -selectivity (: = 2:1). However, the anomeric ratio was still not 
satisfactory for ensuring a high stereoselective glycosylation. Alternatively, the Boons 
group described a glycosyl donor with O-4 ester participating group which could 
increase -selectivity of galactosylation.127 For comparison, a series of O-4-acyl 
galactosyl donors were generated. By variation of the O-4 protecting group, the authors 
found that -selectivity of galactosylation could be affected, as shown in Table 3-2. On 
exchanging O-4 benzyl for O-4 acetyl protecting group, the -selectivity increased by 3-
fold (Table 3-2, entry 2). Similarly, replacing O-4 acetyl with O-4 benzoyl protecting 
group increased the / ratio to 17:1 (Table 3-2, entry 3).  Additional donors with 
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electron-donating ester functionality at O-4 position were also evaluated for -
selectivity (Table 3-2, entries 4-7). An ethyl thioglycoside bearing a 4-methoxybenzoyl 
group (PMBz) exhibited very promising results (Table 3-2, entry 7). The authors 
proposed that the -directing effect of selected galactosyl donors was due to a remote 
neighbouring group participation at O-4 position. This finding is generally in agreement 
with the computational investigations of Miljkovic et al. who have introduced a general 
mechanism that involves electron donation from the electronegative substituent at the 
O-4 position of the galactopyranoside ring to the oxacarbenium intermediate.128  
Table 3-2.
127
 Literature data on galactosyl donors bearing different O-4 protecting 
groups 
 
Entry R Ratio α/β 
Yield 
(%)127 
1 Benzyl 2.2:1 91 
2 Acetyl 7.2:1 76 













A possible mechanism for remote neighbouring group participation at O-4 position is 
described in detail in Scheme 3-2. Upon activation, the promoter reacts with the 
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glycosyl donor leading to the departure of the leaving group and the formation of an 
oxacarbenium ion. The remote participating group at the O-4 position helps to stabilise 
the intermediate produced, blocking the  face of the sugar. Therefore, the nucleophilic 
attack of the acceptor takes place preferentially on the bottom face, favouring mostly -
glycoside. 
 
Scheme 3-2. A possible mechanism for remote participating group participation at 
O-4 position.  
On the other hand, neighbouring group participation from the O-4 position has also 
been called into question by Crich et al.129 A specific probe was developed for the 
detection of a bridging intermediate for neighbouring group participation by benzoate-
type esters.  The idea was to detect the existence of the bridging intermediate by 
quenching the reaction with 18O-enriched water to determine the position where the 
label would be incorporated. It was anticipated that upon low-temperature activation of 
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O-4 PMBz substituted phenyl thioglycosyl donor 55 with BSP/Tf2O/TTBP in the 
absence of acceptors, glycosyl cation 56 would be formed, in equilibrium with cyclic 
cation 58 if the remote neighbouring group participation takes place (Scheme 3-3). 18O 
labelled water would be expected to be incorporated to the intermediate, forming either 
hydrolysis product 57 or 59. Their experiment led to isolation of 57/59 mostly as the -
anomer; unfortunately, it was not possible to perform mass spectrometric analysis 
without first converting the products to the corresponding acetate 60. They eventually 
confirmed that there was no evidence of the 18O-label attached to either C-4 or the 
benzoyl carbonyl group, implying that the stereochemical control did not appear to be 
the result of participation by the C-4 substituted ester, in contrast to the previous study 
of Boons and co-workers. However, the authors noted that alternative explanation for 
such -selective effect of this type of benzoate-ester is still needed to be found. It 
should be noted that the evidence for and against the existence of the -directing effect 
arising from remote neighbouring group participation at the O-4 position is still weak. 
The conclusion from the model study established by Crich et al. is still not widely 
accepted as the experiment assumes that the formation of product 59 via the 
hemiorthoester intermediate occurs at an appreciable rate compared to formation of 57 
from either intermediates 56 or 58. Moreover, the use of 18O-labelled water as an 
acceptor may not represent the reactivity of actual sugar acceptors.  
Scheme 3-3.
129
 An isotopic labelling probe designed by Crich and co-workers. 
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Regardless of the mechanism, experiments to investigate whether the use of a glycosyl 
donor in which the benzyl ether protecting group at the O-4 position was replaced with 
PMBz group could help increase the -selectivity for the glycosylation with 1,2-cis-
cyclohexanediol. Therefore, two related glycosyl donors were synthesised (Scheme 3-
4): ethyl thioglycoside 68 as used previously by Boons and thiophenyl glycoside 55 to 
allow direct comparison with the fully-benzylated phenyl glycosyl donor. Acetylated 
ethyl and phenyl thioglycosides 61 and 40 were synthesised via the reaction of 
peracetylated galactose 33 with thiophenol/ethanethiol in the presence of boron 
trifluoride etherate. Zemplén deacetylation and subsequent benzylidene acetal 
protection at the O-4, O-6 positions of resulting galactopyranosides gave 4,6-O-
benzylidene acetals 62 and 63. The remaining hydroxyl groups were thereafter 
protected as benzyl ethers to provide compounds 64 and 65. 
Selective reduction with sodium cyanoborohydride under acidic conditions resulted in 
alcohols 66 and 67. The PMBz protecting group was introduced at the O-4 position by 
treatment with 4-methoxybenzoic acid and 1,1-carbonyldiimidazole in MeCN in the 
presence of DBU, leading to formation of ethyl and phenyl thioglycosides 68 and 
55.  However, under the same conditions, the preparation of ethyl thioglycoside was 
more challenging than that of the phenyl glycoside leading to lower yields of ethyl 




Scheme 3-4. Synthetic route to glycosyl donors 68 and 55. 
Thus, glycosylation reactions of 1,2-cis-cyclohexanediol 49 were repeated using phenyl 
thioglycoside 55 employing BSP/Tf2O/TTBP as a promoter system in two different 
solvent systems, i.e., DCM and DCMdiethyl ether (1:1, v/v; Table 3-3, entries 5-6). 
The crude products were purified by size exclusion chromatography (SX-1 Bio-Beads, 
toluene). 
The use of this benzoate-ester type of glycosyl donor 55 exhibited improved -
selectivity with an  ratio of 5:1 (Table 3-3, entry 5) relative to the completely 
benzylated galactosyl donor 41 with an  of 2:1 (Table 3-3, entry 4). However, 
performing a glycosylation reaction in ethereal solvent (1:1, DCMdiethyl ether) still did 
not improve the stereoselectivity of the product because of the low reactivity (Table 3-3, 
entry 6). It is noteworthy that the product mixture obtained from reactions using 
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substituted benzoate-ester thioglycoside 55 also included a trehalose-like compound 
71 that also part of the quoted yield in the table. It is noteworthy that the product 
mixture obtained from reactions using substituted benzoate-ester thioglycoside 55 also 
included traces of a trehalose-like compound 71 that could not be separated from 
product 70 without employing HPLC methods which would have risked leading to 
changes in / ratios. Therefore, while yields of 70 in the table are based on the molar 
ratio of products estimated from NMR spectra, the / ratios are for the mixture of all 




Table 3-3. Glycosylation of 1,2-cis-cyclohexanediol 49 with glycosyl donors 41 and 





















DCM  1:3 29% 




Diethyl ether  - Trace 











 5:1 30% 
*/ ratio was determined by integration of anomeric signals in the 
1
H NMR spectrum of the 
reaction mixture purified by flash column chromatography (entries 1-3) or size exclusion 
chromatography (entries 4-6).                                                    
**Isolated yields of debenzylated products 51 (entries 1-4) and 70 (entries 5-6). N.B. Only 
approximate yields are given for entries 5-6 as the products also contained small amounts 
of trehalose-like compound 71. 
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The use of thioglycosyl donor 55 with a 4-methoxybenzoyl group, instead of 
perbenzylated glycoside, resulted in a great improvement in -selectivity (: ratio of 
5:1), probably as a result of remote protecting group participation. Furthermore, a 
mixture of compounds 70 and 71 was subjected to de-esterification to remove the O-4 
PMBz protecting group using sodium hydroxide in MeOH (Figure 3-2). The product 
mixture was purified by mass-directed HPLC to provide compound 51 as a mixture of 
anomers (7 mg, / ratio of 8:1). Despite the relatively low yield, these optimal 
conditions were selected to perform further glycosylation reactions. 
 
Figure 3-2.  Synthetic route to pseudo-trisaccharide 51. 
3.4 Variable temperature NMR experiment 
Fully-deprotected pseudo-trisaccharide 51 exhibited two -anomeric proton signals in 
its NMR spectrum. A variable temperature NMR experiment (Figure 3-3) was used to 
investigate whether upon heating the anomeric protons peaks at 5.27 ppm and 5.18 
ppm of the two galactose residues would coalesce, which could be the result of 
cyclohexane ring inversion, undergoing axial/equatorial exchange. However, upon 
varying from room temperature to 90 C, coalescence of the two peaks did not occur; 
suggesting that a cyclohexane ring inversion might be a slow process. It should be 
noted that the coupling constants of the anomeric proton peak at 5.27 ppm were not 
influenced by the temperature change (3.9 Hz at 26 C and 4.0 Hz at 90 C), whereas 
the coupling constants of the peak at  5.18 ppm decreased from 4.1 Hz to 3.5 Hz. 





 Figure 3-3. Stacked plot of 
1
H NMR spectra of pseudo-trisaccharide 51 at variable 
temperature (from 26 C to 90 C, D2O and 500 MHz).  
3.5 Conclusions 
Optimisation of the glycosylation reaction led to the conclusion that the use of 
thioglycosyl donor with a PMBz group instead of a benzyl ether at O-4 position, results 
in a great improvement in -selectivity (: = 5:1) which was possibly due to the 
remote protecting group participation. Unexpectedly, glycosylation reaction of 1,2-cis-
cyclohexanediol to make a more simple analogue of trisaccharide 25 proved to be 
more difficult than manipulating sugars and their protecting groups. As a consequence, 




Chapter 4: Reinvention of the synthesis 





Working with 1,2-cis-cyclohexanediol appeared to be more problematic than 
performing experiments with sugars and manipulating their protecting groups (cf. 
Section 3.3); therefore, synthesis of the trisaccharide had to be redeveloped.  
According to Chapter 3, an improved glycosylation reaction had been identified. The 
remaining challenge to address was to enhance the regioselectivity of the protecting 
group chemistry and to allow stepwise glycosylation at the O-3 and O-4 positions. 
Moreover, as the trisaccharide will be further derivatised and used to attach to a 
multivalent scaffold to make multivalent carbohydrates, it was desirable to change the 
aglycone. A synthetic route to a trisaccharide with a carboxyphenyl aglycone was thus 
developed, starting with the synthesis of a glycosyl acceptor having an ester group. 
4.2 Synthesis of a glycosyl acceptor containing a 4-
methoxycarbonylphenyl group  
The same synthetic procedures were employed as described in Chapter 2 for the 
preparation of a trisaccharide containing a 4-nitrophenyl group; in this case however, a 
4-methoxycarbonylphenyl group was attached to the galactopyranoside instead. -
Trichloroacetimidate 34 was synthesised from galactose pentaacetate 33 by removal of 
the anomeric acetyl group, followed by treatment of the alcohol with trichloroacetonitrile 
under basic conditions (Scheme 4-1). The reaction of imidate 34 with methyl 4-hydroxy 
benzoate in the presence of BF3OEt2 yielded -galactopyranoside 72, which was 
further subjected to Zemplén deacetylation in the presence of sodium methoxide in 
anhydrous MeOH, to give galactopyranoside 73. 
 
Scheme 4-1. Synthetic route to galactopyranoside 73. 
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As mentioned in Section 2.3.1, the arrangement of the protecting group chemistry is 
required for attachment of the sugars one at a time. The next step was to protect 
galactopyranoside 73 at all of the hydroxyl groups except that at O-4 position, which 
would be available to partake in the next coupling reaction. According to the original 
synthesis, the regioselectivity of allylation needed to be improved.  
4.2.1 Improved regioselectivity of allylation 
Reaction of sugar hydroxyl groups with organotin reagents, e.g., dibutyltin oxide 
produces dibutyl stannylene acetals as intermediates that, after the treatment with an 
alkyl halide, give rise to corresponding monosubstituted products. However, the 
structure of the stannylene intermediate is not completely understood but it has been 
suggested that in non-polar solvents, such intermediates are predominantly in dimeric 
forms (Figure 4-1).130 
 
Figure 4-1. Formation of dibutyl stannylene acetal and dimerisation. 
In a stannylene acetal monomer, the tin atom adopts a trigonal bipyramidal geometry. 
The apically bound oxygen atoms (Oa1 and Oa2) are more nucleophilic than the others; 
potentially the result of electron channelling from the tin atom and different effects of 
coordination.130,131 This activation is thought to lead to preferential Sn-O bond cleavage 
and bond formation of the apical oxygen atom with an electrophile, explaining the 
regioselectivity via dibutylstannylene acetals. Several studies showed that a 
dibutylstannylene acetal derived from a cis-diol on a pyranose ring generally gives a 
major product with an alkyl substituent at the equatorial position, whereas 
regioselectivities are usually poor in the case of trans-diols.132 
In the original synthesis in Section 2.3.1, a mixture of three compounds was obtained, 
demonstrating that the allylation of this trans-diol was not regioselective (Scheme 4-2). 
This observation is in the agreement with the hypothesis that the tin complex 
intermediate forming across the two equatorial positions will have similar reactivity. It 
might be more discriminating to use the tin acetal method with a 3,4-diol rather than a 
2,3-diol (Figure 4-2). A method for the selective allylation was thus required to improve 




Scheme 4-2. A non-regioselective allylation, giving a mixture of three products.  
 
Figure 4-2. Possible explanations for non-regioselective and regioselective 
allylation via stannylene acetal intermediates. 
Peters and co-workers have reported a successful selective O-3 allylation by reacting 
unprotected 4-methoxyphenyl galactopyranoside with dibutyltin oxide in toluene, then 
with AllBr/Bu4NBr in THF.
133 To simplify the literature process,133 an attempt was made 
to conduct both tin acetal formation and allylation in toluene only for unprotected 
galactopyranoside 73 containing 4-methoxycarbonylphenyl (Scheme 4-3). However, 
TLC analysis showed multiple products formed, which rendered it difficult to separate 
by flash column chromatography. This unsuccessful reaction gave mostly di-
substitution products, which was confirmed by mass spectrometric analysis. Following 
acetylation, 1H NMR analysis showed that an allyl group was not substituted on the O-4 
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position but the other position, which could be the O-2, O-3 or O-6 positions, was less 
conclusive. Hence, in an attempt to achieve better regioselectivity, another allylation of 
galactopyranoside 73 was carried out by formation of the tin acetal in toluene, and 
subsequently allylation in THF as described in the literature procedures.133 However, 
TLC analysis still showed formation of various products. After partial chromatographic 
purification, the sample was further subjected to 4,6-O-benzylidenation to yield 
compound 75. The position of the allyl group on galactopyranoside 75 was determined 
by acetylation with pyridine-acetic anhydride catalysed by DMAP. According to 1H NMR 
analysis, the downfield shift of the O-2 acetyl group confirmed that the allyl group was 
successfully attached to the O-3 position (Figure 4-3). Nevertheless, compound 75 was 
obtained in a very low isolated yield, as a result of difficulties in purification and non-
regioselective allylation.  
 
Scheme 4-3. Attempted synthesis of compound 74 and synthetic route to 
compound 75.  
Unfortunately, the above tin-mediated allylation reactions on unprotected 
galactopyranoside 73 were not sufficiently selective. This would be because of the 
similar reactivity of the hydroxyl groups on the molecules. An alternative route to a 





Figure 4-3. Confirmation of the presence of an allyl groups occupying at the O-3 
position by acetylation at the O-2 position (cf. proton numbering in Figure 8-1). 
1
H 
NMR spectra of a) galactopyranoside 75 and b) its acetylated product (500 MHz, 
CDCl3). 
Therefore, isopropylidenation of galactopyranoside 73 with 2,2-dimethoxypropane in 
the presence of p-toluenesulfonic acid was carried out and gave 3,4-acetal 76 (Scheme 
4-4). Benzylation of the remaining hydroxyl groups, followed by removal of the 
isopropylidene group, revealed the O-3 and O-4 hydroxyl groups of galactopyranoside 
77. Subsequent stannylene acetal-mediated 3-O-allylation provided galactopyranoside 
79 in a good yield with high regioselectivity. In this case, trying to distinguish between 
one equatorial and one axial hydroxyl groups worked successfully with tin chemistry 
because of their different reactivities. The presence of an allyl group at the O-3 position 
was confirmed by HMBC and HMQC experiments showing a correlation of the allyl 
group to H-3 (Figure 4-4). This result demonstrates a significant improvement in the 










Figure 4-4. Overlay of the HMQC (red) and HMBC (purple) spectra of 
galactopyranoside 79 (75 MHz, CDCl3) showed a correlation of C-allyl group to H-3 
indicating the attachment of an allyl group at the C-3 position. 
4.3 Synthesis of a disaccharide intermediate 
A gram-scale coupling reaction between glycosyl acceptor 79 (1.3 g) and 4-
methoxybenzoyl thioglycosyl donor 55 (1.7 g) was performed, which provided 
disaccharide 80 in 52% yield (Scheme 4-5). 1H NMR signals corresponding to a 
disaccharide with a -linkage was not found, suggesting an -selectivity greater than 




Scheme 4-5. Synthetic route to disaccharide 80. 
4.4 Selective deprotection: deallylation  
Deallylation of disaccharide 80 provided disaccharide 81 with a free O-3 hydroxyl group 
in a good yield (Scheme 4-6). Comparison of 1H NMR spectra showed the 
disappearance of the allyl group peaks that were present for compound 80, confirming 
the selective deprotection was successful (Figure 4-5), and ready to be used as a 
glycosyl acceptor for the synthesis of the target trisaccharide. 
 




Figure 4-5. A stacked plot of 
1
H NMR spectra of a) allylated compound 80 and b) 
deallylated compound 81 (500 MHz, CDCl3).  
4.5 Attaching another galactose residue to the disaccharide 
intermediate 
Glycosylation of disaccharide 81 with glycosyl donor 55 was carried out under the 
same conditions as used in the synthesis of the disaccharide intermediate, providing 
fully-protected trisaccharide 82 (Scheme 4-7).  
 
Scheme 4-7. Synthetic route to trisaccharide 82. 
1H NMR experiments of trisaccharide 82 at 301 and 328 K in CDCl3 were conducted to 
assess the molecular dynamics of the molecule. The spectrum at 301 K showed 
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broadened signals for some atoms, but the resonance peaks sharpened upon warming 
to 328 K (Figure 4-6). The expanded area displayed distinct proton signals, i.e., two 
signals for H-4 next to each PMBz ester group and three anomeric protons; one for 
each monosaccharide unit. The broadening of their anomeric signals was probably due 
to the rate of conformational exchange occurring on a similar time scale to that of the 
NMR experiment. Upon warming to 328 K, the rate of conformational exchange was 
increased and an average signal for two different conformational states was observed.  
The 1H NMR spectrum at a higher temperature also revealed the coupling constants of 
three anomeric protons, which were 2.3 Hz, 3.3 Hz, 6.7 Hz, corresponding to the two -
configurations, and one with -configuration, respectively. It is noteworthy that the 
proton-proton coupling constant of H-1 was slightly lower than the value obtained for 
disaccharide 81 (7.0 Hz) as well as for the deprotected trisaccharide (7.5 Hz).‡ The 
attachment of another galactose residue at the adjacent position was likely to affect the 
structural arrangement of the central galactose residue, which may have deviated from 
a perfect 4C1 chair conformation. The distortion of the bond angle between the coupled 
H-1 and H-2 protons might therefore cause a decrease in their coupling constants. 
However, other proton signals of trisaccharide 82, acquired at 301 and 328 K, were 
difficult to assign but they did not seem to broaden as for the anomeric proton signals, 
suggesting that the NMR signals broadening were not associated with the tumbling of 
the molecule.  
                                               




Figure 4-6.  Stacked plot of the entire 
1
H NMR spectra and the expanded area of 
trisaccharide 82 (500 MHz, CDCl3) a) at higher temperature (328 K) and b) at room 
temperature (301 K). The expanded area showed distinct proton signals, i.e., two 
signals for H-4 next to each C-4 ester group and three anomeric protons (2 × H-1 
and H-1). 
Two dimensional NMR experiments (i.e., COSY, TOCSY, HMQC, HMBC) acquired at 
331 K of trisaccharide 82 were also acquired in order to obtain sharpened peaks and to 
analyse the correlations between galactose residues. The overlayed HMBC and HMQC 
spectra of the trisaccharide 82 showed a correlation between one of the C-1 signals of 
the adjacent galactose units and the H-3 signal of the central galactose residue; the 
other C-1 signal coupled to the H-4 signal of the central galactose residue (Figure 4-7). 
Observation of these correlations enabled unambiguous assignment of the signals to 
each of the terminal galactose residues. 1H - 1H COSY and TOCSY spectra of 
trisaccharide 82 with the complete assignments of sugar proton resonances are shown 





Figure 4-7. Overlay of HMBC (red) and HMQC (blue) spectra of trisaccharide 82 
(75 MHz, CDCl3, 331 K) showed that the C-1 signals of the adjacent galactose 
units correlated with the signals of each H-3 and H-4 of the central galactose 
residue.  
4.6 Removal of the protecting groups 
Benzyl ether protecting groups were removed by hydrogenolysis of trisaccharide 82 to 
give trisaccharide 83, which was subjected to de-esterification to give fully-deprotected 
trisaccharide 27 containing a 4-methoxycarbonylphenyl group (Scheme 4-8). This 
compound will be used as a monovalent compound for the testing for inhibitory effect 
on LOX-1 and for further converting its ester group to a hydrazide group and attaching 





Scheme 4-8. Synthetic route to fully-deprotected trisaccharide 27. 
4.7 Conclusions 
The synthesis of an analogue of the lead trisaccharide containing a carboxyphenyl 
aglycone has been reinvented. After several attempts, the overall yield and the 
regioselectivity of the synthesis of a glycosyl acceptor precursor was significantly 
improved. This precursor was used for coupling with a thioglycosyl donor having a 4-
methoxybenzoyl group at the O-4 position, which resulted in a great improvement in -
selectivity. Subsequent deallylation and another glycosylation reaction, with the same 
glycosyl donor under the optimised conditions, were successful, leading to the 
formation of a protected trisaccharide. After deprotection, the analogous trisaccharide 
was ready to be further derivatised and used to attach to a multivalent scaffold. 
Evaluation of the novel analogues for their inhibitory activity against LOX-1 expressing 




Chapter 5: Carbohydrate-functionalised 





A part of this chapter has been discussed in the following article: “Templating 
carbohydrate-functionalised polymer-scaffolded dynamic combinatorial libraries with 
lectins” Mahon, C. S.; Fascione, M. A.; Sakonsinsiri, C.; McAllister, T. E.; Turnbull, W. 







Carbohydrate-protein interactions are typically of low affinity. Multivalency enhances 
the binding affinities by having multiple interactions that reinforce one another. The 
multivalency effect in synthetic systems can be reproduced through the attachment of 
multiple carbohydrate residues to multivalent scaffolds, e.g., nanoparticles, polymers 
and dendrimers.  
Among the synthetic multivalent forms of carbohydrate structures, glycopolymers have 
attracted much interest as tools to study the multivalent effects of carbohydrates to 
lectins (carbohydrate-binding proteins that are highly specific for carbohydrate 
moieties), cells and pathogens.134,135 Glycopolymers can be prepared either by the 
polymerisation of carbohydrate-bearing monomers or by the post-polymerisation 
glycosylation of synthetic polymers.136 Various polymer backbone monomers, e.g., 
polyacrylamides, poly(p-phenylene ethynylene),  have been incorporated in the 
glycopolymers (Figure 5-1).  
 
Figure 5-1. Representative examples of polymer scaffolds. 
Selected examples of carbohydrate-functionalised polymers will be highlighted here. 
Whitesides and co-workers first successfully synthesised polyacrylamides bearing 
pendant -sialoside groups which could inhibit the heamagglutination of influenza 
viruses. The authors suggested that the inhibitory potency depends on the 
polymerisation conditions and the sialic acid content of the polymers, demonstrating 
that multivalent polymers have amplified inhibitory effects.137  
Another example was the use of a fluorescent-labelled carbohydrate-functionalised 
poly(p-phenylene ethynylene) to detect multivalent pathogens, e.g. E. coli.138 
Multivalent interactions between mannose receptors on the bacterial pili and the 
mannosylated polymer could result in cell aggregation and allowed bacterial detection. 
More recently, the Gibson group successfully prepared galacto-functional polymers by 
a tandem post-polymerisation modification methodology for use as cholera toxin 
inhibitors.139 They used poly(pentafluorophenyl methacrylate) as the template scaffold 
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to react with two amino-functional alkynes  and 2-hydroxypropylamine (Scheme 5-1). -
D-Galactose residues were subsequently „clicked‟ on to pendant alkyne moieties to 
form galacto-functional polymers with varying sugar density, linker length and chain 
length. The series of glycopolymers was used to study the effect of carbohydrate-
binding site accessibility with their target lectins, i.e., the B-subunit of cholera toxin and 
peanut agglutinin. The latter lectin was used as a control because it binds to -
galactose.  Their results showed that the polymer with longer linkers exhibited 
increased inhibition of B subunit of cholera toxin, which was related to the depth of the 
binding pocket.  
 
Scheme 5-1. Preparation of galacto-functionalised polymers by a tandem post-
polymerisation modification. 1) amine (variable amounts)/triethylamine (TEA; 1 
equiv.)/ DMF, 5 h.; 2) GalN3 (1.5 equiv./CuBr/TBTA, DMSO).  
The Fulton group have developed the so called “polymer-scaffolded dynamic 
combinatorial library” (PS-DCL) concept which presents a new strategy to discover 
macromolecular receptors. Functionalised polymers were prepared by coupling 
different acylhydrazide residues onto an aldehyde-bearing polymer scaffold via 






 Preparation of a polymer scaffold dynamic combinatorial library by 
reaction of acylhydrazines (represented as open purple squares and open blue 
circles) with a polymer bearing aldehyde functionalities. Changes of the residual 
composition within the PS-DCL was induced upon addition of a molecular template, 
figure reproduced from reference 124.  
The reversible aspect of these linkages permits compositional changes on the polymer 
scaffold to favour products that bind to the target. Synthetic polymers and proteins, 
which were a 70 kDa poly(sodium-4-styrene sulfonate), bovine serum albumin (BSA) 
and bovine trypsin, were used as molecular templates. Upon the addition of different 
templates, the PS-DCL was shown to re-equilibrate and adapt its composition 
favouring binding to the specific template added, resulting in macromolecules with 
enhanced capabilities for molecular recognition. This approach could be used to 
generate synthetic recognition receptors for selected proteins and inexpensive antibody 
mimics. Moreover, using the same strategy, carbohydrate residues possessing a 
hydrazide group can be incorporated onto the same type of polymer scaffolds to form 
carbohydrate-functionalised polymer-scaffolded dynamic combinatorial libraries which 
will be further discussed in this chapter. 
5.2 Aims and objectives 
One of the aims of this chapter was to synthesise multivalent carbohydrate-based 
polymers presenting multiple copies of the target trisaccharide. These multivalent 
structures could aid in the development of more effective inhibitors with higher 
inhibitory potency towards LOX-1, a major receptor for Ox-LDLs involved in 
atherosclerosis initiation and progression. The inhibition by tri-galactoside polymers 
would be expected to block the binding of Ox-LDLs to its receptor, leading to a 
decrease in atherosclerotic plaque formation. One approach was to append 
carbohydrate compounds possessing reactive hydrazine groups to a multivalent 
polymer bearing aldehyde functions. In this chapter, the synthetic route to -mannosyl 
and -galactosyl hydrazides and the development of glycopolymer dynamic 
combinatorial libraries will first be presented. The derivatisation of the trisaccharide 
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ligand for LOX-1 with a hydrazine to the corresponding hydrazide will subsequently be 
discussed. Preparation of carbohydrate-functionalised polymers and a polymer without 
carbohydrate moieties, which would serve as inhibitors for LOX-1 and a control 
polymer respectively, will also be outlined. 
5.3 Synthesis of -mannosyl and -galactosyl hydrazides for making 
carbohydrate-functionalised polymer-scaffolded dynamic 
combinatorial libraries (PS-DCLs) 
In collaboration with Dr. C. Mahon and Dr. D. Fulton (School of Chemistry, University of 
Newcastle), -galactosyl and -mannosyl hydrazides were used to generate 
carbohydrate-functionalised polymer-scaffolded dynamic combinatorial libraries (PS-
DCLs), which were investigated further as macromolecular receptors for lectin 
templates.125  
5.3.1 Synthesis of -mannosyl and -galactosyl hydrazides 
-Galactosyl and -mannosyl hydrazides 86 and 89 were synthesised both by Dr. M. 
Fascione and C. Sakonsinsiri. The synthesis of mannosyl hydrazide 86 was achieved 
starting from acetylation of -D-mannose 84, followed by glycosylation of 4-
methoxycarbonylphenol. Following recrystallization from MeOH, -D-mannopyranoside 
85 was obtained (Scheme 5-2). The resulting compound was deacetylated under 
Zemplén conditions and was subsequently reacted with hydrazine monohydrate in 





Scheme 5-2. Synthetic route to mannosyl hydrazide 86. 
Similarly, galactose pentaacetate 33 was reacted with 4-methoxycarbonylphenol to 
form-galactopyranoside 87, which was deacetylated under Zemplén conditions 
(Scheme 5-3). The resulting compound 88 was subjected to hydrazinolysis, providing 
-D-galactopyranoside 89 possessing a hydrazide group. 
 
Scheme 5-3. Synthetic route to galactosyl hydrazide 89.  
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5.3.2 Templating carbohydrate-functionalised polymer-scaffolded dynamic 
combinatorial libraries with lectins 
This part of the work was performed by Dr. C. Mahon. The -mannosyl hydrazide 86 
and -galactosyl hydrazide 89 (Figure 5-3) were reversibly conjugated to an aldehyde-
functionalised polymer using acylhydrazone exchange chemistry (Figure 5-4), 
generating carbohydrate-functionalised polymer-scaffold dynamic combinatorial 
libraries (PS-DCLs).125 The PS-DCLs were prepared at pH 4.5. 
PS-DCLs exhibited compositional changes upon the addition of lectin templates. Two 
very different lectins used as molecular templates in the study were Con A, and the B-
subunit of E.coli heat labile toxin (LTB) with specificity for mannose-containing 
molecules and galactose-containing molecules, respectively.  
 
Figure 5-3. -Mannosyl hydrazide 86 (also called MAN) and -galactosyl 
hydrazide 89 (also called GAL) used for the synthesis of carbohydrate-





 Preparation of a carbohydrate-functionalised polymer-scaffold 
dynamic combinatorial library by conjugation of acylhydrazide functionalised 
carbohydrate residues onto an aldehyde-functionalised polymer scaffold. 
Compositional changes within PS-DCL were induced upon addition of a lectin, 
resulting in polymers of improved affinity for the lectin added, figure reproduced 
from reference 125.   
The initial residue composition of the polymer scaffold containing 86 and 89 was 
determined by 1H NMR spectroscopy as a ratio of 1.0:1.0. Upon addition of Con A, an 
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increase in the relative concentrations of mannose residues 86 and galactose residues 
89 was in a 1.2:1.0 ratio, indicating the polymer scaffolds have adapted their 
composition by preferentially incorporating the mannose residues with the loss of 
galactose residues (Figure 5-5). Upon addition of LTB a decrease occurred in the 
relative concentration of mannose and galactose residues to 0.8:1.0, suggesting that 
the polymer scaffolds have also incorporated galactose residues in preference to 
mannose residues. These carbohydrate-functionalised PD-DCLs were shown to 
undergo compositional changes upon the addition of lectin templates, with the polymer 
backbone incorporating residues that are preferentially recognised by the target lectin.  
Furthermore, templating carbohydrate-functionalised PS-DCLs with lectins proved to 









H NMR spectroscopic analysis (500 MHz, D2O, pH 4.5) of PS-
DCL before (t = 0 h) and after (t = 16 h) addition of Con A, highlighting the changes 
in intensity of the diagnostic anomeric resonances of GAL and MAN 16 h after 
addition of template. b) Effect of addition of lectin templates to PS-DCLs upon 
relative concentrations of GAL and MAN as a function of time, suggesting 
preferential incorporation of the carbohydrate residue preferred by the lectin added. 
There is no observed change in the relative concentrations of GAL and MAN in the 
absence of a lectin template, figure reproduced from reference 125.   
5.4 Preparation of the polymers with the LOX-1 ligand trisaccharide 
According to the PS-DCL method, the exchange process only happens when the 
system is at pH 4.5, and at pH 7 is no longer dynamic. Therefore, it is also possible to 
use these polymer scaffolds to prepare glycopolymers without necessarily exploiting 
the PS-DCL method.  
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Since the interaction of individual trisaccharide epitope with LOX-1 was weak, it was 
anticipated to increase the binding affinity to LOX-1 by attachment of trisaccharide 27 
(Figure 5-6) with the above described polymer scaffold. However, prior to the 
attachment, there is a need to derivatise the trisaccharide to the corresponding 
hydrazide.  
 
Figure 5-6. Chemical structure of trisaccharide 27. 
5.4.1 Derivatisation of the trisaccharide for attaching to a multivalent 
scaffold 
To derivatise the previously synthesised trisaccharide 27 (cf. Chapter 4), hydrazinolysis 
reactions of trisaccharide 27 were conducted under different conditions to produce a 
trisaccharide 90 having an aryl hydrazide (Table 5-1). The progress of the reactions 
was monitored by 1H NMR chemical shift changes in the aromatic proton signals. The 
aromatic proton NMR spectrum of the starting material 27 is shown in entry 1 of Table 
5-1. Due to the limited solubility of trisaccharide 27 in MeOH, which had been used for 
previous hydrazide syntheses, hydrazinolysis reactions of trisaccharide 27 were first 
attempted in deuterium oxide (D2O), while varying molar equivalents of hydrazine and 
reaction times. 1H NMR spectrum of the overnight reaction using one equivalent of 
hydrazine showed aromatic signals corresponding to a mixture of two products; 
however, some the starting material also remained in the solution. After adding 
additional hydrazine and heating at 70 °C for further 16 h, the starting material was 
completely consumed (Table 5-1, entry 2); but this reaction still provided a mixture of 
two compounds, which would render the isolation and purification laborious. On the 
assumption that the side reaction might be supressed by increasing the amount of 
hydrazine, another hydrazinolysis was attempted with an excess of hydrazine in water. 
The reaction was monitored by 1H NMR spectroscopy at 2 h, 3 h and 4 h. In spite of 
20-equivalent addition and 80 °C-heating, this hydrazinolysis did not proceed to 
completion and a mixture of two products still formed (Table 5-1, entry 3). These 
observations demonstrated that water might not be the best solvent for performing 
hydrazinolysis of the target trisaccharide.   
 
 
 Entry Solvent Hydrazine  Temp. Time 
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80 °C 4 h 
 
 





Table 5-1. Hydrazinolysis 






All previous hydrazinolysis reactions had been performed in methanol; for example, 
hydrazinolysis of -galactopyranside 73 with hydrazine monohydrate was successful in 
methanol as the solvent; giving rise to -galactosyl hydrazide 91 (Scheme 5-4).  
However, because of the poor solubility of the trisaccharide 27 in methanol, performing 
hydrazinolysis in methanol in was initially avoided.  
 
Scheme 5-4. Synthetic route to -galatopyranoside 91. 
After several attempts in D2O, hydrazinolysis of trisaccharide 27 was eventually 
successful in refluxing MeOH, despite its incomplete solubility, giving trisaccharide 90 
as a sole product (Table 5-1, entry 4). Aromatic proton signals of the product having an 
aryl hydrazide appeared at 7.75 ppm and at 7.32 ppm, whereas those of the starting 
material were at 8.04 ppm and 7.34 ppm. Disappearance of the methoxyl group peak 
that was present for the starting material was also observed, indicating the 
hydrazinolysis had been achieved. In addition, 13C NMR spectrum of the product did 
not show any signal corresponding to the methoxyl functional group that was present 
for the starting material.§  
5.4.2 Identification of the side-product formed in the reaction in D2O using 
1H NMR spectroscopy 
As LC-MS and HRMS analyses did not provide satisfactory results either by employing 
negative- or positive ion mode, 1H NMR spectroscopy was used to identify the side-
product formed when performed hydrazinolysis in D2O (Figure 5-7). The product 
mixture from entry 3 of Table 5-1 was lyophilised to remove the excess hydrazine. The 
sample was then treated with sodium hydroxide (2 equiv., D2O, 2 h) and neutralised 
with H+ ion exchange resin. Aromatic regions of the 1H NMR spectra of the starting 
material and different samples were compared. Aromatic proton signals of the 
attempted hydrazinolysis (Figure 5-7b) showed a mixture of three compounds, which 
was comparable with the starting trisaccharide (Figure 5-7a), the desired hydrazide 
                                               
§ For a detailed assessment of compound 90, see experimental.  
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product (Figure 5-7d), and the hydrolysed product after the treatment with sodium 
hydroxide and ion exchange H+ resin (Figure 5-7c). This experiment with sodium 
hydroxide proves that the side-product formed from hydrazinolysis in D2O was a 
trisaccharide containing a carboxyl group. This might be because there was more 
water than hydrazine present in the solution to react with the ester functionality on the 
trisaccharide. Methanol was thus the solvent of choice for hydrazinolysis of 
carbohydrates. Despite the poor solubility in MeOH, the hydrazinolysis could be carried 
out in suspension. 
 
Figure 5-7. Comparison of the aromatic regions of the 
1
H NMR spectra of: a) the 
trisaccharide with an aryl ester group (starting material), b) the attempted 
hydrazinolysis in D2O which still contains the starting material, c) the hydrolysed 
products of a mixture from previous attempted reaction and d) the desired 
hydrazinolytic product which was formed by the hydrazinolysis in MeOH. All 
1
H 
NMR spectra were acquired at 500 MHz in D2O. 
5.4.3 Synthesis of carbohydrate-functionalised polymers  
Protein-carbohydrate interactions are generally weak; presentating multiple 
carbohydrate moieties on a multivalent scaffold could be a means to improve the 
binding affinity. As mentioned in Section 5.3.2, the collaborative work with Dr. C. 
Mahon and Dr. D. Fulton showed that an aldehyde-functionalised polymer could be 
used as a multivalent scaffold to conjugate with mannose- and galactose-functionalised 
arylhydrazide residues.125 It was therefore anticipated that employing the same strategy 
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would allow the preparation of a target trisaccharide-functionalised polymer for the 
increased inhibition of the trisaccharide with LOX-1 receptor.  
All of the following polymer preparations were performed by Dr. C. Mahon. An 
aldehyde functionalised polymer containing approximately 24 aldehyde units was 
prepared following a general reported procedure of Jackson and Fulton (Scheme 5-
5).124,140 This aldehyde functionalised polymer was then used to conjugate with the 
target trisaccharide 90, using the same procedure as used for conjugating mannose- 
and galactose-functionalised arylhydrazide residues, to form a glycopolymer containing 
approximately 24 units of trisaccharide epitopes (Figure 5-8).125  
 
Scheme 5-5. Synthesis of an aldehyde-functionalised polymer with variation of 
numbers of monomers. 
Also, a monogalactoside polymer, which contains approximately 24 units of -
galactopyranoside residues, was prepared (Figure 5-9) and would be used to assay as 
an inhibitor of LOX-1. -Galactopyranoside 89 was selected to be tested because -
glycosidic linkages were thought to be important for the binding of carbohydrates to 





Figure 5-8. Cartoon presentation of the attachment of target trisaccharide residues 




Figure 5-9. Cartoon presentation of the attachment of -galactopyranoside 
residues 89 onto an aldehyde-functionalised polymer.  
Another polymer containing ethylene glycol units instead of carbohydrate residues 
(Scheme 5-6) was also synthesised by Dr. C. Mahon and would be used as a control 





Scheme 5-6. Synthesis of a control polymer having ethylene glycol units instead of 
carbohydrate residues. 
The generated mono- and tri-galactoside glycopolymers as well as the control polymer 
without sugar moieties appeared to be completely soluble in phosphate-buffered saline 
(PBS) pH 7.4. These synthesised glycopolymers in PBS buffer will be assayed for 
LOX-1 inhibitory effects.  
5.5 Conclusions  
-Galactosyl and -mannosyl hydrazides were synthesised and used for the 
generation of carbohydrate-functionalised polymer-scaffold dynamic combinatorial 
libraries (PS-DCLs) by hydrazine exchange under acidic conditions. These polymers 
induced compositional changes in response to addition of the lectin templates, thus 
producing polymers of enhanced binding affinities towards the lectin template. 
The compositional exchange process in the PS-DCLs only occurs at pH 4.5, but not at 
pH 7. However, these polymers can be used to prepare non-dynamic glycopolymers for 
other purposes, e.g., for preparation LOX-1 polymeric carbohydrate based inhibitors. A 
trisaccharide was therefore derivatised and attached to these polymers for further study. 
Derivatisation of the trisaccharide with hydrazine monohydrate in D2O was problematic, 
giving a hydrolysed trisaccharide with a carboxylic group. This side-product was 
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identified by the treatment of an attempted reaction with sodium hydroxide and 
analysed by 1H NMR spectroscopy. Hydrazinolysis of the trisaccharide was eventually 
achieved in refluxing MeOH despite its insolubility in MeOH.  
Preparation of glycopolymers was performed by Dr. C. Mahon. As expected, the 
derivatised trisaccharide containing a reactive hydrazide group was successfully 
attached to an aldehyde-functionalised polymer using the same procedures as for the 
preparation of polymers conjugated with -mannosyl and -galactosyl hydrazides. In 
addition, a polymer containing approximately 24 of -galactopyranoside residues was 
also synthesised and was to be used to compare the inhibitory effects on LOX-1 with 
the synthesised polymer bearing trisaccharide residues. Another polymer containing 
ethylene glycols instead of sugar residues was prepared to use as a control polymer for 
LOX-1 inhibition assays. Polymeric multivalent carbohydrate structures incorporating 
with mono-and trisaccharide residues as well as the control polymer were successfully 
developed and will be evaluated for their inhibitory effects with LOX-1 receptor.  
Multivalency would be expected to enhance the binding affinity of the inhibitors to LOX-
1, which in turn would efficiently block the binding of OxLDL to its receptor and 









Chapter 6: Synthesis and biological 
evaluations of multivalent probes for 




This chapter is based upon the following article: “Compact, polyvalent mannose 
quantum dots as sensitive, ratiometric FRET probes for multivalent protein-ligand 
interactions” Guo, Y.; Sakonsinsiri, C.; Nehlmeier, I.; Fascione, M.A.; Zhang, H.; Wang, 
W.; Pöhlmann, S.; Turnbull, W.B.; Zhou, D. Angewandte Chemie International Edition, 





DC-SIGN and its homologue DC-SIGNR are C-type (i.e., calcium-dependent) lectins 
that play important roles in HIV/Ebola infection by recognising the viral surface 
glycoproteins via their clustered carbohydrate recognition domains (CRDs). Evidence 
showed that notwithstanding of the 77% shared amino acid identity and similar 
tetrameric structure, they possess different glycan binding affinity, specificity and viral 
transmission. For instance, DC-SIGN recognises and transmits some HIV strains more 
efficiently than DC-SIGNR,141 while DC-SIGNR but not DC-SIGN has the ability to 
recognise the West Nile Virus.116 DC-SIGN and DC-SIGNR are specific to high 
mannose glycan structures; however, only DC-SIGN recognises fucose glycans 
including Lewis-type blood group antigens.99,117 The two homologous proteins are 
differently expressed on different cell types.  DC-SIGN is expressed on the surface of 
dendritic cells, macrophages and placenta whereas DC-SIGNR is present on 
sinusoidal endothelial cells in the liver and on endothelial cells in lymph node sinuses 
and placental villi but not on dendritic cells.34,45,98 However, the biological functions and 
ligand binding properties of DC-SIGN and DC-SIGNR are still not yet thoroughly 
understood.  
Nanomaterials could be used as scaffolds to display multiple copies of carbohydrates 
and to increase the binding strength for multivalent interactions. Several studies have 
been directed towards targeting DC-SIGN using multivalent carbohydrate structures, 
e.g., glycomimetics, glycoclusters, glycodendrimers, glycodendrinanoparticles, 
glycodendrofullerenes.36,41,42,142-148 Quantum dots (QDs) recently attracted increasing 
interest because of their particular photoluminescence properties, which can be 
manipulated to a specific wavelength depending on their size. Generally, carbohydrate-
functionalised quantum dots have been used as a useful tool to investigate multivalent 
carbohydrate-protein interactions, binding specificity, detection of lectins and bacteria, 
cellular monitoring and imaging, and as nanosensors.149-153 The first in vitro application 
of glyco-QDs as fluorescent bio-labels was successfully performed by Robinson et 
al.149 CdSe/ZnS core/shell QDs were functionalised with mannose (Man) and -N-
acetyl glucosamine (GlcNAc) and used to stain pig, mouse, and sea-urchin sperm. The 
optical properties of glycan-functionalised QDs were detected by confocal scanning 
microscope imaging. The results demonstrated that GlcNAc-QDs distinctively 
accumulated only at the sperm heads while Man-QDs were spread over the whole 
sperm body due to specific distribution of the Man and GlcNAc receptors.  
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Seeberger et al. have succeeded in preparing carbohydrate-capped CdSe/ZnS 
core/shell QDs not only for in vitro imaging but also in vivo liver targeting in mice. They 
demonstrated that QDs capped with D-galactose were preferentially bound to 
asialoglycoprotein receptor-mediated endocytosis in vitro. Fluorescence microscopy 
also revealed that QDs capped with D-mannose and D-galactose sequestered in the 
liver.152 Furthermore, QDs conjugated to carbohydrates or viral coat proteins specific to 
DC-SIGN, e.g., LewisX and the HIV-1 envelope protein gp120 have also been utilised 
as a means to visualise the binding and internalisation of antigens mediated by DC-
SIGN in living cells.153 Galan and co-workers also successfully applied QDs 
functionalised with different types of sugar for intercellular localisation in HeLa and 
SV40 epithelial cells. The glycan type on QDs surface could affect cellular uptake and 
lactose-QDs could serve as a „Trojan horse‟ to help internalisation of QDs with other 
non-internalisable sugar moieties into the cell.150 Another example was the use of 
CdSe/ZnS QDs functionalised with lactose, melibiose, and maltotriose for detection of 
lectins, i.e., soybean agglutinin (SBA), jacalin, and Concanavalin A (Con A) through 
agglutination assay and monitored by light scattering.151 According to the results, 
melibiose-QDs selectively bound to SBA and were specifically de-agglutinated using -
D-galactose, confirming the specific and multivalent carbohydrate-protein interaction.  
Despite all recent progress made for the use of QD in glycobiology, carbohydrate-
capped QDs have not yet been applied to probe multivalent protein-ligand interactions 
via Förster resonance energy transfer (FRET), which is a technique of fluorescence 
resonance energy transfer, from a donor fluorophore to an acceptor fluorophore, 
allowing investigation of molecular interactions. Possessing fluorescent properties 
enables QDs to serve as energy donors for FRET, but there is still a need to develop a 
more efficient method to attach many sugar residues on the surface without influencing 
the optical properties of QDs to form dense and compact QDs which are required for 
multivalent binding and detectable FRET signals.154 Therefore, the design and 
preparation of compact and dense carbohydrate-capped QDs to serve as multivalent 
probes for carbohydrate-binding proteins, e.g., DC-SIGN and DC-SIGNRR via FRET 
would provide a better understanding of the roles of proteins in host-pathogen 
interactions. 
6.2 Aims and objectives 
This chapter describes successful synthetic routes to azide-appended mannose 
residues in form of mono- and disaccharides and an efficient and convenient method to 
prepare mannose-capped CdSe/ZnS core/shell quantum dots by cap-exchange using 
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functional ligands appending a deprotonated dihydrolipoic acid (DHLA) moiety. A series 
of mannose-functionalised QDs were prepared and evaluated, for the first time, for the 
binding properties with dye-labelled DC-SIGN and DC-SIGNR using FRET and viral 
inhibition assays. These should provide an insight into how DC-SIGN interacts with 
viral ligands and a better understanding of the structural/functional parameters 
influencing the ligand-receptor binding of DC-SIGN and DC-SIGNR.  
6.3 Synthesis of an azido-mannopyranoside 
Acetylated azido-mannopyranoside 92 was prepared by reaction of mannose 
pentaacetate 91 with 2-2-(2-chloroethoxy)ethoxyethanol in the presence of BF3OEt2 
in dichloroethane and subsequent treatment with sodium azide and 
tetrabutylammonium iodide in DMF (Scheme 6-1). Zemplén deacetylation of the 
resulting compound 92 gave azido-mannopyranoside 29 in a good yield. A proton-
undecoupled NMR experiment revealed a one bond 13C - 1H coupling constant of 169 
Hz, corresponding to -configuration.155   
 
Scheme 6-1. Synthetic route to azido-mannopyranoside 29. 
6.4 Multivalent mannose quantum dots for the study of 
carbohydrate and DC-SIGN and DC-SIGNR interactions 
In collaboration with Dr. Y. Guo and Dr. D. Zhou (School of Chemistry, University of 
Leeds), synthetic azido-mannopyranoside 29 was attached to lipoic acid-poly (ethylene 
glycol)-cyclooctyne linkers**, i.e., LA-EG3-cyclooctyne and LA-PEG13-cyclooctyne, by 
strain-promoted alkyne-azide cycloaddition (Scheme 6-2a). This process provided 
                                               
** Linkers were supplied by Dr. D. Zhou, School of Chemistry, University of Leeds. 
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lipoic acid-poly(ethylene glycol)-mannose, which were referred to as LA-EG3-Man and 
LA-PEG13-Man. Following reduction, the corresponding dihydrolipoic forms (DHLA-
PEG13-Man and DHLA-EG3-Man) were obtained. Lipoic acid-negatively charged 
(zwitterionic) ligand (LA-ZW)†† as also prepared (Scheme 6-2b). The requisite reduced 
form DHLA-ZW was used as a diluent.  
                                               




Scheme 6-2. Preparation of: a) Dihydrolipoic acid-poly(ethylene glycol)-mannose 
(DHLA-PEGn-Man, where n = 3 or 13) and b) Dihydrolipoic acid-zwitterionic ligand 
(DHLA-ZW). N.B. Both LA-EG3-cyclooctyne and LA-PEG13-cyclooctyne were used 
as a mixture of stereosiomers. Both LA-EG3-Man and LA-PEG13-Man were formed 
as a mixture of regioisomers, only the predominant stereoisomer is shown.  
The ligands were designed to each comprise a DHLA moiety for strong chelative QD 
binding; a PEG linker for resisting non-specific adsorption and imposing high stability 
and biocompatibility; and a mannose residue for specific protein binding. The DHLA-
appended PEG ligands functionalised with mannose could therefore provide an 
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effective cap-exchange of commercially available CdSeS/ZnS quantum dots (QDs, 
~4.2 nm diameter, EM ~560 nm) in the presence of sodium hydroxide using MeOH 
and chloroform as a solvent mixture. This highly efficient cap-exchange approach leads 
to preparation of compact, dense polyvalent mannose-QDs with varying PEG chain 
length and mannose density (Figure 6-1).156 The estimation of carbohydrate loading on 
the QDs was performed using the phenol sulfuric acid method157 by measuring the 
separated DHLA-PEGn-Man ligands and comparing the concentration to the starting 
material. The concentration of mannose was determined by comparison to a 
standardised curve. The levels of glycan polyvalency were found to be 330±80 and 
170±30 for QD-EG3-Man and QD-PEG13-Man respectively, which were considered as 
unprecedented high levels of sugar loading per dot. Dynamic light scattering (DLS) 
analysis also showed hydrodynamic diameters (Dh) of 8.9 for QD-EG3-Man and of 9.6 





 (A) Structures of DHLA-appended PEG ligands functionalised with 
mannose (i.e., DHLA-EG3-Man and DHLA-PEG13-Man); Preparation of mannose-
capped QDs (B) QD-PEG13-Man (C) QD-EG3-Man (D) QDs capped with mannose 
and DHLA-zwitterion (DHLA-ZW) spacer ligand, figure reproduced from reference 






 Size distribution histograms of: (A) QD-PEG13-Man and (B) and QD-
EG3-Man, measured by DLS, figure reproduced from reference 156.   
It should be noted that the preparation of mannose-capped QDs, starting from LA-
PEG13-cyclooctyne or LA-EG3-cyclooctyne, and the DLS analysis were performed by C. 
Sakonsinsiri and Dr. Y. Guo. Prepared QDs, including QD-EG3-Man, QD-PEG13-Man 
and QDs diluted with a DHLA-ZW spacer ligand were used for biological evaluations, 
which are discussed in Section 6.5. 
6.5 Biological evaluations  
6.5.1 Binding studies using QD-FRET technique  
This part of the work was performed by Dr. Y. Guo. Previously-prepared QD-EG3-Man 
and QD-PEG13-Man (collectively referred to as QD-PEGn-Man) were tested for the 
binding with dye-labelled DC-SIGN and DC-SIGNR, two closely related receptors of 
HIV/Ebola virus, using a sensitive, ratiometric FRET assay. DHLA-ZW capped QD was 
also used as a control. FRET interactions between QD-PEGn-Man (donors) and two 
proteins DC-SIGN and DC-SIGNR (acceptors) that were labelled with fluorescent dye 






 Schematic representation of the FRET technique used to investigate 
multivalent interactions between carbohydrate-recognition domain (CRD) of 
labelled DC-SIGN and DC-SIGNR and PEG terminated mannose-capped QDs, 
figure reproduced from reference 156.   
It was found that both QD-EG3-Man and QD-PEG13-Man specifically bound to DC-
SIGN, but not to its closely related receptor DC-SIGNR (Figure 6-4). Stronger FRET 
signals and more severely quenched QD fluorescence were observed for DC-SIGN 
binding to QD-EG3-Man over QD-PEG13-Man, indicating more efficient FRET in the 
former pair with a shorter PEG chain (Figure 6-4AB). Presumably, this might be 
because shorter linker in the QD-EG3-Man brings the QD and fluorophore into closer 
proximity. An observed weak FRET responses of the dye-labelled DC-SIGNR to both 
QD-EG3-Man and QD-PEG13-Man (Figure 6-4CD) were barely stronger than those for 
the monomeric CRD (Figure 6-4E) and for the DHLA-capped control QD (data not 
shown), demonstrating minimal QD-DC-SIGNR binding. Ratiometric analysis of donor 
and acceptor signals was used. This detection of FRET changes could provide more 
accurate results than analysing only the absolute fluorescence intensity by reducing 
instrument noise and signal perturbations. Also, an accurate measurement of the 
concentration of the fluorophore is not required when measuring the ratio changes. The 
apparent FRET ratio (I626/I554) for DC-SIGN was found to follow typical binding curves 
(Figure 6-4F), whereas the signals measured for DC-SIGNR remained low and 
comparable to non-specific adsorption throughout the concentrations tested. In spite of 
the high overall amino acid sequence identity of the two proteins, these FRET data 
suggested that QD-PEGn-Man could remarkably discriminate DC-SIGN over DC-
SIGNR, notably in the case of QD-EG3-Man. Therefore, this rapid, sensitive and 
recently established QD-FRET technique could be used for probing multivalent 
carbohydrate-protein interactions as well as for opening up a new method for targeting 






 Fluorescence spectra of the donor-acceptor pair: (A) DC-SIGN + 
QD-PEG13-Man; (B) DC-SIGN + QD-EG3-Man; (C) DC-SIGNR + QD-PEG13-Man; 
(D) DC-SIGNR + QD-EG3-Man; (E) DC-SIGN CRD monomer + QD-EG3-Man. (F) 
Correlation between the FRET ratio and the protein concentrations, figure 
reproduced from reference 156.   
6.5.2 Viral inhibition assays 
This part of the work was performed by Dr. I. Nehlmeier and Dr. S. Pöhlmann (Infection 
Biology Unit, German Primate Center, Gottingen, Germany). The binding specificity 
between QD-EG3-Man and DC-SIGN was further verified by viral inhibition assays, 
following Pöhlmann and Hofmann-Winkler‟s published method.158 Briefly, human 
embryonic kidney cells (293T) were transfected with plasmids encoding DC-SIGN and 
DC-SIGNR or a control transfected with empty plasmid (pcDNA). The cells were 
washed at 6 h post transfection and further cultivated at 37 °C, 5% CO2 in Dulbecco's 
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modified eagle medium (DMEM) containing 10% fetal bovine serum (FBS). At 48 h 
post transfection, after twice treatments with different concentrations of QD-EG3-Man, 
murine leukemia virus (MLV) vectors, retroviral vector encoding luciferase gene, 
bearing either Ebola virus glycoprotein (EBOV-GP) or vesicular stomatitis virus 
glycoprotein (VSV-G), as a control, was used to transduced with the cells. At 72 h after 
transduction, luciferase activities were measured in cell lysates. The EBOV-GP-bearing 
MLV vector (MLV-EBOV-GP) would bind specifically to cell surface DC-SIGN and DC-
SIGNR and facilitate vector cell entry and enhance gene transduction, whereas VSV-G 
bearing MLV vector (MLV-VSV-G) would not bind to DC-SIGN and DC-SIGNR and 
hence did not affect transduction efficiency via these receptors. An increase in 
transduction efficiency was observed on expression of DC-SIGN and DC-SIGNR 
comparing to the pcDNA negative controls (Figure 6-5A). QD-EG3-Man treatment 
significantly reduced the transduction efficiency of DC-SIGN positive cells in a dose-
dependent manner, presumably by inhibiting cell surface DC-SIGN from binding to the 
MLV-EBOV-GP vector and did not induce the vector entry. In contrast, transduction of 
cells expressing DC-SIGNR was unaffected by QD-EG3-Man. Moreover, QD-EG3-Man 
did not affect the transduction driven by the control MLV vector bearing vesicular 
stomatitis virus glycoprotein (MLV-VSV-G), which did not bind to DC-SIGN and DC-
SIGNR (Figure 6-5B). These observations matched to our previous results on the QD‟s 
high affinity to DC-SIGN, but minimal to DC-SIGNR, confirming the specific QD-DC-






 Impact of QD-EG3-Man on viral inhibition. Human 293T cells 
expressing DC-SIGN, DC-SIGNR or empty plasmid (pcDNA) were treated with QD-
EG3-Man (at 0, 62.5 and 250 nm). Cells were transfected with: (A) murine 
leukaemia virus (MLV) vectors bearing Ebola virus glycoprotein (MLV-EBOV-GP) 
or (B) the control vesicular stomatitis virus glyco-protein (MLV-VSV-G) for 
delivering luciferase gene. Luciferase activities in the lysates were determined. In 
the case of MLV-EBOV-GP, the difference between untreated and treated with 250 
nM QD-EG3-Man is statistically significant (p = 0.024, from two-tailed students t-
test), figure reproduced from reference 156.   
According to QD-FRET study and cell-based assay, QD-PEGn-Man has specificity for 
DC-SIGN over DC-SIGNR. We reasoned that the CRDs tetramer of DC-SIGN are 
disposed differently comparing to that of DC-SIGNR, that is, the CRDs of DC-SIGN are 
facing upwardly along the coiled-coil axes, which are readily accessible for multivalent 
binding with the QD-PEGn-Man. In contrast, the CRDs of DC-SIGNR tetramer are 
projecting sideways, which render it unavailable to bind multivalently to the QD (Figure 







 (A) Schematic representation of the structure of DC-SIGN and DC-
SIGNR monomer; proposed ligand-receptor binding modes between the QDs and: 
(B) DC-SIGN or (C) DC-SIGNR due to their different orientations of tetrameric 
CRDs, figure reproduced from reference 156.   
From this perspective, the different spatial CRD arrangements between DC-SIGN and 
DC-SIGNR are potentially associated with their distinct ligand-binding properties and 
their non-identical physiological roles. By presenting all of the DC-SIGN binding sites in 
the same direction, DC-SIGN on dendritic cells would allow interactions with a wider 
range of glycan ligands, compared to DC-SIGNR, as well as rapid antigen 
internalisation and presentation to T-cells.99,117 On the other hand, the binding of the 
outward-facing CRDs of the endothelial cell surface adhesion receptor DC-SIGNR 
could only occur with certain spatial orientations of ligands.  
6.6 Synthesis of the azido-disaccharide analogue 
1,2-Mannobiose is thought to be a better ligand for DC-SIGN159 and its disaccharide 
mimics have been reported to be good ligands for DC-SIGN.41 The objective of this 
section was  therefore to synthesise azide-bearing 1,2-mannobiose 31 (Figure 6-7) and 
evaluate further the binding of DC-SIGN and DC-SIGNR and carbohydrate-capped 













Figure 6-7. Structure of target dimannosyl azide 31. 
6.6.1 Attempted synthesis of the azido-disaccharide analogue starting 
from the azido-monosaccharide version 
An attempt was made to synthesise the target dimannosyl azide using azido-
mannopyranoside 29 as a starting material. Diacetal 93 was synthesised by the 
method of Ley and co-workers:160 Azido-mannopyranoside 29 was selectively protected 
at the O-3 and O-4 positions by treatment with 2,3-butanedione and 
trimethylorthoformate in the presence of p-toluene sulfonic acid in refluxing methanol, 
giving the corresponding butane diacetal 93 in 50% yield (Scheme 6-3). The primary 
alcohol of the resulting diol 93 was further reacted with tert-butyldimethylsilyl chloride 
(TBDMSCl) and imidazole to selectively protect the O-6 position, providing 
mannopyranoside 94.  
 




A small sample of resulting mannopyranoside 94 was acetylated using pyridine-acetic 
anhydride, catalysed by DMAP. 1H NMR analysis of its acetylated derivative 
demonstrated that the acetate group was attached to the O-2 position on basis of the 
downfield shift of the proton attached to C-2 bearing an acetate group (Figure 6-8). 
This indicates that the tert-butyldimethylsilyl (TBDMS) ether protecting group was 
attached at the O-6-position. With a free hydroxyl group at the position C-2, azido-
mannopyranoside 94 was used as a glycosyl acceptor for attempts to glycosylate with 




H NMR spectra of a) mannopyranoside 94 and b) its acetylated 
product (500 MHz, CDCl3), confirming that an acetyl protecting group was attached 
at the O-2 position and a tert-butyldimethylsilyl (TBDMS) ether protecting group 
was at the O-6-position (cf. proton numbering in Figure 8-1). 
Next, trichloroacetimidate donor 95 was prepared in a two-step process from mannose 
pentaacetate 91 (Scheme 6-4). Glycosylation reactions of mannopyranosyl imidate 95 
with the earlier synthesised azido-mannopyranoside 94 were carried out in DCM using 
either TMSOTf or BF3OEt2 as a promoter. In the case of TMSOTf, the formation of the 
desired product 96 was not observed by LC-MS analysis. Instead, one of the LC-MS 
peaks at a m/z ratio of 804.3 correlated to a disaccharide analogue without a TBDMS 
ether protecting group. The resulting loss of the latter protecting group was probably 




Scheme 6-4. Attempted synthesis to azido-disaccharide analogue 96. 
Nevertheless, changing the promoter to BF3OEt2 still did not yield the desired product 
96, suggesting the trichloroacetimidate donor 95 was not reactive enough for the 
glycosylation of this glycosyl acceptor or vice versa. Thus, another type of glycosyl 
donor, such as thioethyl glycoside was investigated and is discussed further in this 
section (cf. Scheme 6-6). Also, as in the previous glycosylation reaction, the use of 
excessive TMSOTf probably caused the removal of the TBDMS ether protecting group. 
Alternatively, tert-butyldiphenylsilyl (TBDPS) ether was used as for protection of C-6 
hydroxyl group because its more bulky substituents could increase resistance to 
hydrolysis. Moreover, according to the literature, this TBDPS ether protecting group 
has been used to protect the O-6 position of a fluoroglycoside bearing butane-2,3-
diacetal protecting group.161 To synthesise azido-mannopyranoside 97, the previously 
synthesised diol 93 was treated with TBDPSCl in the presence of imidazole (Scheme 
6-5).  
 
Scheme 6-5. Synthetic route to azido-mannopyranoside 97. 
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A small sample of azido-mannopyranoside 97 was acetylated using pyridine-acetic 
anhydride, catalysed by DMAP. 1H NMR analysis of the acetylated compound showed 
an acetate group was attached to the O-2 position, implying that the TBDPS ether 
protecting group was successfully attached to the O-6 position (Figure 6-9). Azido-





H NMR spectra of a) mannopyranoside 97 and b) its acetylated 
product (500 MHz, CDCl3), confirming that an acetyl protecting group was attached 
at the O-2 position and a tert-butyldiphenylsilyl (TBDPS) ether protecting group 
was at the O-6-position (cf. proton numbering in Figure 8-1).  
An attempt was made to couple glycosyl acceptor 97 with thioethyl glycosyl donor 98‡‡ 
using NIS/TMSOTf as a promoter system (Scheme 6-6). TLC and LC-MS analyses 
demonstrated that the activated glycosyl donor was formed, but it did not react with the 
acceptor. The hydrolysed donor was also present in the reaction mixture, implying that 
the acceptor 97 was not reactive enough to engage in the glycosylation. Low reactivity 
might be caused by either the presence of the bulky TBDPS group at the O-6 position 
of the glycosyl acceptor or by the presence of the polyethylene glycol (PEG)-azide at 
                                               




the anomeric position that makes the free hydroxyl group less accessible for 
glycosylation reaction. 
 
Scheme 6-6. Attempted synthesis of azido-mannopyranoside 99. 
6.6.2 Successful synthesis of the azido-disaccharide analogue starting 
from D-mannose tetraacetate 
An alternative approach was to synthesise mannopyranosyl acetate 101 (Scheme 6-7), 
having a free hydroxyl group at C-2 position, following a procedure of Deferrari et al.,162 
mannopyranosyl acetate 101 was successfully prepared from D-mannose 100 in a yield 
of 18%, which was similar to the yield reported in the literature.  
 
 
Scheme 6-7. Synthetic route to mannopyranosyl acetate 101. 
Next, the couplings of acceptor 101 and mannosyl imidate 95 using either TMSOTf or 
BF3OEt2 as an activator were successfully performed, giving fully-acetylated 
mannobiose 102 (Table 6-1). The use of BF3OEt2 gave a better yield comparing to 
TMSOTf. However, performing BF3OEt2-mediated reactions for 4.5 h or 20 h did not 













Activator Temperature Time Yield  
1 2 TMSOTf -30 °C  -8 °C 3 h 21% 
1 1 BF3OEt2 -50 °C  2 °C 4.5 h  41% 
1 1 BF3OEt2 -50 °C  r.t. 20 h 47% 
The 13C - 1H coupling constants of anomeric carbons of acetylated mannobiose 102 
were determined by a gated decoupled method (Figure 6-10). The observed coupling 
constants for the anomeric carbon atoms were 174 Hz and 162 Hz, supporting the 
assignment of - and -configurations, respectively.155 Interestingly, a doublet of 
doubles with large and small coupling constants (174 Hz and 6 Hz) for the -anomeric 
carbon signal resonating at 98.3 ppm was observed. This splitting pattern is probably 
due to the couplings of the anomeric carbon to the attached proton (H-1) as well as to 
the proton at C-2 position (H-2) and possibly is arise from the specific conformation of 
this protected disaccharide. However, there does not appear to be any literature 




Figure 6-10. Gated decoupled 
13
C spectrum of dimannose 102 (500 MHz, CDCl3) 
showing a doublet of doublets with a large and a small coupling constants (174 Hz 
and 6 Hz), resonating at 98.3 ppm and a double with a coupling constant of 162 Hz 
resonating at 91.0 ppm. -, -Configurations were determined according to their 
coupling constants. 
As the 1H-decoupled carbon (13C) spectrum enabled - and -configurations of 
individual mannose residue to be distinguished; it was therefore possible to determine 
the direct carbon to hydrogen connectivity using HMQC spectroscopy. The 
corresponding HMQC spectrum showed the correlation between the anomeric carbon 
and the anomeric proton of each mannose residue, permitting the assignment of 











C HMQC spectrum of acetylated mannobiose 102 (500 
MHz, CDCl3), showing the correlation between anomeric carbon and anomeric 
proton of each mannose residue. 
Anomeric deacetylation of acetylated mannobiose 102 with hydrazine acetate and 
subsequent reaction with trichloroacetonitrile gave of mannobiosyl imidate 103 
(Scheme 6-8). Boron trifluoride diethyl etherate-mediated coupling of 2-[2-(2-
chloroethoxy)ethoxy]ethanol with imidate 103 yielded acetylated dimannosyl azide 104. 
The obtained compound was deacetylated under Zemplén conditions to give fully 




Scheme 6-8. Synthetic route to fully deprotected azido-mannopyranoside 31. 
6.7 Multivalent di-mannose quantum dots for the study of 
carbohydrate and DC-SIGN and DC-SIGNR interactions 
This part of the work was performed by E. Poole and Dr. Y. Guo. In a similar fashion to 
the preparation of mono-mannose-capped QDs, azido-di-mannose residue 31 was 
attached to either LA-EG3-cyclooctyne §§  or LA-PEG10-cyclooctyne, ***  by strain-
promoted alkyne-azide cycloaddition, giving LA-EG3-Man--1,2-Man and LA-PEG10-
Man--1,2-Man (Scheme 6-9). After reduction, the corresponding dihydrolipoic forms 
(DHLA-EG3-Man--1,2-Man and DHLA-PEG10-Man--1,2-Man) were obtained. DHLA-
ZW was also used as a control QD, of which the preparation was previously described 
in Section 6.4 (Scheme 6-2b).  
                                               
§§ Linker was supplied by Dr. D. Zhou, School of Chemistry, University of Leeds. 





Scheme 6-9. Preparation of dihydrolipoic acid-poly(ethylene glycol)-dimannose 
(DHLA-PEGn-Man--1,2-Man, where n = 3 or 10). N.B. Both LA-EG3-cyclooctyne 
and LA-PEG10-cyclooctyne were used as a mixture of stereosiomers. Both LA-EG3-
Man--1,2-Man and LA-PEG10-Man--1,2-Man were formed as a mixture of 
regioisomers, only the predominant stereoisomer is shown.  
Di-mannose-capped QDs with varying PEG linker lengths (QD-EG3-Man--1,2-Man 
and QD-PEG10-Man--1,2-Man; collectively called QD-PEGn-Man--1,2-Man, where n 
= 3 or n ~10) were successfully synthesised using the same procedures as for the 
preparation of mono-mannose capped QDs. Thus, di-mannose capped QDs and the 
control DHLA-ZW were available to be used for the QD-FRET experiments.  
6.8 Binding studies using QD-FRET technique  
This part of the work was performed by E. Poole and Dr. Y. Guo. Similarly to the 
previous experiments, QD-PEGn-Man--1,2-Man was employed as a FRET donor to 
assess DC-SIGN and DC-SIGNR-carbohydrate interactions. Two labelled proteins DC-
SIGN and DC-SIGNR were prepared and used as FRET acceptors. Preliminary data 
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suggested an overall view of a preferential interaction of the di-mannose capped QDs 
with DC-SIGN over DC-SIGNR (Figure 6-12), which was likewise the case of mono-
mannose capped QDs that showed a high selectivity with DC-SIGN. This observation 
was confirmed by analysis of the FRET ratio data plotted against DC-SIGN and DC-
SIGNR concentration (Figure 6-13). Di-mannose-functionalised QDs with a long-length 
PEG linker (QD-PEG10-Man--1,2-Man) bound to DC-SIGN with a Kd of 60 nM (Table 
6-2), whereas the binding  of the QD-PEG10-Man--1,2-Man to DC-SIGNR was 
approximately 10-fold weaker (Kd of 607 nM). While the binding of QD-PEG10-Man--
1,2-Man to DC-SIGN could be described by a simple one site binding isotherm, the 
QD-EG3-Man--1,2-Man/DC-SIGN binding could only be fit to Hill equation as the data 
showed apparent positive cooperativity (Hill coefficient n = 2.55; Table 6-2). The fitting 
of QD-PEG10-Man--1,2-Man to DC-SIGN using the Hill equation yielded 
superimposable binding curve that was well fit by a one-site binding model, a Hill 
coefficient of 1.02 and an effective concentration for half maximal binding (EC50) that 
was the same as Kd for the simple one site binding model. EC50 value for QD-EG3-
Man--1,2-Man was higher than that of the QD-PEG10-Man--1,2-Man (104 nM vs. 60 
nM). DC-SIGNR bound to QD-EG3-Man--1,2-Man even more weakly than to the other 
functionalised quantum dots and it was not possible to derive any accurate estimates of 
Kd or EC50. On the whole, di-mannose capped QDs enhanced the binding affinities of 
the QD probe to DC-SIGN and DC-SIGNR. EC50 for the mono-mannosyl quantum dots 
estimated from Fig 6-4(F) were around 300-500 nM, whereas EC50 values for the 
dimannosyl quantum dots were 60-100 nM. This di-mannosyl probe could still 
distinguish DC-SIGN and DC-SIGNR that could further lead to a new insight into their 
binding modes and biological roles. However, there is still a need for performing 
additional experiments on the multivalent interactions of QD-PEGn-Man--1,2-Man and 




Figure 6-12. (A-H) Preliminary data on fluorescence spectra of QD-PEGn-Man-
1,2-Man (EM = 554 nm, final QD concentration, CQD = 40 nM) after binding to 
Atto-594 labelled proteins: (A) DC-SIGN + QD-PEG10-Man-1,2-Man (73%) + ZW 
(27%); (B) DC-SIGN + QD-EG3-Man-1,2-Man (25%) + ZW (75%); (C) DC-SIGN + 
QD-PEG10-Man-1,2-Man (100%); (D) DC-SIGN + QD-EG3-Man-1,2-Man (25%) 
+ ZW (75%); (E) DC-SIGNR + QD-PEG10-Man-1,2-Man (73%) + ZW (27%) ; (F) 
DC-SIGNR + QD-PEG10-Man-1,2-Man (25%) + ZW (75%); (G) DC-SIGNR + QD-





Figure 6-13. FRET ratio (I626/I554) between di-mannose capped QDs donors and 
dye-labelled DC-SIGN and DC-SIGNR acceptors (collectively called DC-SIGN/R).  
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6.9 Conclusions  
The synthetic routes to azido-mannopyranosides in form of mono- and disaccharides 
have been successfully developed. The azido-disaccharide version was unfortunately 
difficult to synthesise from the previously-prepared azido-monosaccharide as a starting 
material. The synthesis of disaccharide analogue was achieved by performing O-2-
selective de-acetylation of D-mannose pentaacetate to render 2-OH available for 
glycosylation with another mannosyl donor, and further attachment to azido-PEG-
alcohol. Azido-mannopyranosides were functionalised with DHLA-PEG linkers via 
strain-promoted alkyne-azide cycloaddition before conjugating to commercially 
available CdSe/ZnS core/shell QDs via an efficient newly established method to make  
the functionalised QDs dense, compact and biocompatible. Mono and di-mannose 
capped QDs (Man-QDs) were employed to probe multivalent receptor-glycan 
interactions for DC-SIGN and DC-SIGNR via FRET. The results showed that 
multivalent Man-QDs exhibited higher binding affinities to DC-SIGN than its related 
receptor DC-SIGNR. This distinct function may be due to different arrangements of the 
CRDs of DC-SIGN and DC-SIGNR. Moreover, mono-mannose capped QDs 
specifically inhibited DC-SIGN- but not DC-SIGNR-mediated pseudo-Ebola viral entry 
of target cells. This work thus establishes a new strategy for targeting DC-SIGN from 
DC-SIGNR mediated viral infection. 
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This thesis contributes to the development of multivalent galactose-based compounds 
for targeting LOX-1 and the other mannose-based compounds for probing multivalent 
DC-SIGN/ligand interaction.  
7.1 LOX-1 project  
7.1.1 Summary  
The previous work of Dr. K. Lacey, Dr. P. Mandal and Dr. S. Ponnambalam (University 
of Leeds) has led to the identification, both in vitro and in vivo, of a trisaccharide 
inhibitor of LOX-1, a receptor involved in atherosclerosis. However, enhancement of 
inhibition was thought to be possible by the attachment of multiple copies of the lead 
trisaccharide epitopes on a multivalent scaffold.  As a consequence, to build such 
multivalent structures, two main questions were raised: 1) what type of a scaffold would 
be used for the multivalent presentation of the sugars? and 2) what functional group on 
the sugar would be amenable for the multivalent scaffold attachment?  
In collaboration with Dr. C. Mahon and Dr. D. Fulton (University of Newcastle), 
aldehyde-functionalised polymers were used for the attachment of mannosyl- and 
galactosyl hydrazides, permitting the production of carbohydrate-functionalised polymer 
scaffold dynamic combinatorial libraries (PS-DCLs). Thereafter, this type of polymer 
was used as a multivalent scaffold for the attachment of LOX-1 inhibitors. The 
preparation of a trisaccharide containing a 4-nitrophenyl was first considered. It was 
anticipated that the final compound with a nitro group could be converted to the 
corresponding amine, which would then be treated with dimethyl squarate ester and 
used to conjugate to Dr. C. Mahon‟s aldehyde-bearing polymer. The synthesis of a 4-
nitrophenyl trisaccharide resulted in a very low yield, due to poor regioselectivity of 
allylation and low -selectivity of glycosylations. Prior to improving the synthesis, a 
more simple sugar containing a 4-aminophenyl group was used as a model to react 
with a squarate ester and subsequently treated with hydrazine; however, this method 
was ineffective probably because of hydrazine was too reactive or it could cleave the 
initial group of dimethyl squarate. Hence, the linkage of this squarate ester with the 
trisaccharide was thus likely to be unattainable.  
An alternative strategy was to synthesise a trisaccharide containing an aryl ester as 
this could be reacted with hydrazine to form the corresponding hydrazide and used for 
polymer conjugation. Before developing an improved synthetic strategy to a 
trisaccharide containing an aryl ester based on the initial synthesis, the simplification of 
the molecular structure of the lead compound was performed by replacing the central 
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galactose residue with cyclic diols. The other objective of this simplified model system, 
which was achieved at the same time, was to optimise the glycosylation conditions. 
Related glycosyl donors were also prepared. According to the results, the use of a 
glycosyl donor with ester group at O-4 instead of perbenzylated glycoside 
demonstrated a significant improvement in -selectivity, possibly owing to the remote 
protecting group participation. Unfortunately, it was even more difficult to perform 
glycosylation with the cyclic diols to produce more simple analogues of the lead 
compound.  
To improve the trisaccharide synthesis, controlling the regioselectivity of protecting 
group chemistry and stereochemical outcome of glycosylation reactions was indeed 
necessary. The synthesis of a trisaccharide having a 4-methoxycarbonylphenyl 
aglycone was therefore reinvented. Several attempts to perform tin-mediated 
regioselective allylation reactions with an unprotected 4-methoxycarbonylphenyl 
galactopyranoside were unsuccessful. An alternative approach was employed to 
protect the same galactopyranoside at the O-1 and O-6 positions and make only O-3 
and O-4 positions available for the tin-mediated allylation. This method led to a 
regioselective O-3-allylation. The other challenging problem to deal with was the -
selectivity of glycosylation. Similar to the case of cyclohexanediol, the glycosylation 
involved a glycosyl donor having an O-4 substituted ester group gave the best -
selectivity. On the whole, the synthetic route towards a trisaccharide containing 4-
methoxycarbonylphenyl aglycone was greatly improved in terms of the -selectivity, 
regioselectivity and overall yield.  Converting the obtained 4-methoxycarbonylphenyl 
trisaccharide to the corresponding hydrazide was attempted in D2O; however, this 
hydrazinolysis resulted in the hydrolysed product having a carboxylic acid instead. The 
trisaccharide with an aryl ester group was successfully converted to the corresponding 
hydrazide in refluxing MeOH. Subsequently, 4-benzoylhydrazide trisaccharide was 
used for the attachment to a multivalent polymeric scaffold by Dr. C. Mahon. A 
monosaccharide version was also synthesised and attached to the same type of 
multivalent scaffold. This work establishes new and improved synthetic methods 
towards a trisaccharide, and its multivalent version, which could be suitable candidates 






The key achievements of this LOX-1 project are as follows: 
 The use of a glycosyl donor having an O-4 PMBz group for glycosylation on a 
cyclohexane diol or a galactose residue demonstrated a great improvement of 
-selectivity.   
 A pseudo-trisaccharide having a central cyclohexane ring was successfully 
synthesised; however in a very low yield.  
 Synthetic strategy towards a trisaccharide analogue of the lead inhibitor of LOX-
1 was improved, notably on the regioselectivity of allylation and -selectivity of 
glycosylation.  
 A trisaccharide analogue of the lead inhibitor was successfully synthesised. 
This trisaccharide contains an ester functional group with could be converted to 
the corresponding hydrazide that was ready for the attachment to a multivalent 
scaffold.    
 Multivalent glycopolymers bearing mono- and tri-saccharide units were 
successfully prepared by Dr. C. Mahon. These were anticipated to be better 
candidates for LOX-1 inhibitors. 
7.1.3 Challenges and limitations 
The challenges and limitations of this LOX-1 project are as follows. 
 The glycosylation reactions with a more simple, non-sugar moiety (i.e., 1,2-cis-
cyclohexanediol) were even more difficult to manipulate than glycosylation with 
sugar residues. Generating more diverse structures of compounds, i.e., 
trisaccharide in which its central galactose was replaced with different cyclic 
diols was not yet possible.  
 LOX-1 binding domain and its recognition mode are still not yet fully understood; 
therefore, it is difficult to find a functional and appropriate inhibitor for LOX-1. As 
LOX-1 was proved to be inhibited by a trisaccharide, modifying the 
carbohydrate structures still required challenging and consecutive reactions, 
which were attributed to the need of elaborate protecting group strategies and 
the difficulties to perform glycosylation of building blocks in a stereoselective 




7.1.4 Future work  
It would be of interest to test the synthesised carbohydrate-based compounds both in 
mono- and multivalent forms in cellular assays for their inhibitory effects for LOX-1. 
Porcine aortic endothelial cells expressing LOX-1 were established by Ms. I. Abul Zani 
and Dr. S. Ponnambalam (University of Leeds) and will be used to assess whether 
these carbohydrates or glycopolymers could inhibit OxLDL binding and uptake by LOX-
1-expressing cells using similar protocols which was developed by Dr. K. Lacey. After 
the treatment of cells expressing LOX-1 with carbohydrates or glycopolymers, the 
binding of DiI-OxLDL to LOX-1 transfected cells will be detected by confocal 
microscopy. A decrease in Ox-LDL particles bound to LOX-1 expressing cells is 
expected. 
Moreover, any relevant analogues exhibiting effective inhibition in vitro would then be 
selected to evaluate further for anti-atherogenic effects in animal models of 
atherosclerosis, e.g., in mouse lacking Apo-E, which could develop atherosclerotic 
lesions after feeding a high-fat „Western diet‟. These in vitro and in vivo results would 
provide the molecular basis of the interaction between LOX-1 and the carbohydrate 
epitopes and also an insight into the development of a more potent inhibitor of LOX-1. 
This could ultimately lead to a new therapeutic approach for the atherosclerosis 
treatment. Expanding the sugar structures to determine which part of the trisaccharide 
is more essential to be recognised by LOX-1 may also be beneficial for further studies. 
Although many carbohydrate-binding proteins have been identified and could be 
potential drug targets, the development of new carbohydrate-based therapeutics is still 
a challenge. One of the main obstacles is that carbohydrates exhibit poor 
pharmacokinetic properties  in particular, low bioavailability and serum half-life. These 
are possibly due to high polarity of carbohydrates, which limits passive intestinal 
absorption and therefore oral availability. In addition, after parenteral administration, 
carbohydrates are potentially excreted rapidly from the kidney.163 Possible strategies to 
improve pharmacokinetic properties are the bioisoteric replacement of crucial groups164 
or a pro-drug approach.165 A successful example of the pro-drug strategy is oseltamivir, 
an ethyl ester pro-drug, which is able to converted to active metabolite oseltamivir 
carboxylate.166 Its bioavailable of the ester pro-drug is high (80%). Following dosing, 
Oseltamivir is detectable in plasma within 30 minutes and reaches maximal 
concentrations after 3-4 hours.167 Another approach is to conjugate sugars with carriers, 
e.g., peptides, polymers, antisense oligonucleotides (ASOs). A recent example is the 
conjugation of ASOs with triantennary N-acetyl galactosamine (GalNAc3), a high-affinity 
130 
  
ligand for hepatocyte-specific asialoglycoprotien receptor (ASGPR). The resulting 
ASOs conjugate could improve drug distribution to target cells, thus, it greatly 
enhances the targeted distribution of these molecules to hepatocytes and resulted in 
significant improvement in potency in cells and mice.168,169 Moreover, Tanaka et al. 
successfully prepared glycopolymers bearing triazole-linked sialyloligosaccharides 
which could strongly bind to both human and avian influenza A viruses.170 On the other 
hand, Synsorb-Pk, a shigatoxin-binding molecule, was one of the examples of 
carbohydrate compounds that reached phase II clinical trials in patients but it did not 
reduce the severity of hemolytic uremic syndrome. Evaluation of the Synsorb-Pk in 
phase II clinical trials was therefore abandoned.171,172 PEGylation (i.e., the covalent 
conjugation with polyethylene glycol (PEG)), is a widely used technique to achieve long 
blood circulation times of protein-polymer conjugates for clinical use.173,174 The process 
of PEGylation can be extended to carbohydrates.175 
However, the use of the newly synthesised glycopolymer bearing trisaccharide from 
this PhD project as a therapeutic agent depends on the results from biological testings. 
The pharmacokinetic properties and toxicity of the synthesised trisaccharide-
conjugated polymer are needed to be evaluated in the future.  
There is also a need to perform parallel experiments such as molecular dynamics, 
crystallographic data, NMR-based structural analysis, to gain a better understanding of 
structural knowledge of LOX-1 receptor and carbohydrate ligands. This information 
would also be useful to predict more correct binding orientations of both receptor and 
relevant ligands.  
Another potential application of these carbohydrate-based compounds could be 







7.2 DC-SIGN project 
7.2.1 Summary 
Two different mannose-based ligands containing either mono- or dimannose units were 
developed and used, in collaboration with Dr. Y. Guo, as QD-based FRET probes for 
the study of DC-SIGN/ligand interaction. An azido-mannopyranoside was prepared 
from the glycosylation of peracetyl protected mannose with a chloro-PEG-alcohol and 
converted to the corresponding compound with an azido-PEG linker. Following a 
Zemplén deacetylation, the desired azido-mannopyranoside was obtained.   
The azido-mannopyranoside was further functionalised with DHLA-PEG linkers via 
strain-promoted alkyne-azide cycloaddition and conjugated to commercially available 
CdSe/ZnS core/shell QDs. Mono-mannose capped QDs were used as a tool to probe 
multivalent receptor/glycan interactions for DC-SIGN and DC-SIGNR via FRET 
technique. Mono-mannose capped QDs were shown to preferentially bind to DC-SIGN 
over DC-SIGNR. The functional differences between these two receptors may arise 
from the different spatial aspects of CRDs arrangements of DC-SIGN and DC-SIGNR. 
Furthermore, the binding specificity of mono-mannose capped QDs with DC-SIGN and 
DC-SIGNR were confirmed by Ebola virus inhibition assays using pseudo-types, which 
were performed by Dr. I. Nehlmeier and Dr. S. Pöhlmann (German Primate Center, 
Gottingen, Germany). Their results showed that the mono-mannose capped QDs could 
specifically inhibit DC-SIGN- but not DC-SIGNR-mediated pseudo-Ebola viral entry of 
target cells.  
A more complex carbohydrate epitope, Man-1,2-Man was thought to be a better 
ligand for DC-SIGN. Synthesis of an azido-disaccharide version starting from the 
available off-the-shelf azido-mannopyranoside proved to be problematic. The synthesis 
of Man-1,2-Man  was eventually accomplished by another approach, which was firstly 
the preparation of a mannose building block having solely a 2-OH available to perform 
glycosylation. After the optimised glycosylation step, the acetylated disaccharide was 
converted to the corresponding imidate and used for the preparation of a mannobiose 
containing an azido-PEG chain via the same experimental procedures as for the mono-
Man version. 
The azido-Man-1,2-Man was also conjugated with QDs in a similar manner to that of 
azido-Man. The preliminary QD-FRET data of di-mannose capped QDs showed higher 
binding affinities to both lectins in comparison to the mono-mannose capped QDs and 
exhibited a more intimate binding with DC-SIGN than its related receptor DC-SIGNR. 
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The interaction between lectin (e.g., DC-SIGN and DC-SIGNR) with synthetic glyco-
QDs was investigated for the first time by QD-based FRET technique. This work also 
provides a new strategy for probing multivalent interactions between the lectin and its 
ligand.   
7.2.2 Achievements 
The key achievements of this DC-SIGN project are as follows: 
 Azido-mannopyranosides in form of mono- and disaccharide were successfully 
synthesised.   
 Conjugations between both azido-compounds and CdSe/ZnS core/shell QDs 
were achieved.  
 Man-QDs were used to probe multivalent interactions of DC-SIGN and DC-
SIGNR by QD-FRET experiments and viral entry inhibition assays. Man-QDs 
exhibited higher binding affinities to DC-SIGN than DC-SIGNR, confirming their 
distinct functions potentially due to differences in the CRD orientations.  
7.2.3 Challenges and limitations 
The challenges and limitations of this DC-SIGN project are as follows. 
 The azido-disaccharide could not be synthesised from the mannoside bearing 
an azido-PEG chain. The disaccharide could only be prepared by first 
synthesising a disaccharide donor and then performing glycosylation of the 
chloro-PEG-alcohol. 
7.2.4 Future work  
The evaluation of di-Man-QDs for the binding effects with DC-SIGN and DC-SIGNR 
using FRET will be performed by Dr. Y. Guo, Dr. I. Nehlmeier and Dr. S. Pöhlmann. It 
would also be of interest to test the di-Man-QDs with the same Ebola virus inhibition 
assays using virus-like particles to compare its effect with the mono-Man-QDs. It is 
anticipated that these QD-based FRET probes will have a great impact on DC-SIGN-
mediated HIV-1 inhibition. HIV inhibition assays would give an insight into the 
interaction and the fundamental roles of DC-SIGN in HIV infection. This could be a 
starting point leading to a rational design of potential DC-SIGN inhibitors as therapeutic 
drugs for the treatment of viral infections and other related diseases in the future. 
Similar to the case of glycopolymers, pharmacokinetic and toxicity assesments of the 
mannose-conjugated QDs are needed to be taken into account. However, the toxicity 
of quantum-dots is still of a great concern because they contain metal ions, e.g, Cd2+, 
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which are known to be toxic to cells. Another option is to prepare carbohydrate-
conjugated gold-nanoparticles since gold-nanoparticles has been reported to be 
nontoxic and used to treat rheumatoid arthritis.176 Moreover, a recent review showed 
that the tumour-targeting applications of nanoparticles still resulted in low delivery 
efficiency as nanoparticles may interact with other components in tumour matrix. A 
higher dosage may enhance the delivery efficiency but potentially increase toxicity.177 
Furthermore, this newly established conjugation method to produce dense and 
compact carbohydrate-functionalised QDs could be further applied for the investigation 
of other lectins by varying the carbohydrate epitopes on the surfaces of the QDs. FRET 



























































































































































































































































Chapter 8: Experimental 
8.1 General methods  
Dry DCM, THF, MeOH, MeCN, EtOAc were obtained through an Innovative 
Technology solvent drying system. Anhydrous DMF and DCE were purchased from 
Sigma-Aldrich, and all other commercially available reagents were used as received. 
Boron trifluoride diethyl etherate (BF3OEt2) and triflic anhydride (Tf2O) were distilled 
prior to use. All solvents used for flash chromatography were GPR grade, except 
hexane and ethyl acetate, for which HPLC grade was used. All concentrations were 
performed in vacuo, unless otherwise stated. CdSe/ZnS core/shell QDs with EM of 560 
nm were purchased commercially from PlasmaChem GmbH (Berlin, Germany). The 
QDs were supplied as dry powder, capped with mixed hydrophobic ligands including 
trioctyl-phosphine oxide (TOPO), hexadecylamine and oleic acid.   
NMR spectra were acquired at room temperature (r.t.), unless noted otherwise. 1H 
NMR spectra were recorded at 500 MHz on a Bruker Avance 500 instrument or at 600 
MHz on a JEOL Resonance ECA600II spectrometer. 13C NMR spectra were recorded 
at 75 MHz on a Bruker Avance 300 instrument or at 500 MHz on a Bruker Avance 500 
machine. Chemical shifts () are reported in parts per million (ppm) using 13C and 
residual 1H signals from deuterated solvents as references. Assignments of NMR 
spectra were achieved using 2D methods (COSY, TOCSY, NOESY, HMBC, HMQC) 
when necessary. Splitting patterns are described by using the following abbreviations: 
br, broad; s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; or combinations 
thereof. 1H NMR data of mono-, di- and trisaccharides were assigned in agreement 




Figure 8-1. Proton numbering in 
1
H NMR for a) galacto-configured mono- and di- 
and trisaccharides b) manno-configured mono- and disaccharides. 
Low resolution electrospray (ES+) ionisation mass spectra were obtained on a Bruker 
HCTUltra mass spectrometer,  and  high  resolution  ES+  were  performed  on  a  
Bruker  Daltonics MicroTOF or a Bruker maXis Impact™ mass spectrometer. Infra-red 
(IR) spectra were recorded on a PerkinElmer Spectrum One FT-IR spectrometer. 
Melting points were obtained on a Griffin melting point apparatus. Optical rotations 
were measured at the sodium D-line with a Schmidt+Haensch Polartronic 
H532 polarimeter. Specific rotation   D  values are given in units of 10
-1 deg cm2 g-1. All 
solution reactions were monitored by thin layer chromatography (TLC) on silica gel 
plates 60-F254 (Merck) with visualisation under UV (254 nm) and/or by staining with 
iodine vapour or detection charring following immersion in a 5% H2SO4/MeOH solution, 
unless otherwise indicated. Column chromatography was carried out using silica gel 
(60 mesh) with elution solvents as described. Gel filtrations were performed on 
Sephadex LH-20 eluting with water/MeOH or on Bio-Beads SX-1 eluting with toluene. 
Water soluble compounds were freeze dried using Virtis Benchtop K freeze dryer.  
UV-vis absorption spectra were recorded on a Varian Cary 50 bio UV-Visible 
spectrophotometer over 200-800 nm using a 1 mL-quartz cuvette with an optical path 
of 1 cm or on a Nanodrop 2000 spectrophotometer (Thermo scientific) over the range 
of 200-800 nm using 1 drop of the solution with an optical path length of 1 mm. All 
centrifugations were carried out on a Thermo Scientific Heraeus Fresco 21 
microcentrifuge using 1.5 mL-microcentrifuge tubes at room temperature, unless 
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otherwise stated. The QD purification was performed by Amicon ultra-centrifugal filter 
tubes with a molecular weight cut-off (MWCO) of 30,000. DLS was performed using a 
Zetasizer NanoZS (Malvern) using a laser wavelength of 633 nm in disposable 
polystyrene cuvettes. Readings of 10 scans were taken in triplicate and the average 
values were calculated.  
8.2 Chemical synthesis 




Sodium methoxide (3.2 mg, 0.1 mmol) was added to a solution of 4-
methoxycarbonylphenyl-3,4-bis-O-(4-O-4-methoxybenzoyl--D-galactopyranosyl) -D-
galactopyranoside 83 (24 mg, 0.03 mmol) in MeOH (1 mL). The reaction mixture was 
stirred for 48 h at r.t., neutralised with Amberlite® IRC 86 H+ resin, filtered and 
concentrated to give 4-methoxycarbonyl 3,4-bis-O-(-D-galactopyranosyl)--D-
galactopyranoside 27 as a colourless oil (17 mg, 100%); Rf 0.38 (6:4:1 
ChloroformMeOHH2O);   25 D   10.64 (c, 0.1, H2O); H (500 MHz, D2O); 8.04 (d, 2H, J 
8.8 Hz, ArH), 7.24 (d, 2H, J 8.8 Hz, ArH), 5.34 (d, 1H, J1a,2a 7.5 Hz, H-1a), 5.29 (d, 1H, 
J1c,2c 4.0 Hz, H-1c), 5.14 (d, 1H, J1b,2b 3.6 Hz, H-1b), 4.42 (d, 1H, J 2.2 Hz, H-4a), 4.29 
(t, 1H, J 6.4 Hz, H-5), 4.20 (t, 1H, J 6.5 Hz, H-5), 4.08-3.63 (m, 18H, H-2a, H-2b, H-2c, 
H-3a, H-3b, H-3c, H-4b, H-4c, H-5a, H-6a, H-6a, H-6b, H-6b, H-6c, H-6c, OCH3); C 
(75 MHz, D2O); 168.9 (C=O), 160.4 (C-O), 131.7 (ArC), 124.0 (C-O), 116.3 (ArC), 
101.0 (C-1a), 99.9 (C-1c), 95.5 (C-1b), 76.5, 75.5, 75.1, 71.7, 70.8, 69.6, 69.1, 68.9, 
68.8, 68.6, 60.9, 60.9, 60.6 (3 × C-2, 3 × C-3, 3 × C-4, 3 × C-5, 3 × C-6), 52.5 (OCH3);  
IR (max/cm
-1): 3375 (OH), 1704 (C=O); HRMS: Found [M+Na]+ 661.1960, C26H38NaO18 




1-Azido-3,6-dioxaoct-8-yl -D-mannopyranoside (29)178  
 
Sodium methoxide (103 mg, 2 mmol) was added to a solution of 1-azido-3,6-dioxaoct-
8-yl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside 92 (1.20 g, 2.4 mmol) in anhydrous 
MeOH (50 mL). After stirring for 3 h at r.t., the reaction mixture was diluted with MeOH 
and neutralised with Amberlite® IRC 86 H+ resin, filtered, re-dissolved in hot MeOH, 
cooled down, filtered through Celite® pad and concentrated to afford compound 29 
(0.72 g, 90%) as a colourless oil; Rf 0.10 (9:1 DCMMeOH);   22 D   54.24 (c, 0.25, 
MeOH) (lit.179   25 D   38.7 (c, 1.0, MeOH)); H (500 MHz, D2O); 4.91 (d, 1H, J 1.6 Hz, H-
1), 3.99 (dd, 1H, J2,3 3.5 Hz, J1,2  1.6 Hz, H-2), 3.92-3.88 (m, 2H, ManOCH2), 3.86-3.83 
(m, 1H, H-3), 3.80-3.66 (m, 12H, H-4, H-5, H-6, H-6', 4 × OCH2), 3.52 (t, 2H, J 5.1 Hz, 
CH2-N); C (75 MHz, D2O); 100.0 (JC,H 169 Hz, , C-1), 72.7 (C-4), 70.5 (C-3), 70.0 (C-
2), 69.6, 69.5, 69.5, 69.3 (4 × CH2O), 66.7 (C-5), 66.4 (ManOCH2), 60.9 (C-6), 50.2 
(CH2-N); IR (max/cm
-1): 3373 (OH), 2106 (N3); HRMS: Found [M+Na]
+ 360.1377, 
C12H23N3NaO8  requires 360.1381.  
 
1-Azido-3,6-dioxaoct-8-yl 2-O--D-mannopyranosyl--D-mannopyranoside (31) 
 
Sodium methoxide (5.3 mg, 0.10 mmol) was added to a solution of 1-azido-3,6-
dioxaoct-8-yl 3,4,6-tri-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyl)--D-
mannopyranoside 104 (38 mg, 0.05 mmol) in anhydrous MeOH (1 mL). After stirring for 
17 h at r.t., the reaction mixture was neutralised with Amberlite® IRC 86 H+ resin, 
filtered and concentrated to afford compound 31 (22 mg, 90%) as a colourless oil; Rf 
0.38 (6:4:1 ChloroformMeOHH2O);   21 D   0.94 (C, 0.1, H2O); H (500 MHz, D2O); 
5.14 (d, 1H, J1a,2a 1.7 Hz, H-1a), 5.05 (d, 1H, J1b,2b  1.7 Hz, H-1b), 4.09 (dd, 1H, J2b,3b 3.4 
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Hz, J1b,2b 1.7 Hz, H-2b), 4.01 (dd, 1H, J2a,3a 3.4 Hz, J1a,2a 1.7 Hz, H-2a), 3.95 (dd, 1H, 
J3a,4a 9.2 Hz, J2a,3a 3.4 Hz, H-3a), 3.93-3.84 (m, 4H, H-3b, H-6, H-6, CH2O), 3.82-3.61 
(m, 15H, C-4a, C-4b, C-5a, C-5b, C-6, C-6, CH2O), 3.55-3.51 (t, 2H, J 4.87 Hz, CH2-N); 
C (75 MHz, D2O); 102.3 (JC,H 171 Hz, 4.1 Hz, , C-1b), 98.4 (JC,H 172 Hz, , C-1a), 
78.6 (C-2a), 73.3, 72.8, 66.6, 61.1 (2 × C-4, 2 × C-5), 70.3, 70.2 (C-3b), 69.9 (C-2b), 
69.6 (C-3a), 69.5, 69.5, 69.3, 66.9 (4 × CH2O), 60.9, 50.2 (2 × C-6); IR (max/cm
-1):  
3331 (OH), 2103 (N3); HRMS: Found [M+NH4]
+ 517.2372, C18H37N4O13 requires 
517.2352. 
 
2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl trichloroacetimidate (34)180  
 
Hydrazine acetate (8.86 g, 96.1 mmol) was added to a solution of -D-galactose 
pentaacetate 33 (25.0 g, 64 mmol) in DMF (80 mL), and the reaction mixture was 
stirred at r.t. for 1 h, concentrated to leave a pale yellow oil, which was purified by flash 
column chromatography (silica; 2:1 hexaneEtOAc) to afford a hemiacetal intermediate 
as a colourless oil (17.6 g). The oil was dissolved in anhydrous DCM (40 mL). 
Trichloroacetonitrile (24.5 mL, 244 mmol) and DBU (2.5 mL) were added to the solution, 
which was stirred at -10 °C for 1 h, concentrated and purified by flash column 
chromatography (silica; 4:1 hexaneEtOAc), yielded trichloroacetimidate 34  (13.9 g, 
44% over two steps) as a pale yellow solid; Rf 0.14 (double-run, 2:1 hexaneEtOAc); 
m.p. 124-125 °C (from diethyl etherhexane) (lit.180 m.p. 126-127 °C);   24 D   128 (c, 1, 
CHCl3) (lit.
180   25 D  124 (c, 1, CHCl3)); H (500 MHz, CDCl3); 8.66 (s, 1H, NH), 6.59 (d, 
1H, J1,2 3.5 Hz, H-1), 5.55 (dd, 1H, J4,5 1.23 Hz, J3,4 3.2 Hz, H-4), 5.42 (dd, 1H, J2,3 10.9 
Hz, J3,4 3.2 Hz , H-3), 5.35 (dd, 1H, J1,2 3.5 Hz, J2,3 10.9 Hz, H-2), 4.45-4.41 (m, 1H, H-
5), 4.15 (dd, 1H, J6,5 6.7 Hz, J6,6' 11.3 Hz, H-6), 4.07 (dd, 1H, J6,5  6.7 Hz, J6,6' 11.3 Hz, 
H-6'), 2.16 (s, 3H, C(O)CH3), 2.10-2.00 (m, 9H, 3 × C(O)CH3); C (75 MHz, CDCl3); 
170.4, 170.2, 170.2, 170.1 (C=O), 161.1 (C-N), 93.7 (C-1), 90.9 (CCl3), 69.1 (C-5), 67.6 
(C-3), 67.5 (C-2), 67.0 (C-4), 61.4 (C-6), 20.8, 20.8, 20.7, 20.6 (4 × C(O)CH3); IR 
(max/cm
-1): 3349 (NH), 1747 (C=O), 1645 (C=N); HRMS: Found [M+Na]+ 514.0055, 
C16H20Cl3NNaO10 requires 514.0045.  
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4-Nitrophenyl 2,3,4,6-tetra-O-acetyl--D-galactopyranoside (35)181,182 
 
A solution of 2,3,4,6-tetra-O-acetyl -D-galactopyranosyl trichloroacetimidate 34 (14.0 g, 
28 mmol), 4-nitrophenol (5.9 g, 42 mmol) and 4 Å MS (7.0 g) in anhydrous DCM (80 
mL) was stirred at -5 °C for 5 min before freshly distilled boron trifluoride diethyl 
etherate (0.7 mL, 5 mmol) was added dropwise. After 15 min the reaction mixture was 
washed with saturated aq. NaHCO3 (3 × 20 mL) and extracted with DCM (3 × 20 mL). 
The organic layer was dried (MgSO4) and concentrated to afford a colourless oil. The 
crude oil was purified by flash column chromatography (silica; 3:1 hexaneEtOAc → 
2:1 hexaneEtOAc) to afford compound 35 (12.3 g, 93%) as a colourless solid; Rf 0.21 
(3:1 hexaneEtOAc); m.p. 145-146 °C (from EtOH) (lit.181 m.p. 146-147 °C);   21 D   -9.8 
(c, 2, CHCl3) (lit.
182   25 D   -10 (c, 2, CHCl3)); H (500 MHz, CDCl3); 8.22-8.18 (m, 2H, 
ArH), 7.10-7.05 (m, 2H, ArH), 5.51 (dd, 1H, J2,3 10.4 Hz, J1,2 7.9 Hz, H-2), 5.47 (d, 1H, 
J3,4 3.4 Hz, H-4), 5.17 (d, 1H, J1,2 7.9 Hz, H-1), 5.13 (dd, 1H, J2,3 10.4 Hz, J 3,4 3.4 Hz, 
H-3), 4.23-4.09 (m, 3H, H-5, H-6, H-6'), 2.18 (s, 3H, C(O)CH3), 2.06 (s, 6H, 2 × 
C(O)CH3), 2.01 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 170.5, 170.3, 170.2, 169.5 
(C=O), 161.4, 143.5, 126.0, 116.8 (ArC), 98.8 (C-1), 71.7 (C-5), 70.8 (C-3), 68.5 (C-2), 
66.9 (C-4), 61.6 (C-6), 20.9, 20.9, 20.8, 20.7 (4 × C(O)CH3); IR (max/cm
-1): 1752 (C=O), 
1520, 1342 (NO2); HRMS: Found [M+Na]










4-Nitrophenyl -D-galactopyranoside (36)183 
 
Anhydrous potassium carbonate (0.8 g, 5.1 mmol) was added to a solution of 4-
nitrophenyl 2,3,4,6-tetra-O-acetyl--D-galactopyranoside 35 (11.8 g, 25 mmol) in 
anhydrous MeOH (150 mL), and stirred at r.t. for 2 h. The reaction mixture was then 
neutralised by adding acetic acid dropwise. The solvent was evaporated to afford 
compound 36 (8.08 g, 99%) as a yellow oil. This material was used for the next 
reaction without purification. The spectroscopic and analytical data are obtained from a 
partially purified material by recrytallisation from EtOH to give colourless needles; Rf 
0.29 (9:1 DCMMeOH); m.p. 177-179 °C (from EtOH) (lit.183 m.p. 180-182 °C);   25 D     
-74.0 (c, 0.5, H2O) (lit.
183   D   -80.6 (c, 0.5, H2O)); H (500 MHz, CD3OD); 8.23-8.19 (m, 
2H, ArH), 7.27-7.23 (m, 2H, ArH), 5.02 (d, 1H, J1,2 7.7 Hz, H-1), 3.92 (d, 1H, J3,4 3.3 Hz, 
H-4), 3.84 (dd, 1 H, J1,2 7.7 Hz, J2,3 9.7 Hz, H-2), 3.80-3.73 (m, 3H, H-5, H-6, H-6'), 3.61 
(dd, 1H, J2,3  9.7 Hz, J3,4  3.3 Hz, H-3); C (75 MHz, CD3OD); 164.0, 143.9, 126.6, 117.8 
(ArC), 102.3 (C-1), 77.3 (C-5), 74.8 (C-3), 72.0 (C-2), 70.2 (C-4), 62.4 (C-6); IR 
(max/cm
-1): 3368 (OH), 1509, 1347 (NO2); HRMS: Found [M+Na]
+ 324.0694, 
C12H15NNaO8 requires 324.0690.  
 
4-Nitrophenyl 4,6-O-benzylidene--D-galactopyranoside (37)184,185 
 
Benzaldehyde dimethylacetal (5.31 g, 34.9 mmol) was added to a solution of 4-
nitrophenyl -D-galactopyranoside 36 (8.08 g, 26.8 mmol) in DMF (30 mL). (+/-)-10-
Camphorsulfonic acid was added to the solution dropwise until the reaction mixture 
was acidic. The reaction mixture was then stirred at r.t. overnight. Triethylamine (33 mL, 
22 mmol) was added to the solution mixture and concentrated to give a crude product, 
which was purified by flash column chromatography (silica; 4:1 EtOAchexane) to 
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afford compound 37 (6.55 g, 62%) as a colourless solid; Rf 0.46 (EtOAc); m.p. 231-
233 °C (from EtOH) (lit.184 m.p. 236-238 °C);   21 D   -112.5 (c, 1, DMF) (lit.
185   D  -120 
(c, 0.6, DMF));  H (500 MHz, DMSO-d6); 8.22 (d, 2H, J 8.3 Hz, ArH), 7.48-7.34 (m, 5H, 
ArH), 7.27 (d, 2H, J 8.3 Hz, ArH), 5.60 (s, 1H, PhCHO2), 5.44 (d, 1H, J 5.0 Hz, OH), 
5.20 (d, 1H, J1,2 7.4 Hz, H-1), 5.16 (d, 1H, J 5.9 Hz, OH), 4.19 (s, 1H, H-4), 4.07 (q, 2H, 
J6,6 12.5 Hz, H-6, H-6), 3.86 (s, 1H, H-5), 3.73-3.61 (m, 2H, H-2, H-3); C (75 MHz, 
DMSO-d6); 162.3, 141.6, 138.5, 128.7, 127.9, 126.2, 125.7, 116.5 (ArC), 100.0 (C-1), 
99.8 (PhCHO2), 75.7 (C-4), 71.6 (C-2), 69.5 (C-3), 68.3 (C-6), 66.4 (C-5); IR (max/cm
-1): 
3468 (OH), 1666, 1390 (NO2); HRMS: Found [M+Na]
+ 412.1002, C19H19NNaO8 
requires 412.1003.  
 
4-Nitrophenyl 3-O-acetyl-2-O-allyl-4,6-O-benzylidene--D-galactopyranoside (38a) 
and 4-nitrophenyl 2-O-acetyl-3-O-allyl-4,6-O-benzylidene--D-galactopyranoside 
(38b)  
 
Dibutyltin oxide (5.44 g, 21.9 mmol) was added to a solution of 4-nitrophenyl 4,6-O-
benzylidene--D-galactopyranoside 36 (6.55 g, 16.8 mmol) in MeOH (200 mL), and the 
reaction mixture was heated under reflux at 90 °C for 5 h under N2(g) atmosphere. 
After removal of the solvent under vacuum, cesium fluoride (3.07 g 20.2 mmol) was 
added to the residue which was coevaporated and dried with toluene two times. 
Dimethylformamide (100 mL) was added to the resulting residue, followed by the 
addition of tetrabutylammonium iodide (0.4 g, 1 mmol). The reaction mixture was 
154 
  
stirred at 90 °C overnight and was concentrated to leave a solid which was dissolved in 
pyridine (50 mL). 4-Dimethyaminopyridine (0.5 g, 4 mmol) and acetic anhydride (4 mL) 
were added to the reaction mixture, which was stirred at r.t. overnight. The reaction 
mixture was concentrated to leave a crude solid, which was purified by flash column 
(silica; 4:1 hexaneEtOAc → 3:1 hexaneEtOAc →  :1 hexaneEtOAc → 1:1 
hexaneEtOAc) to afford first compound 38a (2.20 g, 28%) as a pale yellow solid; Rf 
0.35 (2:1 hexane-EtOAc); m.p. 170-171 °C (from EtOH);   21 D   24.9 (c, 1, CHCl3); H 
(500 MHz, CDCl3); 8.22-8.18 (m, 2H, ArH), 7.55-7.49 (m, 2H, ArH), 7.43-7.34 (m, 3H, 
ArH), 7.12 (m, 2H, ArH), 5.92-5.82 (m, 1H, CH2=CHCH2), 5.54 (s, 1H, PhCHO2), 5.25 
(m, 1H, CH2=CHCH2), 5.17-5.13 (m, 2H, CH2=CHCH2, H-1), 4.99 (dd, 1H, J3,4 3.6 Hz, 
J2,3 10.5 Hz, H-3), 4.45 (d, 1H, J3,4 3.6 Hz, H-4), 4.38-4.32 (m, 2H, H-6, CH2=CHCH2), 
4.26-4.21 (m, 1H, CH2=CHCH2), 4.11 (dd, 1H, J5,6 1.7 Hz, J6,6' 12.53 Hz, H-6'), 4.06 (dd, 
1H, J1,2 7.7 Hz, J2,3 10.5 Hz, H-2), 3.69 (d, 1H, J5,6  1.7 Hz, H-5), 2.17 (s, 1H, C(O)CH3); 
C (75 MHz, CDCl3); 170.8 (C=O), 162.0, 143.0, 137.6, 129.3, 128.4, 126.4, 125.9, 
116.8 (ArC), 134.6 (CH2=CHCH2), 117.1 (CH2=CHCH2), 101.2 (PhCHO2), 101.1 (C-1), 
75.4 (C-2), 74.2 (CH2=CHCH2), 73.5 (C-4), 73.3 (C-3), 68.9 (C-6), 66.8 (C-5), 21.2 
(C(O)CH3); IR (max/cm
-1): 1746 (C=O), 1592, 1345 (NO2); HRMS: Found [M+Na]
+ 
494.1440, C24H25NNaO9 requires 494.1422. Further elution gave an inseparable 
mixture of  38b and 38c (4.84 g containing 38b and 38c in a ratio of 3:2), which was 
used for the next step; Rf 0.19 (2:1 hexaneEtOAc); H (500 MHz, CDCl3) only signals 
for compound 38b are listed; 8.22-8.14 (m, 2H, ArH), 7.57-7.48 (m, 2H, ArH), 7.42-7.30 
(m, 3H, ArH), 7.14-7.07 (m, 2H, ArH), 5.95-5.81 (m, 1H, CH2=CHCH2), 5.63 (dd, 1H, 
J1,2 7.9 Hz, J2,3 10.1 Hz, H-2), 5.59 (s, 1H, PhCHO2), 5.17 (d, 1H, J1,2 7.9 Hz, H-1), 4.37 
(d, 1H, J3,4 3.4 Hz, H-4), 3.71 (dd, 1H, J2,3 10.1, J3,4 3.4 Hz, H-3), 3.64 (d, 1H, J 1.0 Hz, 
H-5), 4.16-4.09 (m, 4H, H-6), 2.09 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 170.8, 169.3, 
169.3, 161.9, 161.6, 143.1, 143.0, 137.4, 134.6, 128.4, 128.3, 126.5, 125.8, 117.6, 
116.9, 116.7, 101.4, 101.2, 99.0, 98.9, 73.1, 71.7, 70.7, 69.6, 69.0, 67.3, 67.0, 21.0, 
21.0, 20.9; IR (max/cm
-1): 1750 (C=O), 1593, 1518 (NO2); HRMS: Found [M+Na]
+ 







4-Nitrophenyl 2-O-acetyl-3-O-allyl-6-O-benzyl--D-galactopyranoside (39)186 
 
4 Å MS (2.5 g) were added to a solution of the crude product mixture (4.84 g, 10.2 
mmol) of the previous step containing 38b (6.15 mmol) in anhydrous THF (100 mL) 
and the reaction was stirred at 0 °C for 10 min under N2(g) atmosphere. Sodium 
cyanoborohydride (3.23 g, 51.38 mmol) was added to the reaction mixture, which was 
stirred for further 10 h. Ethereal hydrochloric acid (12 mL) was added dropwise to the 
reaction mixture until the solution was acidic. The reaction mixture was stirred at r.t. for 
2 h and was washed with saturated aq. NaHCO3 (25 mL). The aqueous phase was 
washed with DCM (2 × 25 mL). The organic phase was collected, dried (MgSO4) and 
concentrated to leave a crude oil, which was purified by flash column chromatography 
(silica; 2:1 hexaneEtOAc) to afford galactopyranoside 39 (2.33 g, 80%) as a 
colourless oil; Rf 0.14 (2:1 hexaneEtOAc);  m.p. 90-91 °C (from hexaneEtOAc) (lit.
186 
m.p. 89.5-90 °C);   22 D   -1.1 (c, 1, MeOH); H (500 MHz, CDCl3); 8.18-8.08 (m, 2H, 
ArH), 7.35-7.25 (m, 5H, ArH), 7.15- 7.05 (m, 2H, ArH), 5.92-5.80 (m, 1H, CH2=CHCH2), 
5.48 (dd, 1H, J1,2 8.1 Hz, J2,3 9.5 Hz, H-2), 5.33-5.16 (m, 2H, CH2=CHCH2), 5.09 (d, 1H, 
J1,2 8.1 Hz, H-1), 4.60-4.49 (m, 1H, PhCHO2), 4.25-4.14 (m, 1H,  H-6), 4.12 (d, 1H, J3,4  
3.2 Hz, H-4), 4.07-3.95 (m, 1H, H-6'), 3.91-3.76 (m, 3H, H-5, CH2=CHCH2), 3.61 (dd, 
1H, J2,3  9.5 Hz, J3,4 3.2 Hz, H-3), 2.97 (s, 1H, OH), 2.10 (s, 3H, C(O)CH3), C (75 MHz, 
CDCl3); 107.0 (C=O), 161.7, 142.7, 134.5, 137.7 (ArC), 128.4 (CH2=CHCH2), 127.8, 
127.6, 125.6 (ArC), 117.7 (CH2=CHCH2), 116.6 (ArC), 98.5 (C-1), 78.5 (C-3), 74.5 (C-
5), 73.7 (PhCHO2), 70.2 (C-6), 70.0 (C-2), 69.3 (CH2=CHCH2), 66.2 (C-4), 20.8 
(C(O)CH3); IR (max/cm
-1): 1746 (C=O), 1592, 1514 (NO2); HRMS: Found [M+Na]
+ 




Phenyl 2,3,4,6-tetra-O-acetyl-1-thio--D-galactopyranoside (40)187 
 
Thiophenol (6.8 mL, 66 mmol) was added to a solution of -D-galactose pentaacetate 
33 (20.0 g, 51 mmol) in anhydrous DCM (200 mL) and the reaction was stirred at 0 °C 
for 10 min. Freshly distilled boron trifluoride diethyl etherate (9.5 mL, 77 mmol) was 
added to the reaction mixture, which was stirred at 0 °C for further 2 h. The reaction 
mixture was washed with water (2 × 50 mL). The aqueous phase was washed with 
DCM (2 × 50 mL). The organic phase was collected and washed with saturated aq. 
NaHCO3 (2 × 50 mL), dried (MgSO4) and concentrated to leave a crude oil, which was 
purified by flash column chromatography (silica; 6:1 hexaneEtOAc → 5:1 
hexaneEtOAc →  :1 hexaneEtOAc → 3:1 hexaneEtOAc) →  .5:1 hexaneEtOAc) 
to afford galactopyranoside 40 (13.7 g, 61%) as a colourless solid; Rf 0.21 (2:1 
hexaneEtOAc); m.p. 82-83°C (from diethyl etherhexane) (lit.188 m.p. 80-81 °C);   22 D 
4.5 (c, 1, CHCl3) (lit.
189   25 D  4.9   (c, 1, CHCl3)); H (500 MHz, CDCl3); 7.53-7.48 (m, 2H, 
ArH), 7.33-7.29 (m, 3H, ArH), 5.41 (d, 1H, J3,4  3.2 Hz, H-4), 5.24 (t, 1H, J1,2 10.0 Hz, H-
2), 5.05 (dd, 1H, J3,4 3.2 Hz, J2,3 10.0 Hz, H-3), 4.71 (d, 1H, J1,2 10.0 Hz, H-1), 4.21-4.08, 
(m, 2H, H-6, H-6'), 3.94 (t, 1H, J5,6=5,6 6.6 Hz, H-5), 2.12 (s, 3H, C(O)CH3), 2.09 (s, 3H, 
C(O)CH3), 2.04 (s, 3H, C(O)CH3), 1.97 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 170.5, 
170.3, 170.2, 169.6, 132.7, 132.6, 129.0, 128.3 (4 × C=O, ArC), 86.7 (C-1), 74.6 (C-5), 
72.2 (C-3), 67.4, 67.4 (C-2, C-4), 61.8 (C-6), 21.0, 20.8, 20.7, 20.7 (4 × C(O)CH3); IR 
(max/cm










Phenyl 2,3,4,6-tetra-O-benzyl-1-thio--D-galactopyranoside (41)187 
 
Sodium methoxide (5 mL, 88 mmol) was added dropwise to a solution of phenyl 
2,3,4,6-tetra-O-acetyl-1-thio--D-galactopyranoside 40 (13.7 g, 31 mmol) in MeOH (100 
mL) and the reaction was stirred at r.t. for 45 min. The reaction mixture was neutralised 
by slow addition of acetic acid and concentrated to give a crude oil, which was 
dissolved in DMF (120 mL). Sodium hydride (7.2 g, 300 mmol) was added portionwise 
to the reaction mixture, which was stirred at 0 °C for 5 min.  Benzylbromide (18.5 g, 
155 mmol) was slowly added to the mixture, which was stirred at r.t. overnight. 
Methanol (20 mL) was added to the solution to remove trace sodium hydride. The 
solvent was evaporated and the residue was recrystallised from EtOH to give 
compound 41 (17.4 g, 88%, 2 steps) as a colourless solid; Rf 0.23 (6:1 hexaneEtOAc); 
m.p. 86-88 °C (from diethyl etherhexane) (lit.187 m.p. 86-88 °C);   22 D   0.8 (c, 1, CHCl3) 
(lit.187   D   5 (c, 1, CHCl3));  H (500 MHz, CDCl3); 7.55-7.48 (m, 2H, ArH), 7.38-7.08 (m, 
23H, ArH), 4.91 (d, 1H, J 11.5 Hz, OCH2Ph), 4.76-4.63 (m, 4H, OCH2Ph), 4.59 (d, 1H, 
J 9.8 Hz, H-1), 4.55 (d, 1H, J 11.5 Hz, OCH2Ph), 4.45-4.34 (m, 2H, OCH2Ph), 3.93 (d, 
1H, J 2.4, H-4), 3.89 (t, 1H, J1,2=2,3  9.4 Hz, H-2), 3.64-3.52 (m, 4H, H-3, H-5, H-6, H-6'); 
C (75 MHz, CDCl3); 138.9, 138.5, 138.4, 138.0, 134.3, 131.6, 128.9, 128.5, 128.4, 
128.3, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6, 127.1 (ArC), 87.8 (C-1), 84.3 
(C-3), 77.4 (C-2, C-5), 75.7 (OCH2Ph), 74.6 (OCH2Ph), 73.7 (C-4, OCH2Ph), 72.8 
(OCH2Ph), 68.9 (C-6); IR (max/cm
-1): 2915, 2864 (C-H), 1098 (C-OR); HRMS: Found 












Donor 41 (1.0 g, 2 mmol) was added to a solution of acceptor 39 (1.74 g, 2.8 mmol) 
and 4 Å MS (1.4 g) in anhydrous DCM (40 mL), and the reaction was stirred at r.t. for 
30 min under N2(g) atmosphere.  The reaction mixture was cooled to -45 °C and NIS 
(0.68 g, 3.0 mmol) and TMSOTf (0.083 mL, 0.42 mmol) were added to the reaction 
mixture, which was stirred at the same temperature for 20 min. The reaction mixture 
was washed with saturated aq. NaHCO3 (20 mL) and sodium thiosulfate (20 mL) to 
remove traces of acid and iodine. The aqueous phase was washed with DCM (2 × 30 
mL). The organic phase was collected, dried (MgSO4), filtred and concentrated to leave 
a crude oil, which was purified by flash column chromatography (silica; 8:1 →  .5:1 
hexaneEtOAc) to afford disaccharide 42 (0.73 g, 35%) as a yellow oil; Rf 0.12 (3:1 
hexaneEtOAc);   27 D   57.1 (c, 0.5, CHCl3); H (500 MHz, CDCl3); 8.07 (d, 2H, J 9.2 Hz, 
ArH), 7.36-6.99 (m, 27H, ArH), 5.76-5.68 (m, 1H, CH2=CHCH2), 5.47 (dd, 1H, J2a,3a 
10.2 Hz, J1a,2a 7.7 Hz, H-2a), 5.16 (dd, 1H, J 17.3, J 1.5 Hz, CH2=CHCH2), 5.06 (d, 1H, 
J 10.6 Hz, CH2=CHCH2), 4.99 (d, 1H, J1a,2a 7.7 Hz, H-1a), 4.91 (d, 1H, J1b,2b 2.5 Hz, H-
1b), 4.89-4.83 (m, 2H, OCH2Ph), 4.73 (s, 1H, OCH2Ph), 4.60 (d, 1H, J 11.8 Hz, 
OCH2Ph ), 4.52 (d, 1H, J 11.2 Hz, OCH2Ph), 4.45-4.34 (m, 3H, OCH2Ph, H-5b), 4.19-
4.02 (m, 7H, CH2=CHCH2, H-4a, H-2b, H-3b, H-4b, OCH2Ph), 3.89-3.79 (m, 2H, H-6a, 
CH2=CHCH2), 3.69 (t, 1H, J5a, a 5a, ‟a  6.5 Hz, H-5a), 3.63-3.53 (m, 1H, H-6'a, H-6'b), 
3.45-3.38 (m, 2H, H-6b, H-3a), 1.93 (s, 3H, C(O)CH3); C (75 MHz, CDCl3);  169.4 
(C=O), 161.8, 142.8, 139.1, 138.9, 138.8, 138.4, 137.9, 134.5, 128.6, 128.4, 128.4, 
128.3, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 127.5, 127.5, 125.7, 
117.0 (ArC, CH2=CHCH2 ), 117.3 (CH2=CHCH2), 100.4 (C-1b), 99.2 (C-1a), 79.3, 76.4, 
73.4 (CH2=CHCH2, C-4a, C-2b, C-3b, C-4b, OCH2Ph), 78.3 (C-3a), 75.1 (OCH2Ph), 
74.8 (C-5a), 74.1 (OCH2Ph), 73.2, 69.4 (C-5b, OCH2Ph), 72.5 (OCH2Ph), 71.2 




3435 (CH=CH2), 2917, 2870 (C-H), 1754 (C=O), 1517 (NO2), 1079, 1099, 1054 (C-OR); 





 A catalytic amount of palladium (II) chloride (0.1 g, 0.6 mmol) was added to a solution 
of 4-nitrophenyl 2-O-acetyl-3-O-allyl-6-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl--D-
galactopyranosyl)--D-galactopyranoside 42 (0.73 g, 0.7 mmol) in MeOH (40 mL), and 
the reaction was stirred at r.t. overnight.  The reaction mixture was concentrated to 
leave a crude product, which was purified by flash column chromatography (silica; 4:1 
hexaneEtOAc → 3:1 hexaneEtOAc →  :1 hexaneEtOAc) to afford disaccharide 43 
(0.51 g, 73%) as a colourless solid; Rf 0.21 (3:1 hexaneEtOAc);  m.p. 138-139 °C 
(from EtOH);   23 D   23.6 (c, 0.5, CHCl3); H (500 MHz, CDCl3);  8.19-8.12 (m, 2H, ArH), 
7.43-7.20 (m, 25H, ArH), 7.16-7.11 (m, 2H, ArH), 5.31 (dd, 1H, J2a,3a 10.4 Hz, J1a,2a 7.8 
Hz, H-2a), 5.08 (d, 1H, J1a,2a 7.8 Hz, H-1a), 5.00 (d, 1H, J1b,2b 3.8 Hz, H-1b), 4.94 (d, 1H, 
J 11.3 Hz, OCH2Ph),  4.88 (d, 1H, J 11.6 Hz, OCH2Ph), 4.82-4.75 (m, 2H, OCH2Ph), 
4.66 (d, 1H, J 11.6 Hz, OCH2Ph), 4.60 (dd, 2H, J 11.6, 6.6 Hz, OCH2Ph), 4.52 (d, 1H, J  
11.6 Hz, OCH2Ph), 4.36 (t, 1H, J 6.7 Hz, H-5b), 4.28-4.22 (m, 2H, OCH2Ph), 4.16 (dd, 
1H, J2b,3b 10.2 Hz, J1b,2b 3.8 Hz, H-2b), 4.11-4.01 (m, 3H, H-4a, H-3b, OH), 3.97 (d, 1H, 
J 2.4 Hz, H-4b), 3.92 (dd, 1H, J 10.9, 5.4 Hz, H-6a), 3.84-3.76 (m, 2H, H-5a, H-6'a), 
3.73-3.61 (m, 2H, H-3a, H-6b), 3.56-3.48 (m, 1H, H-6'b), 2.09 (s, 3H, C(O)CH3); C (75 
MHz, CDCl3); 170.0 (C=O), 161.8, 142.9, 138.6, 138.5, 138.5, 138.2, 138.1, 128.5, 
128.4, 128.3, 128.3, 128.0, 127.8, 127.8, 127.7, 127.6, 127.5, 127.5, 125.8, 116.7 
(ArC), 101.5 (C-1b), 98.9 (C-1a), 8.16 (C-4b), 78.9, 76.3, 74.3 (C-2b, C-3b, C-4a), 75.3 
(C-6b), 74.9, 74.2, 73.6, 73.2 (OCH2Ph), 72.8 (C-3a), 72.3 (C-2a), 71.8 (OCH2Ph), 71.1 
(C-5b), 69.6 (C-5a), 68.4 (C-6b), 21.0 (C(O)CH3); IR (max/cm
-1): 3445, (OH), 1749 
(C=O), 1592, 1517 (NO2); HRMS: Found [M+Na]




4-Nitrophenyl bis-O-(-D-galactopyranosyl)--D-galactopyranoside (44) 
 
Donor 41 (167 mg, 0.26 mmol) was added to a solution of acceptor 43 (180 mg, 0.19 
mmol) and 4 Å MS (200 mg) in anhydrous DCM (25 mL), and the reaction was stirred 
at r.t. for 30 min under N2(g) atmosphere.  The reaction mixture was cooled to -45 °C 
and NIS (65 mg, 0.6 mmol) and TMSOTf (7 L, 0.08 mmol) were added to the reaction 
mixture, which was stirred at the same temperature for further 30 min. The reaction 
mixture was washed with saturated aq. NaHCO3 (30 mL) and sodium thiosulfate (30 
mL) to remove traces of acid and iodine. The aqueous phase was washed with DCM (2 
× 30 mL). The organic phase was collected, dried (MgSO4), filtred and concentrated to 
leave a crude oil, which was partially purified by flash column chrom atography (silica; 
7:1 → 5.5:1 hexaneEtOAc).  The mixture was then dissolved in a mixture of EtOAc 
and MeOH (2:3, v/v, 25 mL). Palladium on carbon (10% wt., 200 mg) was added to the 
solution, which was stirred at r.t. under hydrogen atmosphere overnight. The reaction 
mixture was filtered through Celite® pad under vacuum eluting with MeOH, and 
evaporated to dryness. The residue was dissolved in MeOH (30 mL). Potassium 
carbonate anhydrous (15 mg, 0.1 mmol) was added to the reaction mixture, which was 
stirred at r.t. overnight.  The resulting solution was neutralised with acetic acid, 
evaporated, purified by size-exclusion chromatography (Sephadex LH-20, MeOH) to 
give a mixture of compounds 44 with different configurations of glycosidic linkages as 
coulourless oil (8 mg, 4%, 3 steps); only signals for the major compound are listed; H 
(500 MHz, D2O); 7.09-7.05 (m, 2H, ArH), 6.87-6.84 (m, 2H, ArH), 5.29 (d, J1,2 4.1 Hz, 
H-1), 5.13 (d, 1H, J1,2 3.7 Hz, H-1), 5.10 (d, 1H, J1,2 7.3 Hz, H-1), 4.39 (bs, 1H, H-4), 
4.29 (t, 1H, J 6.4 Hz, H-5), 4.14 (t, 1H, J 6.01 Hz, H-5), 4.08-3.37 (m, 15H, 3 × H-2, 3 × 




4-Aminophenyl -D-galactopyranoside (45)190 
 
Palladium on carbon (10% wt., 50 mg) was added to a solution of 4-nitrophenyl -D-
galactopyranoside 36 (0.34 g, 1.12 mmol) in anhydrous MeOH (14 mL), and the 
reaction was stirred at r.t. under hydrogen atmosphere overnight. The reaction mixture 
was filtered through Celite® pad under vacuum eluting with MeOH, and evaporated to 
leave compound 45 (0.32 g, 100%) as a colourless solid; Rf 0.22 (8:2 EtOAcMeOH);  
m.p. 156-157 °C (from MeOH) (lit.190 m.p. 158-159°C);   23 D   -35.5 (c, 1, MeOH) (lit.
190 
  D  -40.5 (c, 1, MeOH)); H (500 MHz, DMSO-d6 with D2O exchange);  6.75 (d, 2H, J 
8.6 Hz, ArH), 6.50 (d, 2H, 8.6 Hz, ArH), 4.53 (d, 1H, J1,2 7.7 Hz, H-1), 3.66 (d,  1H, J 
3.0 Hz, H-4), 3.48-3.55 (m, 4H, H-2, H-5, H-6, H-6),3.36 (d, 1H, J 12.7 Hz, H-3); C (75 
MHz, DMSO-d6); 148.9, 143.5, 117.7, 114.5 (ArC), 102.7 (C-1), 75.3 (C-3), 73.3 (C-5), 
70.4 (C-2), 68.1 (C-4), 60.4 (C-6); IR (max/cm
-1): 3435 (OH, NH), 1642 (NH); HRMS: 





3,4-dimethoxy-3-cyclobutene-1,2-dione (0.06 g, 0.4 mmol) was added to a solution of 
4-aminophenyl -D-galactopyranoside 45 (0.095 g, 0.35 mmol)  in DMF (2 mL). The 
reaction mixture was stirred at r.t., filtered under vacuum through Celite® pad eluting 
with MeOH, and evaporated to leave compound 47 (0.32 g, 80%) as a yellow oil; Rf 0.6 
(1:1 EtOAcMeOH);   24 D  78.0 (c, 0.5, DMSO); H (500 MHz, DMSO-d6 with D2O 
exchange);  7.18 (bs, 2H, ArH), 6.98 (d, 2H, 8.9 Hz, ArH), 4.73 (d, 1H, J1,2 7.7 Hz, H-1), 
4.30 (s, 3H, CH3), 3.66 (d, 1H, J3,4  3.3 Hz, H-4),  3.51-3.85 (m, 4H, H-2, H-5, H-6, H-6), 
3.37 (dd, 1H, J3,4 3.3 Hz, J2,3  9.7 Hz, H-3) ; C (75 MHz, DMSO-d6); 121.0, 116.8 (ArC), 
162 
  
101.5 (C-1), 75.5, 73.5, 73.3, 68.2 (C-2, C-3, C-5), 70.1 (C-4), 60.4 (C-6, OCH3); IR 
(max/cm
-1): 3466 (OH), 1658 (C=O); HRMS: Found [M+Na]+ 404.0964, C17H19NNaO9 
requires 404.0952. 
 
meso-1,2-bis-(D-Galactopyranosyloxy)-cyclohexane (51)  
 
 Glycosylation reaction using NIS/TMSOTf  
Thioglycosyl donor 41 (213 mg, 3 mmol) and 1,2-cis-cyclohexanediol 49 (150 mg, 1 
mmol) were co-evaporated with toluene several times before adding 4 Å MS (120 mg) 
and anhydrous DCM (25 mL). The reaction was stirred at r.t. for 30 min under N2(g) 
atmosphere, cooled to -45 °C and NIS (750 mg, 4 mmol) and TMSOTf (100 µL, 0.5 
mmol) were added to the reaction mixture, which was stirred at -45 °C temperature for 
3 h. The reaction mixture was washed with saturated aq. NaHCO3 (20 mL) and 10% aq. 
Na2S2O3 (20 mL) to remove traces of acid and iodine. The aqueous phase was washed 
with DCM (2 × 30 mL). The organic phase was collected, dried (MgSO4), filtred and 
concentrated to leave a crude yellow oil, which was purified by flash column 
chromatography (silica; 13:1 →  :1 hexaneEtOAc). The residue was re-dissolved in a 
mixture of EtOAc (12 mL) and MeOH (12 mL). Palladium on carbon (Pd/C, 10% wt., 
104 mg, 2 mmol) was added to the reaction mixture, which was allowed to stir at r.t. 
under a positive pressure of hydrogen overnight. The reaction mixture was filtered 
through a Celite® pad and evaporated to dryness to give compound 51 as colourless oil 
(230 mg, 29% over 2 steps). A mixture of anomers was obtained. The :ratio (1:3) 
was determined by integration of anomeric signals in the 1H NMR spectrum. Signal 
integrations are normalised to give a total of 2 anomeric protons across all isomers; H 
(500 MHz, D2O); 5.19 (d, 0.25H, J 3.9 Hz), 5.11 (d, 0.23H, J 4.0 Hz), 4.59 (d, 0.65H, J 
7.9 Hz), 4.54 (d, 0.23H, J 7.9 Hz), 4.45 (d, 0.64H, J 7.9 Hz), 4.12-3.47 (m, 14H), 1.94-




 Glycosylation reaction using BSP/Tf2O/TTBP  
Thioglycosyl donor 41 (188 mg, 0.3 mmol), BSP (68 mg, 0.3 mmol), and TTBP (148 mg, 
0.6 mmol) were co-evaporated with toluene several times before adding 4 Å MS (100 
mg) and anhydrous DCM (5 mL). The reaction mixture was stirred at r.t. under N2(g) 
atmosphere for 1 h. Glycosyl acceptor 49 (15 mg, 0.13 mmol) was also co-evaporated 
with toluene several times and dissolved in anhydrous DCM (2 mL) in a separate flask. 
After stirring for 1 h, the mixture of thioglycosyl donor, BSP, TTBP and molecular 
sieves 4 Å was cooled to -60 °C before freshly distilled triflic anhydride (Tf2O) (30 L, 
0.17 mmol) was added. The reaction mixture was stirred at -60 °C for further 10 min 
before a solution of glycosyl acceptor 49 was added. The resulting mixture was stirred 
at low temperature (-60 °C to -10 °C) for 2 h, quenched with triethyl phosphite (51 L), 
triethylamine (2 mL), and washed with sat. aq. NaHCO3 (2 × 10 mL), followed by brine 
(2 × 10 mL). The combined organic phase was dried (MgSO4), and concentrated to 
leave crude brown oil, which was purified by gel permeation chromatography (Bio-
beads SX-1, toluene). The residue was re-dissolved in a mixture of EtOAc (3 mL) and 
MeOH (3 mL). Palladium on carbon (Pd/C, 10% wt., 120 mg, 1 mmol) was added to the 
reaction mixture, which was allowed to stir at r.t. under a positive pressure of hydrogen 
overnight. The reaction mixture was filtered through a Celite® pad and evaporated to 
dryness to give compound 51 as colourless oil (72 mg, 87% over 2 steps). A mixture of 
anomers was obtained. The :ratio (2:1) was determined by integration of anomeric 
signals in the 1H NMR spectrum. Signal integrations are normalised to give a total of 2 
anomeric protons across all isomers; H (500 MHz, D2O); 5.28 (d, 0.17H, J 3.9 Hz), 
5.25 (d, 1.08H, J 4.0 Hz), 4.65 (d, 0.19H, J 7.8 Hz), 4.60 (d, 0.30H, J 7.3 Hz), 4.51 (d, 
0.26H, J 8.0 Hz), 4.12-3.47 (m, 14H), 1.94-1.25 (m, 8H); HRMS: Found [M+Na]+ 













4-Methoxybenzoic acid (589.0 mg, 4 mmol) and 1,1-carbonyldiimidazole (657 mg, 4 
mmol) were dissolved in anhydrous MeCN  (25 mL) and stirred at 60 C under N2(g) 
atmosphere for 2.5 h. The reaction mixture was cooled to r.t. before phenyl 2,3,6-tri-O-
benzyl-1-thio--D-galactopyranoside 67 (1.0 g, 2 mmol) in MeCN (20 mL) was added, 
followed by DBU (578 L, 4 mmol). The reaction mixture was stirred at 60 C under 
N2(g) atmosphere for 15 h, cooled to r.t., poured into saturated aq. NaHCO3, and 
extracted with DCM (3 × 40 mL). The combined organic layers were washed with brine, 
dried (MgSO4), and concentrated. The residue was flash column chromatography 
(silica; 4:1 hexaneEtOAc), to give compound 55 (1.1 g, 88%) as a colourless oil; Rf 
0.21 (4:1 hexaneEtOAc);   21 D   30.7 (c, 2.4, CHCl3) (lit.
129   D  22.5 (c, 2.2, CHCl3)); 
H (500 MHz, CDCl3); 8.03 (d, 2H, J 8.5 Hz, ArH), 7.74-7.70 (m, 2H, ArH), 7.49-7.25 (m, 
18H, ArH), 7.01-6.97 (m, 2H, ArH), 5.94 (d, 1H, J3,4 2.9 Hz, H-4), 4.92 (d, 1H, J 11.2 Hz, 
OCH2Ph), 4.82 (s, 2H, OCH2Ph), 4.78 (d, 1H, J  9.1 Hz, H-1), 4.61-4.56 (m, 2H, 
OCH2Ph), 4.52 (d, 1H, J 11.7 Hz, OCH2Ph), 3.97-3.92 (m, 4H, OCH3, H-5), 3.84-3.74 
(m, 3H, H-2, H-3, H-6), 3.69-3.63 (m, 1H, H-6); C (75 MHz, CDCl3); 165.5 (C=O), 
163.7, 138.4, 137.8, 137.7, 133.1, 132.1, 132.9, 132.1, 128.9, 128.5, 128.4, 128.4, 
128.3, 128.3, 128.0, 127.8, 127.8, 127.7, 122.3, 113.7 (ArC), 87.2 (C-1), 81.6 (C-2), 
76.7 (C-3), 76.5 (C-5), 75.7 (OCH2Ph), 73.8 (OCH2Ph), 71.8 (OCH2Ph), 68.6 (C-6), 
67.1 (C-4), 55.6 (OCH3); IR (max/cm
-1): 2868 (C-H), 1716 (C=O), 1257 (C-OR); HRMS: 







Ethyl 2,3,4,6-tetra-O-acetyl-1-thio--D-galactopyranoside (61)191 
 
Ethanethiol (4.9 mL, 60 mmol) was added to a solution of -D-galactose pentaacetate 
33 (20.0 g, 51 mmol) in anhydrous DCM (200 mL) and the reaction was stirred at 0 °C 
for 10 min. Freshly distilled boron trifluoride diethyl etherate (9.5 mL, 77 mmol) was 
added to the reaction mixture, which was stirred at 0 °C for further 3.5 h. The reaction 
mixture was washed with water (2 × 50 mL). The aqueous phase was washed with 
DCM (2 × 50 mL). The organic phase was collected and washed with saturated aq. 
NaHCO3 (2 × 50 mL), dried (MgSO4) and concentrated to leave a crude oil, which was 
purified by flash column chromatography (silica; 2:1 hexaneEtOAc) to afford 
compound 61 (13.12 g, 65%) as a colourless solid; Rf 0.44 (2:1 tolueneEtOAc); m.p. 
75-77 °C (from diethyl etherpetroleum ether) (lit.191 m.p. 77-78 °C);   23 D   13.9 (c, 1, 
CHCl3) (lit.
191   D   20.8 (c, 1.3, CHCl3)); H (500 MHz, CDCl3); 5.43 (dd, 1H, J3,4 3.4 Hz, 
J4,5 0.7 Hz, H-4), 5.22 (t, 1 H, J1,2=2,3 10.0 Hz, H-2), 5.08 (dd, 1H, J2,3 10.0 Hz, J3,4 3.4 Hz, 
H-3), 4.56 (d, 1H, J1,2 10.0 Hz, H-1), 4.18-4.09 (m, 2H, H-6, H-6), 4.01 (td, 1H, J5,6=5,6 
7.0 Hz, J4,5 0.7 Hz, H-5), 2.83-2.65 (m, 2H, SCH2CH3), 2.16, 2.07, 2.04, 1.98 (4 s, 12H, 
4 × C(O)CH3), 1.29 (t, 3H, J 7.5 Hz, SCH2CH3); C (75 MHz, CDCl3); 83.5 (C-1), 74.0 
(C-5), 71.5 (C-3), 67.1 (C-4), 66.9 (C-2), 61.2 (C-6), 23.9 (SCH2CH3), 20.4, 20.3, 20.2 
(4 × C(O)CH3), 14.6 (SCH2CH3); IR (max/cm
-1): 1750 (C=O); HRMS: Found [M+Na]+ 










Ethyl 4,6-O-benzylidene-1-thio--D-galactopyranoside (62)193,194 
 
Sodium methoxide (1.83 g, 33.8 mmol) was added to a solution of ethyl 2,3,4,6-tetra-O-
acetyl-1-thio--D-galactopyranoside 61 (4.74 g, 12.0 mmol) in MeOH (30 mL). After 
being stirred at r.t. for 3.5 h, the reaction mixture was neutralised by slow addition of 
acetic acid and concentrated to leave a crude colourless solid, which was dissolved in 
MeCN (50 mL). Benzaldehyde dimethyl acetal (9 mL, 49 mmol) and p-toluenesulfonic 
acid monohydrate (2 g) were added to the solution, which was stirred at r.t. overnight. 
The reaction mixture was quenched by triethylamine, and concentrated. The residue 
was purified by flash column chromatography (silica; 4:1 hexaneEtOAc → 3:1 
hexaneEtOAc → 1:1 hexaneEtOAc with 0.1% triethylamine), yielded compound 62 
(1.55 g, 44%, 2 steps) as a colourless solid; Rf 0.46 (10:1 EtOAcMeOH); m.p. 156-
157 °C (from EtOH) (lit.193 154-156 °C);   21 D  -63.1 (c, 1, CHCl3) (lit.
194   D  -63.3 (c, 1, 
CHCl3)); H (500 MHz, CDCl3); 7.50-7.47 (m, 2H, ArH), 7.39-7.35 (m, 3H, ArH), 5.54 (s, 
1H, PhCHO2), 4.37-4.33 (m, 2H, H-1, H-6), 4.27 (dd, 1H, J4,5  1.2 Hz, J3,4 3.8 Hz, H-4), 
4.04 (dd, 1H, J6',5  1.9 Hz, J6,6' 12.4 Hz, H-6'), 3.81 (t, 1H, J1,2=2.3 9.3 Hz, H-2), 3.69 (m, 
1H, H-3), 3.53 (m, 1H, H-5), 2.80 (m, 2H, SCH2CH3), 2.59 (m, 1H, 2 × OH), 1.35 (t, 3H, 
J 7.3 Hz, SCH2CH3); C (75 MHz, CDCl3); 129.5, 128.5, 126.6 (ArC), 101.7 (PhCH), 
85.5 (C-1), 75.7 (C-4), 74.1 (C-3), 70.3 (C-5), 69.9 (C-2), 69.5 (C-6), 23.6 (SCH2CH3), 
15.4 (SCH2CH3); IR (max/cm
-1): 3325 (OH); HRMS: Found [M+Na]+ 335.0935, 









Phenyl 4,6-O-benzylidene-1-thio--D-galactopyranoside (63)195  
 
Sodium methoxide (6.5 g, 12 mmol) was added to a solution of phenyl 2,3,4,6-tetra-O-
acetyl-1-thio--D-galactopyranoside 40 (19 g, 43 mmol) in MeOH (136 mL) and the 
reaction was stirred at r.t. for 2 h. The reaction mixture was neutralised by slow addition 
of acetic acid and concentrated to give a crude colourless solid, which was dissolved in 
MeCN (150 mL). Benzaldehyde dimethyl acetal (28.6 mL, 188 mmol) and p-
toluenesulfonic acid monohydrate (4.5 g, 24 mmol) added to the reaction mixture, 
which was stirred at r.t. for 48 h, quenched by triethylamine, concentrated, and purified 
by flash column chromatography (silica; 4:1 hexaneEtOAc) to afford phenyl 4,6-O-
benzylidene-1-thio--D-galactopyranoside 63 as colourless solid (12 g, 77% over 2 
steps); Rf 0.53 (9:1 EtOAcMeOH); m.p. 160-161 °C (from EtOH) (lit.
195 m.p. 164-
165.5 °C);   22 D  -28.5 (c, 1.0, CHCl3) (lit.
195   D   -29.7 (c, 1.3, CHCl3));  H (500 MHz, 
CDCl3); 7.70-7.67 (m, 2H, ArH), 7.42-7.25 (m, 8H, ArH), 5.51 (s, 1H, PhCHO2), 4.54-
4.48 (m, 1H, H-1), 4.39 (dd, 1H, J6,6 12.5 Hz, J5,6 1.6 Hz, H-6), 4.22 (bd, 1H, J3,4 1.2 Hz, 
H-4), 4.04 (dd, 1H, J6,6 12.5 Hz, J5,6 1.6 Hz, H-6), 3.70 (m, 3H, H-2, H-3), 3.56 (bd, J5,6 
1.6 Hz, H-5), 2.58 (s, 1H, OH), 1.61 (s, 1H, OH); C (75 MHz, CDCl3); 137.7, 133.9, 
130.9, 129.5, 129.1, 128.4, 128.4, 126.7, 110.1 (ArC), 101.6 (PhCHO2), 87.2 (C-1), 
75.5 (C-4), 74.0 (C-3), 70.2 (C-5), 69.4 (C-6), 69.0 (C-2); IR (max/cm
-1): 3294 (OH); 










Ethyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio--D-galactopyranoside (64)196 
 
Benzyl bromide (2 mL, 16.2 mmol) was added to a solution of ethyl 4,6-O-benzylidene-
1-thio--D-galactopyranoside 62 (1.41 g, 4.5 mmmol) in DMF (20 mL). After cooling the 
reaction mixture to 0 C, sodium hydride (60% in oil dispersion, 2.4 g, 60 mmol) was 
added. The reaction mixture was stirred at r.t. overnight. The mixture was quenched 
with water (5 mL), extracted with DCM twice. The organic layers were combined, 
washed with brine and dried over MgSO4. The solvent was removed and the crude 
product was purified by flash column chromatography (silica; 4:1 hexaneEtOAc) to 
afford compound 64 (1.50 g, 67%) as colourless needles; Rf 0.70 (10:1 EtOAcMeOH); 
m.p. 153-154 °C (from DCM-petroleum ether) (lit.196 m.p. 154-156 °C);   24 D   3.6 (c, 1.3, 
CHCl3) (lit.
196   D   3.5 (c, 1.3, CHCl3)); H (500 MHz, CDCl3); 7.58-7.52 (m, 2H, ArH), 
7.45-7.23 (m, 13H, ArH), 5.48 (s, 1H, PhCHO2), 4.90 (d, 1H, J 10.2 Hz, OCH2Ph), 4.84 
(d, 1H, J 10.2 Hz, OCH2Ph), 4.79-4.72 (m, 2H, OCH2Ph), 4.44 (d, 1H, J1,2 9.6 Hz, H-1), 
4.31 (dd, 1H, J6,6´ 12.3 Hz, J5,6 1.2 Hz, H-6), 4.16 (d, 1H, J3,4  3.2 Hz, H-4), 3.97 (dd, 1H, 
J6,6´  12.4 Hz, J5,6 1.2 Hz, H-6), 3.90 (t, 1H, J1,2=2,3 9.6 Hz, H-2), 3.60 (dd, 1H, J2,3 9.6 Hz, 
J3,4 3.2 Hz, H-3), 3.36 (d, 1H, J5,6=5,6 1.2 Hz H-5), 2.90-2.70 (m, 2H, SCH2CH3), 1.34 (t, 
3H, J 7.5 Hz, SCH2CH3); C (75 MHz, CDCl3); 138.6, 138.4, 138.1, 129.2, 128.5, 128.5, 
128.3, 127.9, 127.9, 127.9, 126.7 (ArC), 101.6 (PhCH), 84.6 (C-1), 81.3 (C-3), 77.0 (C-
2), 75.9 (OCH2Ph), 74.1 (C-4), 71.9 (OCH2Ph), 69.9 (C-5), 69.6 (C-6), 24.0 (SCH2CH3), 
15.2 (SCH2CH3); IR (max/cm
-1): 3019 (C-H), 1215 (C-OR); HRMS: Found [M+Na]+ 











Benzylbromide (3.5 mL, 30 mmol) was added to the solution of 4,6-O-benzylidene-1-
thio--D-galactopyranoside 63 (11.5 g, 32 mmol) in DMF (100 mL). After cooling the 
reaction mixture to 0 C in an ice bath, sodium hydride (60% in oil dispersion, 3.3 g, 
138 mmol) was added. The reaction mixture was stirred at r.t. overnight and quenched 
with water (5 mL), extracted with DCM twice. The organic layers were combined, 
washed with brine and dried over MgSO4. The solvent was removed and the crude 
product was purified by flash column chromatography (silica; 17:3 hexaneEtOAc → 
2:1 hexaneEtOAc) to afford compound 65 as a colourless solid (15.0 g, 87%); Rf 0.26 
(2:1 hexaneEtOAc); m.p. 177-178 °C (from EtOAchexane) (lit.197 m.p. 178-179 °C); 
  21 D   -17.3 (c, 1.2, CHCl3) (lit.
197   D   -19.4 (c, 1.23, CHCl3)); H (500 MHz, CDCl3); 
7.73-7.68 (m, 2H, ArH), 7.57-7.49 (m, 2H, ArH), 7.44-7.16 (m, 16H, ArH), 5.49 (s, 1H, 
PhCHO2), 4.75-4.66 (m, 4H, 2 × OCH2Ph), 4.61 (d, 1H, J1,2 9.4 Hz, H-1), 4.36 (dd, 1H, 
J6,6 12.3 Hz, J5,6 1.6 Hz, H-6), 4.15 (d, 1H, J3,4 3.2 Hz, H-4), 3.98 (dd, 1H, J6,6  12.3 Hz, 
J5,6 1.6 Hz, H-6), 3.90 (t, 1H, J1,2=2,3  9.4 Hz, H-2), 3.62 (dd, 1H, J2,3 9.4 Hz, J3,4 3.2 Hz, 
H-3), 3.40 (d, 1H, J5,6  1.6 Hz, H-5); C (75 MHz, CDCl3); 138.5, 138.1, 137.9, 132.8, 
129.1, 128.9, 129.4, 129.3, 129.2, 129.2, 127.7, 127.5, 126.6 (ArC), 101.3 (PhCHO2), 
86.6 (C-1), 81.4 (C-2), 75.5 (OCH2Ph), 75.4 (C-2), 73.7 (C-4), 71.9 (OCH2Ph), 69.9 (C-
5), 69.4 (C-6); IR (max/cm
-1): 2865 (C-H), 1091 (C-OR); HRMS: Found [M+Na]+ 








Ethyl 2,3,6-tri-O-benzyl-1-thio--D-galactopyranoside (66)198 
 
Sodium cyanoborohydride (0.52 g, 8.3 mmol) and methyl orange (28 mg) were added 
to a stirred solution of ethyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio--D-
galactopyranoside 64 (0.68 g, 1.4 mmol) in anhydrous THF. After cooling the mixture to 
0 C, ethereal HCl was added dropwise until the solution turned pink. The reaction 
mixture was stirred at r.t. under N2(g) atmosphere overnight. The reaction mixture was 
quenched with water, extracted with DCM. The combined organic phases were washed 
with saturated aq. NaHCO3 twice, dried (MgSO4), and concentrated. The residue was 
purified by flash column chromatography (silica; 2:1 hexaneEtOAc), yielded 
compound 66 (200 mg, 28%) as a colourless oil; Rf 0.32 (2:1 hexaneEtOAc);    24 D   
3.5 (c, 1, EtOAc) (lit.198   D   2 (c, 1, EtOAc)); H (500 MHz, CDCl3); 7.41-7.36 (m, 2H, 
ArH), 7.36-7.23 (m, 13H, ArH), 4.86 (d, 1H, J 10.3 Hz, OCH2Ph), 4.76 (d, 1H, J 10.3 Hz, 
OCH2Ph), 4.69 (d, 1H, J 11.7 Hz, OCH2Ph), 4.66 (d, 1H, J 11.7 Hz, OCH2Ph), 4.55 (s, 
2H, OCH2Ph), 4.42 (d, 1H, J1,2 9.7 Hz, H-1), 4.06 (t, 1H, J 2.4 Hz, H-4), 3.79-3.64 (m, 
3H, H-2, H-6, H-6'), 3.57-3.49 (m, 2H, H-3, H-5), 2.81-2.65 (m, 2H, SCH2CH3), 2.62 (d, 
1H, J 1.9 Hz, -OH), 1.30 (t, 3H, J 7.4 Hz, SCH2CH3); C (75 MHz, CDCl3); 138.2, 138.0, 
137.8 (C-O), 128.5, 128.4, 128.3, 127.9, 127.8, 127.7 (ArC), 85.0 (C-1), 82.4 (C-3), 
77.9 (C-2), 76.9 (C-5), 75.8, 73.7, 72.0 (3 × OCH2Ph), 69.4 (C-6), 66.9 (C-4), 24.7 
(SCH2CH3), 15.1 (SCH2CH3); IR (max/cm
-1): 3463 (OH), 2895 (C-H); HRMS: Found 









Phenyl 2,3,6-tri-O-benzyl-1-thio--D-galactopyranoside (67)199 
 
Sodium cyanoborohydride (1.5 g, 24 mmol) and methyl orange (80 mg, 0.2 mmol) were 
added to a stirred solution of phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio--D-
galactopyranoside 65 (2.14 g, 4.0 mmol) in anhydrous THF. After cooling the mixture to 
0 C, ethereal HCl was added dropwise until the solution turned pink. The reaction 
mixture was stirred at r.t. under N2(g) atmosphere overnight. The reaction mixture was 
quenched with water (70 mL), extracted with diethyl ether (3 × 100 mL). The combined 
organic phases were combined, washed with saturated aq. NaHCO3 (2 × 100 mL) and 
water (2 × 100 mL), dried (MgSO4), and concentrated. The crude product was purified 
by flash column chromatography (silica; 2:1 hexaneEtOAc), yielded compound 67 (1.4 
g, 67%) as a colourless oil; Rf 0.34 (2:1 hexaneEtOAc);    21 D   -6.3 (c, 1.03, CHCl3) 
(lit.199   D   -10.5 (c, 1.06, CHCl3)); H (500 MHz, CDCl3); 7.64-7.60 (m, 2H, ArH), 7.46-
7.43 (m, 2H, ArH), 7.39-7.22 (m, 16H, ArH), 4.87 (d, 1H, J 10.4 Hz, OCH2Ph), 4.78 (d, 
1H, J 10.4 Hz, OCH2Ph), 4.74-4.65 (m, 3H, H-1, OCH2Ph), 4.57 (s, 2H, OCH2Ph), 4.10 
(t, 1H, J3,4=4,5 2.8 Hz, H-4), 3.85-3.77 (m, 3H, H-2, H-6, H-6), 3.63-3.56 (m, 2H, H-3, H-
5), 2.74 (d, 1H, J 2.5 Hz, OH); C (75 MHz, CDCl3); 138.2, 137.9, 137.7, 134.0, 131.6, 
128.8, 128.4, 128.3, 128.3, 128.2, 127.9, 127.8, 127.7, 127.7, 127.7, 127.2 (ArC), 87.6 
(C-1), 82.5 (C-3), 77.0 (C-5), 77.0 (C-2), 75.6 (OCH2Ph), 73.6 (OCH2Ph), 72.0 
(OCH2Ph), 69.5 (C-6), 66.8 (C-4); IR (max/cm
-1): 3552 (OH), 2907, 2870 (CH), 1052 (C-












4-Methoxybenzoic acid (127 mg, 0.8 mmol) and 1,1-carbonyldiimidazole (143 mg, 0.9 
mmol) were dissolved in anhydrous MeCN  (5 mL) and stirred at 60 C under N2(g) 
atmosphere for 2 h. The reaction mixture was cooled to r.t. before ethyl 2,3,6-tri-O-
benzyl-1-thio--D-galactopyranoside 66 (196 mg, 0.4 mmol) in MeCN (4 mL) was 
added, followed by DBU (128 L, 0.8 mmol). The reaction mixture was stirred at 60 C 
under N2(g) atmosphere for 16 h, cooled to r.t., poured into saturated aq. NaHCO3, and 
extracted with DCM. The combined organic layers were washed with brine, dried 
(MgSO4), and concentrated. The residue was purified by flash column chromatography 
(silica; 4:1 hexaneEtOAc), to give compound 68 (220 mg, 87%) as a colourless oil; Rf 
0.43 (2:1 hexaneEtOAc);   22 D   28.4 (c, 1.0, CHCl3); H (500 MHz, CDCl3); 8.06 (d, 2H, 
J 8.8 Hz, ArH), 7.39-7.17 (m, 15H, ArH), 6.93 (d, 2H, J 8.8 Hz, ArH), 5.87 (d, 1H, J 2.7 
Hz, H-4), 4.87 (d, 1H, J 11.4 Hz, OCH2Ph), 4.80 (d, 1H, J 10.3 Hz, OCH2Ph), 4.75 (d, 
1H, J 10.2 Hz, OCH2Ph), 4.58-4.45 (m, 3H, H-1, OCH2Ph), 4.42 (d, 1H, J 11.7 Hz, 
OCH2Ph), 3.88-3.78 (m, 4H, OCH3, H-5), 3.74-3.60 (m, 3H, H-2, H-3, H-6), 3.58-3.51 
(m, 1H, H-6'), 2.86-2.71 (m, 2H, SCH2CH3 ), 1.34 (t, 3H, J 7.4 Hz, SCH2CH3); C (75 
MHz, CDCl3); 165.5 (C=O), 163.6, 138.2, 137.9, 137.7, 128.5, 128.4, 128.3, 128.2, 
128.0, 127.8, 127.7, 113.7 (ArC), 85.5 (C-1), 81.2 (C-2), 77.9 (C-3), 76.3 (C-5), 75.9, 
73.8, 71.7 (3 × OCH2Ph), 68.6 (C-6), 67.2 (C-4), 55.5 (OCH3); IR (max/cm-1): 3054 (C-










General method for glycosylation procedure. Thioglycosyl donor 55 (200 mg, 0.3 mmol), 
BSP (68 mg, 0.3 mmol), and TTBP (148 mg, 0.6 mmol) were co-evaporated with 
toluene several times before adding 4 Å MS (100 mg) and either anhydrous DCM (5 
mL) or a mixture of anhydrous DCM (2.5 mL) and anhydrous diethyl ether (2.5 mL). 
The reaction mixture was stirred at r.t. under N2(g) atmosphere for 1 h. Glycosyl 
acceptor 49 (15 mg, 0.13 mmol) was also co-evaporated with toluene several times 
and dissolved either in anhydrous DCM (2 mL) or a mixture of anhydrous DCM (1 mL) 
and anhydrous diethyl ether (1 mL) in a separate flask. After stirring for 1 h, the mixture 
of thioglycosyl donor, BSP, TTBP and molecular sieves 4 Å was cooled to -60 °C 
before freshly distilled triflic anhydride (Tf2O; 30 L, 0.17 mmol) was added. The 
reaction mixture was stirred at -60 °C for further 10 min before a solution of acceptor 49 
was added. The resulting mixture was stirred at low temperature (-60 °C to -10 °C) for 
2 h, quenched with triethyl phosphite (51 L), triethylamine (2 mL), and washed with 
sat. aq. NaHCO3 (2 × 10 mL), followed by brine (2 × 10 mL). The combined organic 
phase was dried (MgSO4), and concentrated to leave crude brown oil, which was 
purified by gel permeation chromatography (Bio-beads SX-1, toluene). The residue 
was re-dissolved in a mixture of EtOAc (1 mL) and MeOH (1 mL). Palladium on carbon 
(Pd/C, 10% wt., 60 mg) was added to the reaction mixture, which was allowed to stir at 
r.t. under a positive pressure of hydrogen overnight. The reaction mixture was filtered 
through a Celite® pad and evaporated to dryness to give a mixture of compound 70 and 
trehalose-like compound 71 as colourless oil; LC-MS: for compound 70: Found 
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[M+Na]+ 731.4, C34H44NaO16 requires 731.7; for compound 71: Found [M+Na]
+ 633.2, 
C28H34NaO15 requires 633.6.  
 Glycosylation reaction in DCM gave a mixture of compounds 70 and 71 in a 
ratio of 5:3 (29 mg of the mixture, 21% of 70 over two steps; calculated from a 
relative mass of 671.90). A mixture of anomers was obtained. The :ratio (5:1) 
was determined by integration of anomeric signals in the 1H NMR spectrum. 
Signal integrations are normalised to give a total of 2 anomeric protons across 
all isomers; H (500 MHz, CD3OD); 8.03-8.00 (m, 4H), 7.04-6.96 (m, 4H), 5.57-
5.51 (m, 2H), 5.34 (d, 0.40H, J 3.7 Hz), 5.31 (d, 0.69H, J 3.8 Hz), 5.25 (d, 0.10H, 
J 3.6 Hz), 5.13 (d, 0.68H,  J 3.8 Hz), 5.11 (d, 0.13H, 3.8 Hz), 4.66 (d, 0.50H, J 
7.9 Hz), 4.62 (d, 0.25, J 7.9 Hz), 4.51 (d, 1.25H, J 7.7 Hz), 4.38-3.49 (m, 14H), 
2.18-1.24 (m, 8H). 
 
 Glycosylation reaction in DCM:diethyl ether (1:1, v/v) gave a mixture of 
compounds 70 and 71 in a ratio of 10:7 (45 mg of the mixture, 30% of 70 over 
two steps; calculated from a relative mass of 668.30); The :ratio (5:1) was 
determined by integration of aromatic signals in the 1H NMR spectrum. Signal 
integrations are normalised to give a total of 2 anomeric protons across all 
isomers;  H (500 MHz, CD3OD); 8.06-7.99 (m, 4H), 7.06-6.95 (m, 4), 5.57-5.51 
(m, 2H), 5.35 (d, 0.48H, J 3.8 Hz), 5.31 (d, 0.68H, J 3.9 Hz), 5.25 (d, 0.07H, J 
3.9 Hz), 5.13 (d, 0.65H, J 3.7 Hz), 5.11 (d, 0.12H, J 3.9 Hz), 4.65 (d, 0.15H, J 
7.1 Hz), 4.62 (d, 0.10H, J 7.4 Hz), 4.55-4.49 (m, 1.20H), 4.38-3.51 (m. 14H), 
2.11-1.24 (m, 8H). 
A mixture of compounds 70 and 71 of the above reactions were combined (62 mg) was 
dissolved in anhydrous MeOH (5 mL). Sodium hydroxide (14 mg, 0.53 mmol) was 
added to the reaction mixture, which was stirred for 1.5 h, concentrated and purified by 
mass-directed HPLC to provide compound 51 as a mixture of anomers (7 mg, / ratio 




The :ratio was determined by integration of aromatic signals in the 1H NMR 
spectrum. Signal integrations are normalised to give a total of 2 anomeric protons 
across all isomers; H (500 MHz, D2O); 5.27 (d, 0.90H, J 4.0 Hz), 5.25 (d, 0.09H, J 3.9 
Hz), 5.18 (d, 1.01H, J 4.0 Hz), 4.68 (d, 0.96 H, J 7.3 Hz), 4.56 (d, 1.04H, J 7.8 Hz), 
4.30-3.59 (m, 14H), 2.09-1.20 (m, 8H). 
 
4-Methoxycarbonylphenyl 2,3,4,6-tetra-O-acetyl--D-galactopyranoside (72)200 
 
A solution of 2,3,4,6-tetra-O-acetyl--D-galactopyranosyl trichloroacetimidate 34 (720.0 
mg, 1.46 mmol), methyl 4-hydroxybenzoate (333.0 mg, 2.2 mmol) and 4Å MS (500 mg) 
in anhydrous DCM (6 mL) was stirred at -5 °C for 1 h before freshly distilled boron 
trifluoride diethyl etherate (40 µL, 0.3 mmol) was added dropwise. After stirring at -5 °C 
for 1 h, the reaction mixture was washed with saturated aq. NaHCO3 three times and 
extracted with DCM three times. The combined organic layers were dried (MgSO4) and 
concentrated to afford a colourless oil, which was purified by flash column 
chromatography (silica; 2:1 hexaneEtOAc)  to afford compound 72 (515 mg, 73%) as 
a colourless solid; Rf 0.13 (2:1 hexaneEtOAc); m.p. 146-147 °C (from EtOH);   22 D   
1.0 (c, 1, CHCl3) (lit.
200   25 D   1.7 (c 0.8, CHCl3)); H (500 MHz, CDCl3); 8.01-7.98 (m, 2H, 
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ArH), 7.03-7.00 (m, 2H, ArH), 5.51 (dd, 1H, J2,3 10.4, J1,2 7.9 Hz, H-2), 5.47 (d, 1H, J3,4 
3.1 Hz, H-4), 5.15-5.10 (m, 2H, H-1, H-3), 4.24-4.20 (m, 1H, H-6),  4.19-4.14 (m, 1H, H-
6), 4.13-4.08 (m, 1H, H-5), 3.90 (s, 3H, OCH3), 2.18 (s, 3H, C(O)CH3), 2.06 (s, 3H, 
C(O)CH3), 2.06 (s, 3H, C(O)CH3), 2.02 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 170.5, 
170.3, 170.2, 169.5 (4 × C(O)CH3), 166.6 (C=O), 160.4, 131.7, 125.2, 116.3 (ArC), 
99.0 (C-1), 71.4 (C-5), 70.9 (C-3), 68.6 (C-2),   67.0 (C-4), 61.5 (C-6), 52.2 (OCH3), 
20.8, 20.8, 20.8, 20.7 (4 × C(O)CH3),  IR (max/cm
-1): 1755 (C=O); HRMS: Found 
[M+Na]+ 505.1334, C22H26O12Na requires 505.1316.  
 
4-Methoxycarbonylphenyl -D-galactopyranoside (73) 
 
Sodium methoxide (34.5 mg, 0.6 mmol) was added to a suspension of 4-
methoxycarbonylphenyl 2,3,4,6-tetra-O-acetyl--D-galactopyranoside 72 (370 mg, 0.8 
mmol) in anhydrous MeOH (7 mL). After stirring for 2 h at r.t., the reaction mixture was 
diluted with MeOH and neutralised with Amberlite IRC 86 H+ resin, filtered and 
concentrated to afford compound 73 (236 mg, 94%) as a colourless solid; Rf 0.10 (9:1 
DCMMeOH); m.p. 190-191 °C;   23 D  0.8 (c, 1.0, DMSO); H (500 MHz, DMSO-d6) 
7.91 (d, 2H, J 8.8 Hz, ArH), 7.11 (d, 2H, J 8.8 Hz, ArH), 5.30 (s, 1H, OH), 5.04 (s, 1H, 
OH), 4.95 (d, 1H, J1,2 7.7 Hz, H-1), 4.74 (s, 1H, OH), 4.66 (s, 1H, OH), 3.82 (s, 3H, 
OCH3), 3.72 (s, 1H, H-5), 3.64-3.40 (m, 5H, H-2, H-3, H-4, H-6, H-6); C (75 MHz, 
DMSO-d6); 161.2 (C=O), 131.0 (ArC), 122.8 (ArC), 116.0 (ArC), 100.4 (ArC), 75.6 (C-1), 
73.2 (C-5), 70.2, 68.0, 60.2 (C-2, C-3, C-4), 51.9 (OCH3); IR (max/cm
-1): 3589 (OH), 




4-Methoxycarbonylphenyl 3-O-allyl-4,6-O-benzylidene--D-galactopyranoside (75) 
 
A suspension of 4-methoxycarbonylphenyl 2,3,4,6-tetra-O-acetyl--D-
galactopyranoside 73 (5 g, 16 mmol) and dibutyl tinoxide (4 g, 16 mmol) in toluene 
(110 mL) was refluxed overnight under azeotropic conditions. Toulene was removed in 
vacuo and the residue was dissolved in anhydrous THF (70 mL). Allyl bromide (6.9 mL, 
80 mmol) and tetrabutyl aluminium bromide (5.12 g, 16 mmol) were added to the 
reaction mixture, which was refluxed for 8 h, filtered, evaporated, and partially purified 
by flash column chromatography (silica; 1:4 hexaneEtOAc). One fourth of the semi 
crude product (500 mg, 1.45 mmol) was dissolved anhydrous DMF (3mL). 
Benzaldehyde dimethylacetal (2.6 mL, 1.73 mmol) and (+/-)-10-camphorsulfonic acid 
were to the solution until the reaction mixture was acidic. The reaction mixture was 
then stirred at r.t. overnight. Triethylamine was added to neutralise the solution mixture, 
which was then concentrated, and recrystalised from EtOH to afford compound 75 (190 
mg, 10%, 2 steps); Rf 0.50 (1:4 hexaneEtOAc); m.p. 230-231 °C (from EtOH);   22 D  -
61.4 (c, 1.0, CHCl3); H (500 MHz, CDCl3); 8.01-7.94 (m, 2H, ArH), 7.55-7.50 (m, 2H, 
ArH), 7.39-7.30 (m, 3H, ArH), 7.12-7.05 (m, 2H, ArH), 5.93-6.04 (m, 1H, CH2=CHCH2), 
5.57 (s, 1H, PhCHO2), 5.39-5.33 (m, 1H, CH2=CHCH2), 5.27-5.22 (m, 1H, 
CH2=CHCH2), 5.06 (d, 1H, J1,2  7.7 Hz, H-1), 4.39-4.19 (m, 5H, H-2, H-4, H-6, 
CH2=CHCH2), 4.15-4.10 (m, 1H, H-6), 3.89 (s, 3H, OCH3), 3.64-3.55 (m, 2H, H-3, H-5); 
C (75 MHz, CDCl3); 166.8 (C=O), 160.9, 137.7, 134.8 (CH2=CHCH2), 131.6, 129.2, 
128.3, 126.5, 124.6 (ArC), 118.1 (CH2=CHCH2), 116.5 (ArC), 101.3 (PhCHO2), 100.6 
(C-1), 79.0 (C-3), 72.9 (C-4), 70.9 (CH2=CHCH2), 69.6 (C-2), 69.3 (C-6), 67.1 (C-5), 
52.1 (OCH3); IR (max/cm
-1): 3419 (OH), 1718 (C=O); HRMS: Found [M+Na]+ 465.1524, 
C24H26O8Na requires 465.1520. 
A small sample (30 mg) of this purified product was acetylated using pyridine-acetic 
anhydride catalysed by DMAP and purified by flash column chromatography (silica; 1:1 
hexaneEtOAc) to give 4-methoxycarbonylphenyl 2-O-acetyl-3-O-allyl-4,6-O-
benzylidene--D-galactopyranoside as colourless solid; Rf 0.25 (1:1 hexaneEtOAc); 
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  25 D  -22.93 (c, 1.0, CHCl3); m.p. 166-168 °C (from hexane-EtOAc); H (500 MHz, 
CDCl3); 7.96 (d, 2H, J 8.7 Hz, ArH), 7.56-7.51 (m, 2H, ArH), 7.35 (q, 3H, J 7.6 Hz, ArH), 
7.02 (d, 2H, J 8.7 Hz, ArH), 5.88 (m, 1H, CH2=CHCH2), 5.62-5.53 (m, 2H, PhCHO2, H-
2), 5.33-5.26 (m, 1H, CH2=CHCH2), 5.22-5.18 (m, 1H, CH2=CHCH2), 5.10 (d, 1H, J1,2 
7.9 Hz, H-1), 4.38-4.31 (m, 2H, H-4, H-6), 4.22-4.16 (m, 1H, CH2=CHCH2), 4.15-4.07 
(m, 2H, CH2=CHCH2, H-6), 3.88 (s, 3H, OCH3), 3.68 (dd, 1H, J2,3 10.1 Hz, J3,4 3.5 Hz, 
H-3), 3.58 (bs, 1H, H-5), 2.07 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 169.4, 166.8 
(C=O), 160.9, 137.6, 134.7 (CH2=CHCH2), 131.5, 129.1, 128.3, 126.5, 124.6 (ArC), 
117.5 (CH2=CHCH2), 116.4 (ArC), 101.3 (PhCHO2), 99.1 (C-1), 77.1 (C-3), 73.3 (C-4), 
70.6 (CH2=CHCH2), 69.9 (C-2), 69.0 (C-6), 67.1 (C-5), 52.1 (OCH3), 21.0 (C(O)CH3); 
IR (max/cm
-1): 1716 (C=O); HRMS: Found [M+Na]+ 507.1633, C26H28NaO9 requires 
507.1626. 
 
4-Methoxycarbonylphenyl 3,4-O-isopropylidene--D-galactopyranoside (76) 
 
4-Methoxycarbonylphenyl -D-galactopyranoside 73 (3.16 g, 10 mmol) in DMF (30 mL) 
was stirred at 80 °C, and p-toluenesulfonic acid (0.7 g, 3.6 mmol) was added 
portionwise, followed by adding 2,2-dimethoxypropane (3.7 mL, 30 mmol) dropwise. 
The resulting mixture was stirred for 4 h at 80 °C.  The reaction was quenched with 
triethylamine (3 mL) and concentrated to leave pale yellow syrup, which was 
suspended in EtOAC (30 mL) and MeOH (10 mL). Aqueous TFA (0.2 mL, 50% v/v) 
was added to the mixture. After stirring for further 1 h, the reaction mixture was again 
quenched with triethylamine (2 mL) and evaporated onto silica. Flash column 
chromatography (silica, 19:1 EtOAchexane) gave compound 76 as colourless foam 
(2.41 g, 68%); Rf 0.58 (19:1 EtOAcMeOH);   22 D  -35.4 (c, 1.0, CHCl3); H (500 MHz, 
CD3OD); 8.00-7.92 (m, 2H, ArH), 7.16-7.10 (m, 2H, ArH), 4.97 (d, 1H, J1,2 8.0 Hz, H-1), 
4.29 (dd, 1H, J3,4 5.5 Hz, J4,5 2.1 Hz, H-4), 4.16 (1H, dd, J2,3 7.1 Hz, J3,4  5.5 Hz, H-3), 
4.11-4.06 (m, 1H, H-5), 3.87 (s, 1H, OCH3), 3.81-3.77 (m, 2H, H-6, H-6), 3.71 (dd, 1H, 
J1,2 8.0 Hz, J2,3 7.1 Hz, H-2), 1.52 (s, 3H, C(CH3)), 1.36 (s, 3H, C(CH3)); C (75 MHz, 
CD3OD); 168.2 (C=O), 162.7, 132.4, 125.1, 117.3 (Arc), 111.2 (C(CH3)2), 101.1 (C-1), 
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80.7 (C-3), 75.3 (C-5), 74.9 (C-4), 73.9 (C-2), 62.4 (C-6), 52.5 (OCH3), 28.4, 26.5 (2 × 
CH3); IR (max/cm
-1): 3365 (OH), 1722 (C=O); HRMS: Found [M+Na]+ 377.1212, 





4-Methoxycarbonylphenyl 3,4-O-isopropylidene -D-galactopyranoside 76 (2.23 g, 6.2 
mmol) was dissolved in anhydrous DMF (50 mL), the reaction mixture was cooled to 
0 °C, to which NaH (60%, 1.13 g, 47.2 mmol) was added portionwise. After stirring at 
0 °C for 15 min, benzyl bromide (2.7 mL, 22.7 mmol) was added. The resulting mixture 
was stirred at r.t. for 2 h before MeOH (18 mL) was added to quench the reaction. 
Solvent removal gave a crude oil, which was purified by flash column chromatography 
(silica; 3:1 Petroleum etherEtOAc), yielded compound 77 as colourless oil (1.96, 58%); 
Rf 0.67 (19:1 Petroleum etherEtOAc);   22 D  4.13 (c, 1.0, CHCl3); H (500 MHz, CDCl3); 
7.99-7.95 (m, 2H, ArH), 7.41-7.24 (m, 10H, ArH), 7.09-7.05 (m, 2H, ArH), 5.01 (d, 1H, 
J1,2 7.8 Hz, H-1), 4.87 (s, 2H, OCH2Ph), 4.61 (d, 1H, J 11.8 Hz, OCH2Ph), 4.53 (d, 1H, J 
11.8 Hz, OCH2Ph), 4.29 (t, 1 H, J2,3=3,4 6.1 Hz, H-3), 4.23 (dd, 1H, J3,4 6.1 Hz, J4,5 1.9 
Hz, H-4), 4.09 (m, 1H, H-5), 3.90 (s, 3H, OCH3), 3.86-3.75 (m, 2H, H-6, H-6), 3.71 (dd, 
1H, J1,2 7.8 Hz, J2,3 6.1 Hz, H-2), 1.42 (s, 3H, C(CH3)), 1.36 (s, 3H, C(CH3)); C (75 MHz, 
CDCl3); 166.8 (C=O), 160.9, 138.2, 138.0, 131.7, 128.5, 128.4, 128.3, 127.9, 127.9, 
127.7, 124.5, 116.3 (Arc), 110.5 (C(CH3)2), 100.2 (C-1), 79.1 (C-2), 79.1 (C-3), 73.8 
(OCH2Ph), 73.8 (OCH2Ph), 73.7 (C-4), 73.0 (C-5), 69.6 (C-6), 52.1 (OCH3), 27.8, 26.4 
(2 × CH3); IR (max/cm
-1): 1750 (C=O); HRMS: Found [M+Na]+ 557.2155, C31H34O8Na 






4-Methoxycarbonylphenyl 2,6-di-O-benzyl--D-galactopyranoside (78) 
 
An aqueous acetic acid (80% v/v, 17 mL) was added to 200 mg of 4-
methoxycarbonylphenyl 3-O-allyl-2,6-di-O-benzyl--D-galactopyranoside 77. The 
reaction mixture was stirred at 80 °C for 2.5 h, brought to r.t., concentrated to give 
compound 78 as a colourless oil (172 mg, 94%); Rf 0.06 (1:1 HexaneEtOAc);   27 D  -
12.0 (c, 0.7, CHCl3); H (500 MHz, CDCl3); 7.99 (d, 2H, J 8.8 Hz, ArH), 7.37-7.27 (m, 
10H, ArH), 7.09 (d, 2H, J 8.8 Hz, ArH), 5.05 (s, 1H, J1,2 7.7 Hz, H-1), 5.01 (d, 1H, J 11.3 
Hz, OCH2Ph), 4.78 (d, 1H, J 11.4 Hz, OCH2Ph), 4.57 (s, 2H, OCH2Ph), 4.07 (d, 1H, J3,4 
3.3 Hz, H-4), 3.90 (s, 3H, OCH3), 3.86-3.77 (m, 4H, H-2, H-5, H-6, H-6), 3.71 (dd, 1H, 
J2,3 9.4 Hz, J3,4 3.3 Hz, H-3), 2.68, (s, 1H, OH), 2.56 (s, 1H, OH); C (75 MHz, CDCl3); 
166.8 (C=O), 160.8, 138.1, 137.8, 131.7, 128.8, 128.6, 128.4, 128.3, 128.0, 128.0, 
127.9, 124.6, 116.3 (ArC), 101.1 (C-1), 78.8 (C-2), 75.1 (OCH2Ph), 74.1 (C-5), 74.0 
(OCH2Ph), 73.3 (C-3), 69.5 (C-6), 69.0 (C-4), 52.1 (OCH3); IR (max/cm
-1): 3438 (OH), 
1717 (C=O); HRMS: Found [M+Na]+ 517.1838, C28H30O8Na requires 517.1833. 
 
4-Methoxycarbonylphenyl 3-O-allyl-2,6-di-O-benzyl--D-galactopyranoside (79) 
 
A suspension of 4-methoxycarbonylphenyl 2,6-di-O-benzyl -D-galactopyranoside 78 
(103 mg, 0.2 mmol) and dibutyl tinoxide (49 mg, 0.2 mmol) in anhydrous toluene (3 mL) 
was refluxed under azeotropic conditions. Toluene was removed in vacuo and the 
residue was co-evaporated with several times toluene, and then was dissolved in 
anhydrous THF (2 mL). Allyl bromide (90 L, 1.0 mmol) and tetrabutyl aluminium 
bromide (64 mg, 0.2 mmol) were added to the reaction mixture, which was refluxed for 
4 h, filtered, evaporated, and the residue was purified by flash column chromatography 
(silica; 2:1 hexaneEtOAc) to give compound 79 (80 mg, 75%) as a colourless solid; Rf 
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0.52 (1:1 hexaneEtOAc); m.p. 136-138 °C (from EtOH);   27 D  -33.0 (c, 1.0, CHCl3); H 
(500 MHz, CDCl3); 7.98 (d, 2H, J 8.8 Hz, ArH), 7.40-7.26 (m, 10H, ArH), 7.08 (d, 2H, J 
8.8 Hz, ArH), 6.00-5.90 (m, 1H, CH2=CHCH2), 5.32 (dd, 1H, J 17.2, 1.7 Hz, 
CH2=CHCH2), 5.22 (dd, 1H, J 1.07, 10.37 Hz, CH2=CHCH2), 5.04 (d, 1H, J1,2 7.8 Hz, H-
1), 4.93 (d, 1H, J 11.0 Hz, OCH2Ph), 4.82 (d, 1H, J 11.0 Hz, OCH2Ph), 4.58 (s, 2H, 
OCH2Ph), 4.24-4.22 (m, 2H, CH2=CHCH2), 4.09 (d, 1H, J3,4   3.5 Hz, H-4), 3.90 (s, 3H, 
OCH3), 3.86-3.74 (m, 4H, H-2, H-5, H-6, H-6), 3.53 (dd, J2,3  9.3 Hz, J3,4 3.5 Hz, H-3), 
2.58 (s, 1H, OH); C (75 MHz, CDCl3); 166.8 (C=O), 161.0, 138.3, 138.0 (ArC), 134.5 
(CH2=CHCH2), 131.7, 128.6, 128.5, 128.3, 128.0, 127.9, 124.4 (ArC), 117.8 
(CH2=CHCH2), 116.3, 110.1 (ArC), 101.0 (C-1), 80.5 (C-3), 78.5 (C-2), 75.6 (OCH2Ph), 
74.0 (C-5), 74.0 (OCH2Ph), 71.8 (CH2=CHCH2), 69.4 (C-6), 67.0 (C-4), 52.1 (OCH3); IR 
(max/cm






Thioglycosyl donor 55 (1.67 g, 2.4 mmol), 1-benzenesulfinyl piperidine (0.57 g, 2.7 
mmol), and 2,4,6-tri-tert-butylpyrimidine (1.26 g, 4.9 mmol) were co-evaporated with 
toluene several times before adding molecular sieves 4 Å and anhydrous DCM (72 mL). 
The reaction mixture was stirred at r.t. under N2(g) atmosphere for 1.5 h. Glycosyl 
acceptor 79 (1.08 g, 2.0 mmol) was also co-evaporated with toluene several times and 
dissolved in anhydrous DCM (36 mL) in a separate flask. After stirring for 1.5 h, the 
mixture of thioglycosyl donor, BSP, TTBP and molecular sieves 4 Å was cooled to -
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60 °C before freshly distilled triflic anhydride (Tf2O) (0.5 mL, 3 mmol) was added. The 
reaction mixture was stirred for 10 min at -60 °C before a solution of acceptor was 
added. The resulting mixture was stirred at low temperature (-60 °C to -10 °C) for 2 h, 
quenched with triethyl phosphate (0.4 mL), triethylamine (9.6 mL), and washed with sat. 
aq. NaHCO3 (2 × 150 mL), followed by brine (2 × 150 mL). The combined organic 
phase was dried over MgSO4, and concentrated to leave a crude yellow oil, which was 
purified by Biotage® flash column chromatography (Redisef®Rf 40 g silica column, 1.5 g 
of sample loaded each time, hexane:EtOAc (0% EtOAc (1 col. vol.)  0-30% EtOAc 
(over 19 col. vol.)  30-100% EtOAc (over 3 col. vol.)). The partially purified products 
were further purified by size exclusion chromatography (BioBeads SX-1, 500 mg of 
sample loaded each time, toluene). Further purification was performed by Biotage® 
flash column chromatography (Redisef®Rf 40 g silica column, Hexane:EtOAc (0% 
EtOAc (1 col. vol.)  0-30% EtOAc (over 8 col. vol.)  30% EtOAc (over 9 col. vol.)) to 
give compound 80 as colourless oil (1.15 g, 52%); Rf 0.25 (2:1 hexaneEtOAc);   22 D   
47.5 (c, 1.0, CHCl3); H (500 MHz, CDCl3); 8.03-7.96 (m, 4H, ArH), 7.35-7.15 (m, 25H, 
ArH), 7.15 (d, 2H, J 8.9 Hz, ArH), 6.93 (d, 2H, J 8.9 Hz, ArH), 5.97 (dd, 1H, J3b,4b 3.1 Hz, 
J4b,5b  1.4 Hz, H-4b), 5.88 (m, 1H, CH2=CHCH2), 5.27 (dd, 1H, J 17.3 Hz, 1.7 Hz, 
CH2=CHCH2), 5.13 (dd, 1H, J 10.5, 1.4 Hz, CH2=CHCH2), 5.04 (d, 1H, J1b,2b 3.6 Hz, H-
1b), 5.02 (d, 1H,  J1a,2a 7.6 Hz, H-1a), 4.93 (d, 1H, J 10.8 Hz, OCH2Ph), 4.88-4.80 (m, 
3H, OCH2Ph), 4.72-4.68 (m, 1H, H-5b), 4.59 (d, 1H, J 11.3 Hz, OCH2Ph), 4.55 (d, 1H, J 
10.9 Hz, OCH2Ph), 4.46-4.38 (m, 2H, OCH2Ph), 4.32-4.21 (m, 3H, OCH2Ph, 
CH2=CHCH2), 4.18 (dd, 1H, J2b,3b 10.1 Hz, J3b,4b 3.2 Hz, H-3b), 4.14-4.08 (m, 2H, H-4a, 
CH2=CHCH2), 3.99-3.91 (m, 3H, H-2a, H-2b, H-6a), 3.88 (s, 6H, 2 × OCH3), 3.70 (t, 1H, 
J5a,6a=5a,6a 6.3 Hz, H-5a), 3.63 (m, 1H, H-6a), 3.54 (m, 1H, H-6b), 3.50-3.43 (m, 2H, H-
6b, H-3a); C (75 MHz, CDCl3); 166.8, 165.5 (C=O), 163.5, 161.1 (C-O), 138.7, 138.4, 
138.1, 137.9 (ArC), 135.1 (CH2=CHCH2), 132.0, 131.6, 128.5, 128.4, 128.4, 128.3, 
128.3, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5, 124.3, 122.8 (ArC), 
117.2 (CH2=CHCH2), 116.4, 113.7 (ArC), 101.3 (C-1a), 100.3 (C-1b), 80.3 (C-3a), 78.1 
(C-2a), 76.7 (C-3b), 75.4 (C-2b, OCH2Ph), 74.4 (C-4a, C-5a), 73.9 (2 × OCH2Ph), 77.8 
(OCH2Ph), 73.4 (OCH2Ph), 72.2 (CH2=CHCH2), 71.5 (C-5b), 68.3 (C-6b), 68.2 (C-4b), 
68.2 (C-6a), 55.6 (OCH3), 52.1 (OCH3); IR (max/cm
-1): 3013 (CH=CH2), 2924, 2870 (C-
H), 1714 (C=O), 1097, 1048 (C-OR); HRMS: Found [M+NH4]










methoxybenzoyl--D-galactopyranosyl)--D-galactopyranoside 80 (100 mg, 0.09 mmol) 
was stirred in MeOH (6 mL) for 1 h before adding palladium (II) chloride (12.8 mg, 
0.072 mmol) to the reaction mixture, which was stirred at r.t. under N2(g) atmosphere 
for 22 h. The resulting mixture was filtered through Celite® pad. The filtrate was 
concentrated, purified by Biotage® flash column chromatography (Redisef®Rf 12 g 
silica column, Hexane:EtOAc (0% EtOAc (1 col. vol.)  0-30% EtOAc (over 11 col. 
vol.)  30% EtOAc (over 6 col. vol.)  30-40% (over 2 col. vol.)  40% EtOAc (over 
16 col. vol.)) to afford compound 81 as a colourless oil (90 mg, 95%); Rf 0.45 (1:1 
hexaneEtOAc);   22 D   39.1 (c, 1.0, CHCl3); H (500 MHz, CDCl3); 7.99-7.94 (m, 4H, 
ArH), 7.34-7.17 (m, 25H, ArH), 7.10-7.05 (m, 2H, ArH), 6.93-6.90 (m, 2H, ArH), 5.80 
(dd, 1H,  J3b,4b 3.1 Hz, J4b,5b 1.2 Hz, H-4b), 5.08 (d, 1H, J1b,2b 3.7 Hz, H-1b), 5.03 (d, 1H, 
J1a,2a 7.0 Hz, H-1a), 4.90-4.78 (m, 4H, 2 × OCH2Ph), 4.62-4.31 (m, 5H, 2 × OCH2Ph, H-
5b), 4.31-4.24 (m, 2H, OCH2Ph), 4.16-4.09 (m, 1H, H-3b), 4.02 (d, 1H, J3a,4a 2.0 Hz, H-
4a), 3.95 (dd, 1H, J2b,3b 10.1 Hz, J1b,2b 3.7 Hz, H-2b), 3.90-3.82 (m, 8H, 2 × OCH3, H-5a, 
H-6a), 3.79-3.70 (m, 3H, H-2a, H-3a, H-6a), 3.68-3.64 (m, 1H, H-3a), 3.57 (m, 1H, H-
6b), 3.51 (m, 1H, H-6b); C (75 MHz, CDCl3); 166.8, 165.6 (C=O), 163.7, 161.0 (C-O), 
138.5, 138.3, 138.2, 137.4, 132.1, 131.6, 128.4, 128.4, 127.9, 124.4, 122.2, 116.3, 
113.8 (ArC), 101.2 (C-1a, C-1b), 80.9 (C-4a), 80.1, 74.1 (C2a, C-3a), 76.6 (C-3b), 75.5 
(C-2b), 75.4 (OCH2Ph), 74.8 (C-5a), 74.2 (OCH2Ph), 73.7 (OCH2Ph), 73.3 (OCH2Ph), 
71.7 (OCH2Ph), 70.0 (C-5b), 69.5 (C-6a), 69.3 (C-6b), 68.3 (C-4b), 55.6 (OCH3), 52.0 
(OCH3); IR (max/cm
-1): 3471 (OH), 2917, 1714 (C=O), 1097, 1048, (C-OR); HRMS: 







Thioglycosyl donor 55 (84 mg, 0.12 mmol), 1-benzenesulfinyl piperidine (30 mg, 0.14 
mmol), and 2,4,6-tri-tert-butylpyrimidine (64 mg, 0.25 mmol) were co-evaporated with 
toluene several times before adding molecular sieves 4 Å and anhydrous DCM (6 mL). 
The reaction mixture was stirred at r.t. under N2(g) atmosphere for 1.5 h. Glycosyl 
acceptor 81 (88 mg, 0.08 mmol) was also co-evaporated with toluene several times 
and dissolved in anhydrous DCM (2.8 mL) in a separate flask. After stirring for 1.5 h, 
the mixture of thioglycosyl donor, BSP, TTBP and molecular sieves 4 Å was cooled to -
60 °C before freshly distilled triflic anhydride (Tf2O) (23 L, 0.14 mmol) was added. The 
reaction mixture was stirred for 10 min at -60 °C before a solution of acceptor was 
added. The resulting mixture was stirred at low temperature (-60 °C to -49 °C) for 1 h, 
quenched with triethyl phosphite (20 L), triethylamine (450 L), and washed with sat. 
aq. NaHCO3 (2 × 10 mL), followed by brine (2 × 10 mL). The combined organic phase 
was dried over MgSO4, and concentrated to leave crude yellow oil. The residue was 
purified by Biotage® flash column chromatography (Redisef®Rf 12 g silica column, 
Hexane:EtOAc (0% EtOAc (1 col. vol.)  0-25% EtOAc (over 12 col. vol.)  25% 
EtOAc (over 3 col. vol.)  25-35% EtOAc (over 10 col. vol.)) to give compound 82 as a 
pale yellow oil (100 mg, 80%); Rf 0.2 (2:1 hexaneEtOAc);   24 D   56.34 (c, 1.0, CHCl3); 
H (500 MHz, CDCl3, 327 K); 8.03-8.00 (m, 2H, ArH), 8.00-7.96 (m, 4H, ArH), 7.35-7.11 
(m, 40H, ArH), 7.08-7.04 (m, 2H, ArH), 6.96-6.92 (m, 2H, ArH), 6.87-6.83 (m, 2H, ArH), 
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5.83 (d, 1H, J3b,4b 2.39 Hz H-4b), 5.75 (d, 1H, J3c,4c 2.26 Hz, H-4c), 5.57 (d, 1H, J1b,2b 
2.27 Hz, H-1b), 5.27 (d, 1H, J1c,2c 3.30 Hz, H-1c), 5.00 (d, 1H, J1a,2a 6.67 Hz, H-1a), 
4.91-4.77 (m, 5H, OCH2Ph), 4.66 (d, 2 H, J 11.6 Hz, OCH2Ph), 4.62 (td, 1H, J5c,6c=5c,6c 
6.2 Hz, J4c,5c 1.4 Hz, H-5c), 4.60-4.51 (m, 3H, H-5b, OCH2Ph), 4.51-4.40 (m, 3H, 
OCH2Ph), 4.33-4.22 (m, 6H, H-3c, H-4a, OCH2Ph), 4.11-4.06 (m, 2H, H-3c, H-2a), 4.00 
(dd, 1H, J2c,3c 10.0 Hz, J1c,2c 3.3 Hz, H-2c), 3.92 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 
3.86-3.80 (m, 5H, H-3a, H-2b, OCH3), 3.78-3.65 (m, 4H, H-5a, H-6a, H-6a, H-6b), 
3.59-3.64 (m, 1H, H-6b), 3.48-3.43 (m, 1H, H-6c), 3.4.42-3.37 (m, 1H, H-6c); C (75 
MHz, CDCl3, 331 K); 166.8, 165.7, 165.7 (C=O), 163.7, 163.7, 161.3 (C-O), 139.0, 
138.8, 138.7, 138.6, 138.3, 138.2, 132.0, 132.0, 131.7, 128.6, 128.5, 128.5, 128.4, 
128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 
127.8, 127.7, 127.7, 127.6, 127.6, 127.6, 127.5, 127.5, 124.9, 123.1, 123.1, 116.5, 
113.9 (ArC), 101.7 (C-1a), 99.2 (C-1c), 98.9 (C-1b), 78.7 (C-2a), 77.4 (C-2b), 77.2 (C-
3a), 77.1 (C-4a), 77.0 (C-3c), 76.8 (C-2c), 76.7 (C-3b), 75.7 (C-5a), 75.2, 74.3, 73.9, 
73.8, 73.5, 73.5, 72.0, 71.7 (OCH2Ph), 71.0 (C-6a), 69.7 (C-5b), 69.5 (C-6b), 69.2 (C-
6c), 69.2 (C-5c), 69.0 (C-4c), 68.8 (C-4b), 55.6, 51.9 (3 × OCH3); IR (max/cm
-1): 2926 
(C-H), 1716 (C=O), 1263 (C-O), 1098 (C-OR); HRMS: Found [M+Na]+ 1649.6443, 


















methoxybenzoyl--D-galactopyranosyl)--D-galactopyranoside 82 (87 mg, 0.05 mmol) 
was dissolved in a mixture of MeOH (9 mL) and EtOH (6 mL) and stirred at r.t. under 
N2(g) atmosphere for 15 min. Palladium on carbon (Pd/C, 10% wt., 104 mg, 0.98 mmol) 
was added to the solution. The reaction mixture was allowed to stir at r.t. under a 
positive pressure of hydrogen overnight. The reaction mixture was filtered through a 
Celite® pad and evaporated to dryness to give trisaccharide 83 as a white powder (36 
mg, 75%); Rf 0.57 (9:1 EtOAcMeOH);   25 D   97.88 (c, 1.0, MeOH); H (500 MHz, 
MeOD); 8.03-7.97 (m, 6H, ArH), 7.19-7.15 (m, 2H, ArH), 7.01-6.97 (m, 4H, ArH), 5.59 
(dd, 1H, J3b,4b 3.4 Hz, J4b,5b 1.3 Hz, H-4b), 5.54 (d, 1H, J3c,4c 3.37 Hz, H-4c), 5.35 (d, 1H, 
J1c,2c 3.8 Hz, H-1c), 5.28 (d, 1H, J1b,2b 3.6 Hz, H-1b), 5.17 (d, 1H, J1a,2a 7.4 Hz, H-1a), 
4.66-4.62 (m, 1H, H-5c), 4.44-4.41 (m, 2H, H-4a, H-5b), 4.22-4.16 (m, 2H, H-3b, H-3c), 
4.07-3.83 (m, 16H, H-2a, H-2b, H-2c, H-3a, H-5a, H-6a, H-6a, 3 × OCH3), 3.65 (d, 2H, 
J5b,6b=6b,6b 6.3 Hz, H-6b, H-6b), 3.55 (d, 2H, J5c,6c=6c,6c 6.4 Hz, H-6c, H-6c); C (75 MHz, 
MeOD); 168.2, 167.7, 167.7 (C=O), 165.3, 162.7 (C-O), 132.9, 132.5, 125.2, 123.4, 
117.2, 114.8 (ArC), 103.1 (C-1b), 102.0 (C-1a), 97.8 (C-1c), 78.7 (C-2c), 77.1 (C-4a), 
76.0 (C-5a), 73.1 (C-4c), 73.0 (C-4b), 72.9 (C-5b), 71.6 (C-3a), 71.4 (C-5c), 71.2 (C-2b), 
70.8 (C-2a), 70.1 (C-3b), 69.6 (C-3c), 62.2 (C-6b, C-6c), 61.4 (C-6a), 56.0 (2 × OCH3), 
52.5 (OCH3); IR (max/cm
-1): 3359 (OH), 2921 (C-H), 1698 (C=O), 1021 (C-OR); HRMS: 
Found [M+NH4]






4-Methoxycarbonylphenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (85)125  
 
Acetic anhydride (21 mL, 222 mmol) was added to a solution of -D-mannopyranose 84 
(4 g, 22.2 mmol) in pyridine at 0 °C. The reaction mixture was sealed and stored at       
-20 °C overnight. The reaction mixture was slowly poured into ice water (100 mL) and 
extracted with ethyl acetate (3 × 150 mL). The organic layer was washed with sat. aq. 
NaHCO3 (3 × 150 mL), distilled water (2 × 100 mL), and brine (1 × 150 mL). The 
organic phase was dried (MgSO4) and concentrated to leave a crude oil, which was 
dissolved in anhydrous dichloroethane (50 mL). 4-methoxycarbonylphenol (6.7 g, 44 
mmol) and freshly distilled boron trifluoride diethyl etherate (8.2 mL, 66 mmol) were 
added to the reaction mixture, which was heated to 50 °C and stirred overnight. The 
reaction was quenched by addition of sat. aq. NaHCO3 (50 mL). The organic layer was 
then washed with sat. aq. NaCl (50 mL), dried (MgSO4), concentrated, and purified by 
flash column chromatography (silica; 2:1hexaneEtOAc). Semi crude product was 
recrystalised from MeOH to give compound 85 (5.9 g, 50%) as colourless solid; Rf 0.34 
(1:1 HexaneEtOAc); m.p. 147-149 °C (from MeOH);   22 D  89.6 (c, 1.5, CHCl3) (lit.
125 
  25 D  88.8 (c, 0.65, CHCl3)); H (500 MHz, CDCl3); 8.01 (d, 2H, J 8.7 Hz, ArH), 7.14 (d, 
2H, J 8.7 Hz, ArH), 5.62 (d, 1H, J1,2 1.8 Hz, H-1), 5.55 (dd, 1H, J3,4 10.1 Hz, J3,2  3.5 Hz, 
H-3), 5.46 (dd, 1H, J2,3  3.5 Hz, J2,1 1.8 Hz, H-2), 5.37 (t, 1H, J4,3=4,5 10.1 Hz, H-4), 4.28 
(dd, 1H, J6,6' 12.3 Hz, J5,6  5.7 Hz, H-6), 4.10-4.03 (m, 2H, H-5, H-6'), 3.89 (s, 3H, OCH3), 
2.21 (s, 3H, C(O)CH3), 2.06 (s, 3H, C(O)CH3), 2.05 (s, 3H, C(O)CH3), 2.02 (s, 3H, 
C(O)CH3); C (75 MHz, CDCl3); 170.3, 169.8, 169.6, 166.3 (C=O), 158.0, 131.5, 124.9, 
116.0 (ArC), 95.4 (C-1), 69.4 (C-5), 69.1 (C-2), 68.7 (C-3), 65.7 (C-4), 62.0 (C-6), 52.0 
(OCH3), 20.8, 20.6, 20.6, 20.6 (4 × COCH3); IR (max/cm
-1): 1753 (C=O); HRMS: Found 







--D-Mannopyranosyloxy benzoylhydrazide (86)125 
 
Sodium methoxide (470 mg, 8 mmol) was added to a solution of 4-
methoxycarbonylphenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside 85 (5.2 g, 10 
mmol) in anhydrous MeOH (100 mL). The reaction mixture was stirred overnight at r.t., 
neutralised with Amberlite IRC 86 H+ resin, filtered and concentrated to give a 
colourless solid, which was dissolved in MeOH (12 mL). Hydrazine monohydrate (3.2 
mL, 63 mmol) was added to the mixture, which was heated at reflux for 4 h. The 
solution was then concentrated and lyophilized from water to afford compound 86 (1.03 
g, 100%, 2 steps) as colourless lyophilisate; Rf 0.23 (6:4:1 ChloroformMeOHH2O); 
m.p. 174-176 °C;   23 D  109.2 (c, 1.0, H2O) (lit.
125   25 D  94.2 (c, 0.52, Η2Ο); H (500 
MHz, D2O); 7.72 (d, 2H, J 8.8 Hz, ArH), 7.21 (d, 2H, J 8.8 Hz, ArH), 5.69 (d, 1H, J1,2  
1.8 Hz, H-1), 4.18 (dd, 1H, J2,3 3.5 Hz, J1,2 1.8 Hz, H-2), 4.06 (dd, 1H, J3,4 9.6 Hz, J2,3  
3.5 Hz, H-3), 3.81-3.71 (m, 3H, H-4, H-6, H-6'), 3.69-3.64 (m, 1H, H-5); C (75 MHz, 
D2O); 169.4 (C=O), 158.4, 128.9, 126.2, 116.7 (ArC), 97.7 (C-1), 73.5 (C-5), 70.3 (C-3), 
69.8 (C-2), 66.5 (C-4), 60.6 (C-6); IR (max/cm
-1): 3373 (OH, NH), 1605 (C=O); HRMS: 
Found [M+H]+ 315.1183, C13H19N2O7 requires 315.1187.  
 
4-Methoxycarbonylphenyl 2,3,4,6-tetra-O-acetyl--D-galactopyranoside (87)125 
 
Freshly distilled boron trifluoride diethyl etherate (4.84 mL, 38.4 mmol) was added 
dropwise to a solution of -D-galactose pentaacetate 33 (5 g, 12.8 mmol) and 4-
(methoxycarbonyl)phenol (3.89 g,  25.6 mmol) in anhydrous dichloroethane (30 mL). 
The resulting solution was warmed to 50 °C, and stirred for a further 22 h at 50 °C 
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before quenching by addition of aq. NaHCO3 (3 × 30 mL). The organic layer was then 
separated and washed with aq. NaCl (2 × 50 mL), dried (MgSO4), concentrated 
Biotage® flash column chromatography (Redisef®Rf 80 g silica column, Hexane:EtOAc 
(0% EtOAc (1 col. vol.)  0-50% EtOAc (over 10 col. vol.)  50% EtOAc (over 10 col. 
vol.) to give a mixture of two anomers. The mixture was then recrystallised from MeOH 
to afford compound 87 as colourless plates as only the -anomer (2.97 g, 48%); Rf 
0.38 (1:1 HexaneEtOAc); m.p. 114-119°C (from MeOH) (Lit.125 112-117 C from 
MeOH);   23 D   208.27 (c, 0.22, CH2Cl2) (Lit.
125   25 D   212.7 (c, 0.22, CH2Cl2); H (500 
MHz, CDCl3); 8.01-7.95 (m, 2H, ArH), 7.08 (m, 1H, ArH), 5.83 (d, 1H, J1,2 3.4 Hz, H-1), 
5.54 (dd, 1H, J2,3 10.8 Hz, J3,4 3.1 Hz, H-3), 5.50 (dd, 1H, J3,4 3.1 Hz, J4,5 1.4 Hz, H-4), 
5.28 (dd, 1H, J2,3 10.8 Hz, J1,2  3.4 Hz, H-2), 4.27 (t, 1H, J5,6=5,6 6.2 Hz, H-5), 4.15-4.09 
(m, 1H, H-6), 4.09-4.03 (m, 1H, H-6), 3.86 (s, 1H, OCH3), 2.14 (s, 1H, C(O)CH3), 2.04 
(s, 1H, C(O)CH3), 2.00 (s, 1H, C(O)CH3), 1.89 (s, 1H, C(O)CH3); C (75 MHz, CDCl3); 
170.4, 170.3, 170.2, 170.0, 166.5 (C=O), 159.8, 131.7, 124.9, 116.3 (ArC), 94.6 (C-1), 
67.8 (C-4), 67.7 (C-2), 67.6 (C-5), 67.5 (C-3), 61.5 (C-6), 52.1 (OCH3), 20.8 (C(O)CH3), 
20.7 (C(O)CH3), 20.7 (C(O)CH3), 20.6 (C(O)CH3); IR (max/cm
-1): 1746 (C=O); HRMS: 
Found [M+Na]+ 505.1327, C22H26O12Na requires 505.1316.  
 
4-Methoxycarbonylphenyl -D-galactopyranoside (88)125 
 
Sodium methoxide (152 mg, 2.8 mmol) was added to a solution of 4-
methoxycarbonylphenyl 2,3,4,6-tetra-O-acetyl--D-galactopyranoside 87 (1.7 g, 3.5 
mmol) in anhydrous MeOH (30 mL). The reaction mixture was stirred for 18 h at r.t., 
neutralised with Amberlite® IRC 86 H+ resin, filtered and concentrated to afford 
compound 88 (1.17 g, 100%) as a colourless glassy solid; Rf 0.14 (6:4:1 
ChloroformMeOHH2O);   23 D   222.47 (c, 0.17, H2O) (Lit.
125   25 D   231.8 (c, 0.17, 
H2O)); H (500 MHz, DMSO-d6 with D2O exchange); 7.92-7.88 (m, 2H, ArH), 7.20-7.14 
(m, 2H, ArH), 5.54 (d, 1H, J1,2 3.4 Hz, H-1), 3.81 (s, 3H, OCH3), 3.80-3.77 (m, 2H, H-2, 
H-4), 3.75 (dd, 1H, J2,3 10.2 Hz, J3,4 3.0 Hz, H-3), 3.65-3.62 (m, 1H, H-5), 3.51 (dd, 1H, 
J6,6 10.9 Hz, J5,6=5,6 6.3 Hz, H-6), 3.35 (dd, 1H, J6,6 10.9 Hz, J5,6=5,6 6.3 Hz, H-6); C (75 
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MHz, DMSO-d6 with D2O exchange); 166.0 (C=O), 161.2, 131.1, 122.8, 116.6 (ArC), 
97.9 (C-1), 72.6 (C-5), 69.3, 68.4, 67.8 (C-2, C-3, C-4), 60.2 (C-6), 52.0 (OCH3); IR 
(max/cm
-1): 3293 (OH), 1613 (C=O); HRMS: Found [M+Na]+ 337.0895, C14H18O8Na 
requires 337.0894.  
 
4--D-galactopyranosyloxy benzoylhydrazide (89)125 
 
Hydrazine monohydrate (719 L, 14.8 mmol) was added to a solution of 4-
methoxycarbonylphenyl -D-galactopyranoside 88 (230 mg, 0.79 mmol) in MeOH (3 
mL) and heated at reflux for 2 h. The solvent was evaporated and the residue was 
lyophilized from water to afford compound 89 (220 mg, 89%) as colourless lyophilisate; 
Rf 0.24 (6:4:1 ChloroformMeOHH2O);   23 D   171.9 (c, 0.2, H2O) (Lit.
125   25 D   141.0 
(c, 0.2, H2O)); H (500 MHz, DMSO-d6 with D2O exchange); 8.43 (s, 1H, NH), 7.78-
7.73 (m, 2H, ArH), 7.13-7.07 (m, 2H, ArH), 5.48 (d, 1H, J1,2 3.2 Hz, H-1), 3.81-3.73 (m, 
3H, C-2, C-3, C-4), 3.65 (t, 1H, J5,6=5,6 6.4 Hz, H-5), 3.50 (dd, 1H, J6,6 11.0 Hz, J5,6=5,6 
6.3 Hz, H-6), 3.35 (dd, 1H, J6,6 11.0 Hz, J5,6=5,6 6.3 Hz, H-6); C (75 MHz, DMSO-d6 with 
D2O exchange); 166.7 (NH), 166.0 (C=O), 128.8, 126.6, 116.5, 109.8 (ArC), 98.1 (C-1), 
72.6 (C-5), 69.45, 68.6, 68.0 (C-2, C-3, C-4), 60.4 (C-6); IR (max/cm
-1): 3278 (OH, NH), 











Hydrazine monohydrate (15.7 L, 0.3 mmol) was added to a suspension of 4-
methoxycarbonylphenyl bis-O-(-D-galactopyranosyl)--D-galactopyranoside 27 in 
MeOH (2 mL). The resulting mixture was heated at reflux for 4 h. The solution was then 
concentrated and lyophilized from water to afford compound 90 (9 mg, 88%) as 
colourless lyophilisate; Rf 0.80 (6:4:1 ChloroformMeOHH2O);   24 D  24.72 (c, 0.2, 
H2O); H (500 MHz, D2O); 7.75 (d, 2H, J 8.7 Hz, ArH), 7.24 (d, 2H, J 8.7 Hz, ArH), 5.32 
(d, 1H, J1a,2a 7.5 Hz, H-1a), 5.29 (d, 1H, J1c,2c 4.0 Hz, H-1c), 5.13 (d, 1H, J1b,2b 3.7 Hz, 
H-1b), 4.42 (d, 1H, J 2.3 Hz, H-4a), 4.29 (t, 1H, J 6.4 Hz, H-5), 4.19 (t, 1H, J 6.4 Hz, H-
5), 4.07-3.68 (m, 15H, H-2a, H-2b, H-2c, H-3a, H-3b, H-3c, H-4b, H-4c, H-5a, H-6a, H-
6a, H-6b, H-6b, H-6c, H-6c); C (75 MHz, D2O); 169.4 (C=O), 159.2 (C-O), 129.0 
(ArC), 126.7 (C-O), 116.5 (ArC), 100.9 (C-1a), 100.0 (C-1c), 95.5 (C-1b), 76.5, 75.5, 
75.1, 71.7, 70.8, 69.6, 69.1, 68.9, 68.8, 68.6, 61.0, 60.9, 60.7 (3 × C-2, 3 × C-3, 3 × C-4, 
3 × C-5, 3 × C-6); IR (max/cm
-1): 3375 (OH, NH), 1606 (C=O); HRMS: Found [M+H]+ 
639.2246, C25H39N2O17 requires 639.2243.  
 
4--D-Galactopyranosyloxy benzoylhydrazide (91) 
 
Hydrazine monohydrate (937 L, 19.1 mmol) was added to a suspension of 4-
methoxycarbonylphenyl -D-galactopyranoside 73 (300 mg, 0.95 mmol) in MeOH (4 
mL) and heated at reflux for 2 h, over the course of which a colourless solid 
precipitated. The solid was filtered and lyophilized from water to afford compound 91 
(226 mg, 76%) as colourless lyophilisate; Rf 0.19 (6:4:1 ChloroformMeOHH2O); 
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  24 D α 23.3 (c, 1.0, DMSO); H (500 MHz, DMSO-d6); 9.62 (s, 1H, NH), 7.78 (d, 2H, J 8.4 
Hz, ArH), 7.05 (d, 2H, J 8.4 Hz, ArH), 4.90 (d, 1H, J1,2 7.7 Hz, H-1), 3.70 (d, 1H, J3,4 3.8 
Hz, H-4), 3.63-3.38 (m, 5H, H-2, H-3, H-5, H-6, H-6'); C (75 MHz, DMSO-d6); 165.5 
(C=O), 159.6, 128.5, 126.6, 115.6 (ArC), 100.6 (C-1), 75.6, 73.3, 70.2 (C-2, C-3, C-5), 
68.1 (C-4), 60.6 (C-6); IR (max/cm
-1): 3435 (OH, NH), 1662 (C=O); HRMS: Found 
[M+Na]+ 337.1014, C13H18N2NaO7 requires 337.1006. 
 
1-Azido-3,6-dioxaoct-8-yl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (92)201 
 
Freshly distilled boron trifluoride diethyl etherate (23.70 mL, 192.2 mmol) were added 
dropwise to a solution of mannose pentaacetate 91 (25.0 g, 64 mmol), and 2-[2-(2-
chloroethoxy)ethoxy]ethanol (18.62 mL, 128.1 mmol) in anhydrous dichloroethane (250 
mL) at 0 °C. The reaction mixture was heated to 50 °C and stirred for 22 h. The 
reaction was washed with sat. aq. NaHCO3 (2 × 250 mL), with brine (2 × 250 mL), dried 
(MgSO4), concentrated to leave a brown crude oil, which was partially purified by flash 
column chromatography (silica; 1:1 hexaneEtOAc). Partially separated product (2 g, 4 
mmol) was then dissolved in anhydrous DMF (100 mL). Sodium azide (1.3 mg, 20 
mmol) and TBAI (1.48 g, 4 mmol) were added to the reaction mixture, which was 
stirred at 87 °C for 17 h. The solvent was removed and the residue was purified by 
flash column chromatography (silica; 1:1 Petroleum etherEtOAc) to give compound 92 
(1.02 mg, 59%, 2 steps) as a colourless oil; Rf 0.16 (1:1 petroleum etherEtOAc); 
  22 D  41.01 (c, 2.2, CHCl3) (lit.
201   20 D   61.5 (c, 0.22, CHCl3)); H (500 MHz, CDCl3); 
5.28 (dd, 1H, J2,3 10.0 Hz, J3,4 3.5 Hz, H-3), 5.23-5.19 (m, 2H, H-2, H-4), 4.80 (d, 1H, 
J1,2 1.7 Hz, H-1), 4.22 (dd, 1H, J6,6' 12.1 Hz, J5,6 4.9 Hz, H-6), 4.06-3.97 (m, 2H, H-5, H-
6'), 3.79-3.71 (m, 1H, ManOCH2), 3.66-3.56 (m, 9H, ManOCH2, 4 × CH2O ), 3.33 (t, 2H, 
J 5.1 Hz, CH2-N), 2.08 (s, 3H, C(O)CH3), 2.03 (s, 3H, C(O)CH3), 1.97 (s, 3H, C(O)CH3), 
1.92 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 170.6, 170.0, 169.8, 169.7 (4 × C=O), 97.7 
(C-1), 70.8, 70.6, 70.1, 70.0 (4 × CH2O), 69.5 (C-2), 69.1 (C-3), 68.4 (C-5), 67.4 
(ManOCH2), 66.1 (C-4), 62.4 (C-6), 50.7 (CH2-N), 20.9, 20.7, 20.7, 20.6 (4 × C(O)CH3); 
IR (max/cm
-1): 1741 (C=O), 2106 (N3); HRMS: Found [M+Na]
+ 528.1805, 






Trimethyl orthoformate (525 L, 4.8 mmol), 2,3-butanedione (120 L, 1.32 mmol), and 
p-toluenesulfonic acid (136 mg, 0.72 mmol) were added to a solution of 1-azido-3,6-
dioxaoct-8-yl -D-mannopyranoside 29 (400 mg, 1.2 mmol) in anhydrous MeOH (4 mL). 
The reaction mixture was stirred at reflux for 4 h and then quenched with triethylamine 
(500 L). The mixture was concentrated and purified by flash column chromatography 
(silica; EtOAc) to give compound 93 (272 mg, 50%) as a pale yellow oil; Rf 0.16 
(EtOAc);   25 D  175.0 (c, 0.5, CHCl3); H (500 MHz, CDCl3); 4.90 (d, 1H, J1,2 1.4 Hz, H-1), 
4.08 (t, 1H, J3,4 10.0 Hz, H-4), 4.02 (dd, 1H, J2,3 3.1 Hz, J3,4 10.0 Hz, H-3), 3.96 (bs, 1H, 
H-2), 3.85-3.72 (m, 4H, H-5, H-6, OCH2), 3.71-3.63 (m, 9H, 4 × OCH2, H-6), 3.40 (t, 2H, 
J 5.1 Hz, CH2-N), 3.28 (s, 3H, OCH3), 3.25 (s, 3H, OCH3), 2.83 (s, 1H, OH), 2.34 (s, 1H, 
OH), 1.32 (s, 3H, CH3), 1.28 (s, 3H, CH3); C (75 MHz, CDCl3); 100.4, 99.9 (2 × 
(CH3)C(OCH3)), 100.3 (JC,H 171 Hz, , C-1), 70.8 (2 × OCH2), 70.8 (C-5), 70.4 (OCH2), 
70.2 (OCH2), 69.7 (C-2), 68.2 (C-4), 66.8 (C-6) , 63.2 (C-3), 61.5 (OCH2), 50.8 (CH2-N), 
48.2 (OCH3), 48.0 (OCH3), 17.9 (CH3), 17.8 (CH3); IR (max/cm
-1): 3445 (OH), 2926 
(OCH3), 2109 (N3); HRMS: Found [M+Na]














tert-Butyldimethylsilyl chloride (98 mg, 0.78 mmol) and imidazole (106 mg, 1.56 mmol) 
were added to a solution of 1-azido-3,6-dioxaoct-8-yl 3,4-di-O-(2,3-dimethoxybutane-
2,3-diyl)--D-mannopyranoside 93 (253 mg, 0.52 mmol) in anhydrous DMF (2 mL) in 
an ice bath. The reaction mixture was stirred at r.t. for 24 h, diluted with EtOAc (12 mL) 
and quenched with distilled water (2 mL). The organic layer was washed with distilled 
water (2 × 10 mL) and brine (10 mL), dried (MgSO4), concentrated and purified by flash 
column chromatography (silica; 2:1 hexaneEtOAc) to give compound 94 (168 mg, 
57%) as colourless oil; Rf 0.12 (2:1 hexaneEtOAc);   25 D  111.1 (c, 1.0, CHCl3); H 
(500 MHz, CDCl3); 4.84 (d, 1H, J1,2 1.4 Hz, H-1), 4.01-3.98 (m, 2H, H-3, H-4), 3.92 (bs, 
1H, H-2), 3.80 (m, 3H, H-6, OCH2), 3.73-3.61 (m, 10H, H-5, H-6, 4 × OCH2), 3.39 (t, 
2H, J 5.1 Hz, CH2-N), 3.26 (s, 3H, OCH3), 3.23 (s, 3H, OCH3), 2.31 (s, 1H, OH), 1.31 (s, 
3H, CH3), 1.27 (s, 3H, CH3), 0.37 (s, 9H, C(CH3)3), 0.06 (s, 3H, SiCH3), 0.04 (s, 3H, 
SiCH3); C (75 MHz, CDCl3); 100.4, 100.0, 99.9 (C-1, 2 × (CH3)C(OCH3)), 71.7 (C-5), 
70.8, 70.4, 70.2 (4 × OCH2), 69.4 (C-2), 68.5 (C-4), 66.4 (C-6), 63.0 (C-3), 61.8 (OCH2), 
50.8 (CH2-N), 48.2 (OCH3), 48.0 (OCH3), 26.0 (C(CH3)3), 18.5 (C(CH3)3), 17.9 (CH3), 
17.9 (CH3), -5.0 (SiCH3), -5.2 (SiCH3); IR (max/cm
-1): 3460 (OH), 2928 (OCH3), 2104 
(N3); HRMS: Found [M+Na]
+ 588.2915, C24H47N3O10SiNa requires 588.2923. 
A small sample (30 mg) of this purified product was acetylated using pyridine-acetic 
anhydride catalysed by DMAP and purified by flash column chromatography (silica; 2:1 
hexaneEtOAc) to give 6-O-acetyl-1-azido-3,6-dioxaoct-8-yl 3,4-di-O-(2,3-
dimethoxybutane-2,3-diyl)-6-O-tert-butyldimethylsilyl--D-mannopyranoside as a 
colourless oil; Rf 0.25 (2:1 hexaneEtOAc);   25 D  284.3 (c, 1.0, CHCl3); H (500 MHz, 
CDCl3); 5.03 (dd, 1H, J1,2 1.5 Hz, J2,3 3.2 Hz, H-2), 4.79 (d, 1H, J1,2 1.5 Hz, H-1), 4.16-
4.04 (m, 2H, H-3, H-4), 3.85 (m, 1H, OCH2), 3.77 (m, 2H, H-6, OCH2), 3.71-3.57 (m, 
10H, H-5, H-6, 4 × OCH2), 3.39 (t, 2H, J 5.0 Hz, CH2-N), 3.26 (s, 3H, OCH3), 3.25 (s, 
3H, OCH3), 2.10 (s, 3H, C(O)CH3), 1.27 (s, 3H,CH3), 1.26 (s, 3H,CH3), 0.88 (s, 9H, 
C(CH3)3), 0.06 (s, 3H, SiCH3), 0.04 (s, 3H, SiCH3); C (75 MHz, CDCl3); 170.6 (C=O), 
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100.3, 99.8, 98.1 (C-1, 2 × (CH3)C(OCH3)), 71.7 (C-2), 71.0 (2 × OCH2), 70.8 (C-5), 
70.3 (2 × OCH2), 66.8 (C-6), 66.2 (C-4), 62.9 (C-3), 61.4 (OCH2), 50.8 (CH2-N), 48.2 
(OCH3), 48.0 (OCH3), 25.0 (C(CH3)3), 21.3 (C(O)CH3), 18.4 (C(CH3)3), 18.0 (CH3),  
17.8 (CH3), -5.0 (SiCH3), -5.23 (SiCH3); IR (max/cm
-1): 2930 (OCH3), 2109 (N3), 1742 
(C=O); HRMS: Found [M+Na]+ 630.3027, C26H49N3O11SiNa requires 630.3029. 
 
2,3,4,6-Tetra-O-acetyl -D-mannopyranosyl trichloroacetimidate (95)202 
 
Hydrazine acetate (1.06 g, 11.5 mmol) was added to a solution of -D-mannose 
pentaacetate 91 (3.00 g, 7.7 mmol) in DMF (10 mL). The reaction mixture was stirred 
at r.t. for 2 h, concentrated to leave dark brown oil, which was dissolved in anhydrous 
DCM (7 mL). Trichloroacetonitrile (3.97 mL, 38.5 mmol) and DBU (1.16 mL, 11.5 mmol) 
were added dropwise to the reaction mixture at -10 °C, which was stirred for 3 h, 
concentrated and purified by flash column chromatography (silica; 9:1 DCMEtOAc) to 
leave a yellow oil. The partially purified products was then purified by another flash 
column chromatography (silica; 3:1 hexaneEtOAc), yielded trichloroacetimidate 95 
(1.35 g, 37%, 2 steps) as a colourless oil; Rf 0.20 (2:1 hexaneEtOAc);   25 D  44.1 (c, 
1.0, CHCl3) (lit.
202   25 D  42.7 (c, 1.0, CHCl3)); H (500 MHz, CDCl3); 8.78 (s, 1H, NH), 
6.26 (d, 1H, J1,2 1.9 Hz, H-1), 5.46-5.44 (m, 1H, H-2), 5.41-5.34 (m, 2H, H-3, H-4), 4.26 
(dd, 1H, J5,6 4.8 Hz, J6,6 12.1 Hz, H-6), 4.20-4.07 (m, 2H, H-5, H-6), 2.18 (s, 3H, 
C(O)CH3), 2.06 (s, 3H, C(O)CH3), 2.05 (s, 3H, C(O)CH3), 1.99 (s, 3H, C(O)CH3); C (75 
MHz, CDCl3); 170.6, 169.9, 169.8, 169.7, 159.8 (4 × C=O, CN), 94.6 (JC,H 180 Hz, , C-
1), 90.6 (CCl3), 71.3 (C-5), 68.0 (C-2), 68.9 , 65.5 (C-3, C-4), 62.1 (C-6), 20.9, 20.8, 
20.7 (4 × C(O)CH3); IR (max/cm
-1): 3020 (NH), 1752 (C=O), 1677 (C=N); HRMS: Found 









tert-Butyldiphenylsilyl chloride (141 L, 0.5 mmol) and imidazole (76 mg, 1.2 mmol) 
were added to a solution of 1-azido-3,6-dioxaoct-8-yl 3,4-di-O-(2,3-dimethoxybutane-
2,3-diyl)--D-mannopyranoside 93 (200 mg, 0.4 mmol) in anhydrous DMF (1 mL). The 
reaction mixture was stirred at r.t. for 22 h and quenched with distilled water (1 mL). 
The product was extracted with EtOAc (3 × 10 mL). The organic extracts were 
combined, dried (MgSO4), concentrated and purified by flash column chromatography 
(silica; 2:1 hexaneEtOAc) to give compound 97 (236 mg, 78%) as a colourless oil; Rf 
0.35 (1:1 hexaneEtOAc);   24 D  116.4 (c, 1.0, CHCl3); H (500 MHz, CDCl3); 7.73-7.69 
(m, 4H, ArH), 7.45-7.33 (m, 6H, ArH), 4.89 (d, 1H, J1,2 1.3 Hz, H-1), 4.07-4.00 (m, 2H, 
H-3, H-4), 3.96 (bs, 1H, H-2), 3.89 (d, 2H, J 3.6 Hz, OCH2), 3.87-3.77 (m, 2H, H-5, H-6), 
3.68-3.61 (m, 9H, H-6, 4 × OCH2), 3.37 (t, 2H, J 5.1 Hz, CH2-N), 3.28 (s, 3H, OCH3), 
3.15 (s, 3H, OCH3), 2.38 (s, 1H, OH), 1.31 (s, 3H, CH3), 1.26 (s, 3H, CH3), 1.04 (s, 9H, 
C(CH3)3); C (75 MHz, CDCl3); 136.0, 135.7, 134.1, 133.6, 129.6, 127.7, 127.6, 100.4, 
99.9, 99.9 (C-1, 2 × (CH3)C(OCH3)), 71.8 (C-5), 70.8, 70.3, 70.2 (OCH2), 69.8 (C-2), 
68.6, 63.1 (C-3, C-4), 66.4 (C-6), 62.6 (OCH2), 50.8 (CH2-N), 48.3 (OCH3), 48.1 (OCH3), 
26.9 (C(CH3)3), 19.5 (C(CH3)3), 17.9 (CH3), 17.9 (CH3); IR (max/cm
-1): 3053 (OH), 2930 
(OCH3), 2107 (N3); HRMS: Found [M+Na]
+ 712.3247, C34H51N3O10SiNa requires 
712.3236. 
A small sample (30 mg) of this purified product was acetylated using pyridine-acetic 
anhydride catalysed by DMAP and purified by flash column chromatography (silica; 2:1 
hexaneEtOAc) to give 6-O-acetyl-1-azido-3,6-dioxaoct-8-yl 3,4-di-O-(2,3-
dimethoxybutane-2,3-diyl)-6-O-tert-butyldiphenylsilyl--D-mannopyranoside as 
colourless oil; Rf 0.21 (2:1 hexaneEtOAc);   24 D   86.4 (c, 1.0, CHCl3); H (500 MHz, 
CDCl3); 7.68-7.74 (m, 4H, ArH), 7.45-7.30 (m, 6H, ArH), 5.07 (dd, 1H, J1,2 1.6 Hz, J2,3 
3.1 Hz, H-2), 4.84 (bs, 1H, H-1), 4.24-4.13 (m, 2H, H-3, H-4), 3.96 (dd, 1H, J 11.3, 4.0 
Hz, OCH2), 3.85 (dd, 1H, J 11.3, 2.0 Hz, OCH2), 3.79-3.71 (m, 2H, H-5, H-6), 3.69-3.59 
197 
  
(m, 9H, H-6, 4 × OCH2), 3.38 (t, 2H, J 5.1 Hz, CH2-N), 3.26 (s, 3H, OCH3), 3.22 (s, 3H, 
OCH3), 2.13 (s, 3H, C(O)CH3), 1.27 (s, 3H, CH3), 1.28 (s, 3H, CH3), 1.06 (s, 9H, 
C(CH3)3); C (75 MHz, CDCl3); 170.8 (C=O), 100.3, 99.8 (2 × (CH3)C(OCH3)), 98.0 (C-
1), 71.7 (C-5), 70.9 (OCH2), 70.9 (C-2),  70.8 (OCH2), 70.2 (C-6), 66.8 (C-4), 66.3 (C-3), 
63.0 (OCH2), 50.8 (CH2-N), 48.2 (OCH3), 48.1 (OCH3), 26.9 (C(CH3)3), 21.3 (C(O)CH3), 
19.6 (C(CH3)3), 18.0 (CH3), 17.8 (CH3); IR (max/cm
-1): 2930 (OCH3), 2109 (N3), 1742 





Acetic anhydride (50 mL, 49 mmol) was placed in a 3-neck round bottom flask, 
equipped with a thermometer. D-Mannose (50 mg, 0.28 mmol) 100 was added, 
followed by perchloric acid (70%, 4 drops from a Pasteur pipette). D-Mannose 100 
(13.2 g, 73 mmol) was added in small portions of a period of 1 h, keeping the reaction 
temperature in the range of 40-45 C. Once the addition was complete, the orange-
brown solution was stirred for 1 h at r.t. The reaction mixture was cooled to 10 C (in 
an ice bath) and phosphorus tribromide (10.45 mL, 110 mmol) was added dropwise. 
This led to the formation of HBr and was quite exothermic; the reaction was cooled in 
an ice bath to maintain an internal temperature of 20-25 C. Once the addition was 
complete, the mixture was stirred at r.t. for 1.5 h. The reaction mixture was cooled to 5 
C in an ice bath and a solution of sodium acetate trihydrate (39.9 g, 293 mmol) in 
water (50 mL) also at 5 C was added dropwise. With cooling, the temperature was 
kept at 20-25 C and the addition completed in 30 min. The reaction mixture was stirred 
at r.t. for 20 min. The mixture was then poured onto ice and extracted with chloroform 
(3 × 60 mL). The extracts were combined and washed with ice-water (150 mL), sat. aq. 
NaHCO3 containing ice (150 mL) and ice-water (150 mL) again. The organic layer was 
dried (MgSO4), filtered and concentrated. Diethyl ether (100 mL) was added and the 
product crystallised out of solution. The flask was left in the freezer overnight and the 
product collected by filtration and washed with a little with cold ether, to give 
mannopyranoside 101 as a colourless solid (4.6 g, 18%); Rf 0.39 (1:4 HexaneEtOAc); 
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m.p. 132-133 C (from EtOH) (lit.204 131 C from EtOH);   23 D  -26.3 (c, 1.0, CHCl3) 
(lit.162   30 D   -23.6 (c, 1.4, CHCl3)); H (500 MHz, CDCl3); 5.77 (d, 1H, J1,2 1.0 Hz, H-1), 
5.37 (t, 1H, J3,4=4,5 9.8 Hz, H-4), 5.02 (dd, 1H, J3,4 9.8 Hz, J2,3 3.0 Hz, H-3), 4.28 (dd, 1H, 
J5,6 5.0 Hz, J6,6 12.4 Hz, H-6), 4.18 (td, 1H, J2,3 3.0 Hz, J1,2 1.0 Hz, H-2), 4.11 (dd, 1H, 
J5,6 2.4 Hz, J6,6 12.4 Hz, H-6), 3.76 (m, 1H, H-5), 2.49 (d, 1H, J 4.0 Hz, OH), 2.16 (s, 
3H, C(O)CH3), 2.09 (s, 3H, C(O)CH3), 2.06 (s, 3H, C(O)CH3), 2.03 (s, 3H, C(O)CH3); C 
(75 MHz, CDCl3); 170.9, 170.2, 169.7, 168.6 (C=O), 91.8 (JC,H 163 Hz, , C-1), 73.2 (C-
5), 73.0 (C-3), 68.5 (C-2), 65.4 (C-4), 62.1 (C-6), 21.0, 20.9, 20.9, 20.8 (4 × C(O)CH3); 
IR (max/cm
-1): 3453 (OH), 1712 (C=O); HRMS: Found [M+NH4]
+ 366.1400, C14H24NO10 





1,3,4,6-Tetra-O-acetyl--D-mannopyranoside 101 (1.70 g, 4.9 mmol) and 2,3,4,6-tetra-
O-acetyl--D-mannopyranosyl trichloroacetimidate 95 (2.40, 4.9 mmol) were co-
evaporated with toluene several times before adding molecular sieves 4 Å (2.0 g) and 
anhydrous DCM (17 mL). The resulting mixture was stirred at r.t. under N2(g) for 2 h, 
and cooled to -50 °C. Freshly distilled BF3OEt2 was added to the reaction mixture, 
which was stirred at low temperature and slowly warmed up to r.t. over 18 h. The 
reaction mixture was quenched with sodium hydrogen carbonate (1.28 g), filtered 
through a Celite® pad, concentrated to leave a yellow oil. The crude residue was 
purified by Biotage® flash column chromatography (Redisef®Rf 40 g silica column, 
Hexane:EtOAc (0% EtOAc (1 col. vol.)  0-33% EtOAc (over 3 col. vol.)  33% 
EtOAc (over 2 col. vol.)  33-50% EtOAc (over 16 col. vol.)  50% EtOAc (over 13 col. 
vol.)) to give compound 102 as a white fluffy solid (1. 54, 47%); Rf 0.36 (3:7 




206  18 D   0.7 (c, 0.6, CHCl3)); H (500 MHz, CDCl3); 5.81 (d, 1H, J1a,2a  
1.1 Hz, H-1a), 5.50 (dd, 1H, J2b,3b 10.0 Hz, J3b,4b 3.3 Hz, H-3b), 5.40-5.34 (m, 2H, H-4a, 
H-4b), 5.33-5.30 (m, 1H, H-2b), 5.14 (dd, 1H, J2a,3a 9.7 Hz, J3a,4a 2.9 Hz, H-3a), 5.02 (d, 
1H, J1b,2b 1.9 Hz, H-1b), 4.44 (ddd, 1H, J4b,5b 10.1 Hz, J5b,6b 4.4 Hz, J5b, ‟b 2.5 Hz, H-5b), 
4.33 (dd, 1H, J b, ‟b 12.2 Hz, J5b,6b 4.4 Hz, H-6b), 4.27 (dd, 1H, J a, ‟a 12.4 Hz, J5a,6a 4.7 
Hz, H-6a), 4.21-4.16 (m, 2H, H-2a, H-6a), 4.07 (dd, 1H, J b, ‟b 12.2 Hz, J5b, ‟b 2.5 Hz, H-
6b), 3.82 (ddd, 1H, J4a,5a 9.6 Hz, J5a,6a 4.7 Hz, J5a, ‟a  2.5 Hz, H-5a), 2.16 (s, 6H, 2 × 
C(O)CH3), 2.13 (s, 3H, C(O)CH3), 2.10 (s, 3H, C(O)CH3), 2.09 (s, 3H, C(O)CH3), 2.05 
(s, 3H, C(O)CH3), 2.04 (s, 3H, C(O)CH3), 2.03 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 
170.9, 170.6, 170.2, 169.8, 169.6, 169.5, 169.3, 169.4 (8 × C=O), 98.3 (JC,H 174 Hz, 5.5 
Hz, , C-1b) , 91.0 (JC,H 162 Hz, , C-1a), 74.7 (C-2a), 73.1 (C-5a), 72.2 (C-3a), 69.9 
(C-2b), 68.9 (C-5b), 68.4 (C-3b), 66.2 (C-4a), 65.8 (C-4b), 62.2 (C-6b), 61.8 (C-6a), 
20.9, 20.7, 20.6, 20.5 (8 × C(O)CH3); IR (max/cm
-1): 1739 (C=O); HRMS: Found 
[M+Na]+  701.1904, C28H38NaO19 requires 701.1900. 
 
3,4,6-Tri-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyl)--D-
mannopyranosyl trichloroacetimidate (103)205 
 
Hydrazine acetate (56 mg, 0.6 mmol) was added to a solution of 1,3,4,6-tetra-O-acetyl-
2-O-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyl)--D-mannopyranose 102 (275 mg, 
0.4 mmol) in DMF (1 mL). The reaction mixture was stirred at r.t. for 2 h, concentrated 
to leave dark brown oil, which was dissolved in anhydrous DCM (1 mL). 
Trichloroacetonitrile (212 L, 2.1 mmol) and DBU (62 L, 0.6 mmol) were added 
dropwise to the reaction mixture at 0 °C, which was stirred for 2 h at r.t., concentrated 
and purified by Biotage® flash column chromatography (Redisef®Rf 24 g silica column, 
Hexane:EtOAc (0% EtOAc (1 col. vol.)  0-33% EtOAc (over 16 col. vol.)  33% 
EtOAc (over 25 col. vol.)  33-50% EtOAc (over 5 col. vol.) 50% EtOAc (over 10 col. 
vol.)) to give compound 103 as a yellow oil (86 mg, 27%); Rf 0.23 (1:1 HexaneEtOAc); 
  22 D   32.2 (c, 1.0, CHCl3) (lit.
205   25 D   31.2 (c, 1.4, CHCl3); H (500 MHz, CDCl3); 8.71 
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(s, 1H, NH), 6.40 (d, 1H, J1a,2a 2.2 Hz, H-1a), 5.45 (t, 1H, J3a,4a=4a,5a 10.0 Hz, H-4a), 5.39 
(dd, 1H, J3b,4b 10.0 Hz, J2b,3b 3.4 Hz, H-3b), 5.32 (dd, 1H, J3a,4a 9.9 Hz, J2a,3a 3.1 Hz, H-
3a), 5.30-5.24 (m, 2H, H-2b, H-4b), 4.97 (d, 1H, J1b,2b 1.8 Hz, H-1b), 4.27 (t, 1H, J 2.7 
Hz, H-2a), 4.24-4.06 (m, 6H, H-5a, H-5b, H-6a, H-6a, H-6b, H-6b), 2.13 (s, 3H, 
C(O)CH3), 2.11 (s, 3H, C(O)CH3), 2.07 (s, 3H, C(O)CH3), 2.03 (s, 3H, C(O)CH3), 2.02 
(s, 3H, C(O)CH3), 2.01 (s, 3H, C(O)CH3), 1.99 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 
170.9, 170.7, 170.4, 170.0, 169.8, 169.6, 169.4, 160.2 (7 × C=O, NH), 99.3 (JC,H 173 
Hz, 4.6 Hz, , C-1b), 95.6 (JC,H 180 Hz, , C-1a), 75.1 (C-2a), 71.4, 69.9, 69.7, 69.6, 
68.5, 66.2, 65.4, 62.4, 61.8, 60.5, 21.1, 20.9, 20.8, 20.7 (7 × C(O)CH3); IR (max/cm
-1): 
3056 (NH), 1745 (C=O), 1676 (C=N); HRMS: Found [M+Na]+ 802.0906, 






mannopyranosyl trichloroacetimidate 103 (82 mg, 0.11 mmol) was co-evaporated with 
toluene several times before adding molecular sieves 4 Å (50 mg), anhydrous DCM (1 
mL) and 2-[2-(2-chloroethoxy)ethoxy]ethanol (279 L, 1.5 mmol). The resulting mixture 
was stirred at r.t. under N2(g) atmosphere for 1.5 h, and cooled to -50 °C. Freshly 
distilled BF3OEt2 (14 L, 0.11 mmol) was added to the reaction mixture, which was 
stirred at low temperature and slowly warmed up to 2 °C, over 2.5 h. The reaction 
mixture was washed with sat. aq. NaHCO3 (2 × 2 mL), followed by brine (2 mL). The 
combined organic phase was dried over MgSO4, and concentrated to leave crude 
yellow oil, which was purified by Biotage® flash column chromatography (Redisef®Rf 24 
g silica column, Hexane:EtOAc (0% EtOAc (1 col. vol.)  0-70% EtOAc (over 12 col. 
vol.)  70% EtOAc (over 12 col. vol.). The partially purified mixture was dissolved in 
anhydrous DMF (3.5 mL). Sodium azide (32 mg, 0.1 mmol) and TBAI (37 mg, 0.1 mmol) 
were added to the reaction mixture, which was stirred at 87 °C for 17 h. The reaction 
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mixture was cooled to r.t., concentrated, and purified by Biotage® flash column 
chromatography (Redisef®Rf 24 g silica column, Hexane:EtOAc (0% EtOAc (1 col. vol.) 
 0-70% EtOAc (over 12 col. vol.)  70% EtOAc (over 12 col. vol.) to give compound 
104 as a colourless oil (43 mg, 49%, 2 steps); Rf 0.30 (3:7 HexaneEtOAc);   25 D   27.2 
(c, 1.0, CHCl3); H (500 MHz, CDCl3); 5.40 (dd, 1H, J3b,4b  9.9 Hz, J2b,3b 3.6 Hz, H-3b), 
5.36-5.23 (m, 4H, H-2b, H-3a, H-4a, H-4b), 4.97 (d, 1H, J1a,2a 2.0 Hz, H-1a), 4.91 (d, 1H, 
J1b,2b 1.9 Hz, H-1b), 4.21 (dd, 2H, J6,6 12.1 Hz, J5,6=5,6 4.9 Hz, H-6, H-6), 4.12 (m, 3H, 
H-5b, H-6, H-6), 4.04 (bs, 1H, H-2a), 4.01-3.95 (m, 1H, H-5a), 3.81 (m, 1H, CH2O), 
3.70-3.60 (m, 9H, CH2O), 3.37 (t, 2H, J 5.1 Hz, CH2-N), 2.14 (s, 3H, C(O)CH3), 2.13 (s, 
3H, C(O)CH3), 2.07 (s, 3H, C(O)CH3), 2.06 (s, 3H, C(O)CH3), 2.02 (s, 3H, C(O)CH3), 
2.01 (s, 3H, C(O)CH3), 1.99 (s, 3H, C(O)CH3); C (75 MHz, CDCl3); 171.0, 170.6, 170.5, 
170.0, 169.8, 169.6, 169.5 (7 × C=O), 99.3 (JC,H 173.3 Hz, 5.1 Hz, , C-1b), 98.5 (JC,H 
172 Hz, , C-1a), 77.2 (C-2a), 70.9, 70.8 (2 × CH2O), 70.4 (C-3a), 70.2 (2 × CH2O), 
69.9 (C-2b), 69.3 (C-5b), 68.6 (C-3b), 69.5 (C-5a), 67.6 (ManOCH2), 66.5, 66.3 (C-4a, 
C-4b), 62.6, 62.2 (C-6a, C-6b), 50.8 (CH2-N), 21.0, 20.8, 20.8 (7 × OCH3); IR (max/cm
-
1): 2107 (N3), 1744 (C=O); HRMS: Found [M+Na]
















8.2.2 Synthesis of carbohydrate-functionalised quantum dots   
8.2.2.1 LA-PEGn-Man (n = ~ 13 or 3)††† 
 
LA-PEG13-cyclooctyne (0.175 M, 114 L, 20 mol in EtOH) or LA-EG3-cyclooctyne 
(0.144 M, 138 L, 19.8 mol, in EtOH) was mixed with 1-azido-3,6-dioxaoct-8-yl -D-
mannopyranoside 29 (0.200 M in MeOH, 120 L, 24 mol) and allowed to react at r.t. 
for 48 h for efficient conjugation. The reaction mixture was concentrated and purified by 
Sephadex LH-20 column chromatography using MeOH as eluting solvent. The desired 
product fractions were collected, combined and analysed by HRMS. For LA-EG3-Man, 
LC-MS analysis revealed a single UV absorption band with a retention time of ~1.6 min. 
The MS spectrum displayed two peaks with m/z values of 882.7 and 904.7, 
corresponding to the [M+H]+ and [M+Na]+ peaks, respectively. HRMS analysis found 
[M+Na]+ 904.4046, C38H67N5NaO14S2 requires 904.4018. 
 
                                               
††† Both LA-EG3-cyclooctyne and LA-PEG13-cyclooctyne were used as a mixture of 
stereosiomers. Both LA-EG3-Man and LA-PEG13-Man were formed as a mixture of 




For LA-PEG13-Man, LC-MS analysis provided a single absorption band with a retention 
time of ~1.65 min. The corresponding MS spectrum displayed a series of peaks that 
were separated by 44 m/z units, corresponding to different PEG chain lengths in the 
mixed length PEG13 linker: found: m/z peaks at 1190.9, 1235.0, 1235.0, 1323.0, 1367.0, 
1411.1, 1455.1. The calculated corresponding [M+H]+ peaks for LA-PEGn-Man where n 
= 10, 11, 12, 13, 14, 15 and 16 were 1191, 1235, 1279, 1323, 1367, 1411 and 1455, 
respectively. HRMS analysis showed a series of species with m/z ratios separated by 
multiple numbers of 44 (the molecular weight of the EG unit): 537.7932, 595.8059, 
617.8188, 639.8318, 661.8450, 683.8584, 705.8713, and 727.8832. The corresponding 
expected [M+2H]2+ peaks with PEG repeat number of 9, 10, 11, 12, 13, 14, 15 and 16 
were 573.7922, 595.8059, 617.8184, 639.8315, 661.8446, 683.8576, 705.8709 and 
727.8840, respectively.  
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8.2.2.2 DHLA-PEGn-Man (n = ~13 or 3)‡‡‡ 
 
Tris(2-carboxyethyl)phosphine hydrochloride (TCEPHCl, 1.2 eq) was dissolved in H2O 
and added to a solution of LA-PEG13-Man or LA-EG3-Man in EtOH. The resulting 
mixture was allowed to stand at r.t. for 30 min to reduce disulphide bonds. After 
evaporation of solvent, DHLA-PEG13-Man or DHLA-EG3-Man was purified by flash 
                                               
‡‡‡  Both DHLA-EG3-Man and DHLA-PEG13-Man were formed as a mixture of 
regioisomers, only the predominant stereoisomer is shown. 
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column chromatography (silica; 5:1 ChloroformMeOH). The fractions containing 
reduced ligands were combined and evaporated. The purified DHLA-PEG13-Man or 
DHLA-EG3-Man was further analysed by LC-MS. For DHLA-EG3-Man, a single UV 
band with a retention time of ~1.6 min from the HPLC elution profile gave two MS 
peaks with m/z ratios of 884.6 and 906.7, corresponding to the required [M+H]+ and 
[M+Na]+ peaks. 
 
For DHLA-PEG13-Man, a single UV absorption band from the HPLC eluting profile was 
found. The corresponding MS spectrum revealed a series of m/z ratios separated by 44 
mass units, corresponding to the different PEG lengths of the average of 13.  
 
 
The reduced DHLA-EG3-Man and DHLA-PEG13-Man ligands were concentrated and 
dissolved in chloroform. The concentrations of mannose were determined by phenol-
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DHLA-EG2_Man-N3_f10_114091_1-D,9_01_13810.D: UV Chromatogram, 190-650 nm
DHLA-EG3-Man LC-MS UV chromatogram 190-650nm 









DHLA-PEG12_Man-N3_f24_114150_1-A,8_01_13873.D: UV Chromatogram, 190-650 nm



































































































































































































8.2.2.3 Determination of mannose loading on the QDs157 
Mannose amount was determined by phenol-sulfuric acid method. D-Mannose stock 
(100 mg/mL in H2O) was diluted 100 times to give 1 mg/mL stock in H2O. Different 
amounts of stock solution were then mixed with 5% phenol in H2O and H2SO4 to 
generate a calibration curve as follows: to a solution of D-mannose in H2O (125 L) in a 
5 mL-glass vial was added 125 L of 5% phenol in H2O followed by 625 L of 
concentrated H2SO4. The mixture was vertexed and allowed to stand at r.t. for 30 min. 
The absorbance of the solution at 490 nm was measured against a blank pure water 
control solution to generate a calibration curve.157 Unconjugated DHLA-PEGn-Man 
ligands collected from hexane precipitation supernatant (after removal of organic 
solvent and dissolving in H2O) and spin column filtrate were combined to make a total 
volume of 1300 L for DHLA-PEG13-Man and 1430 µL for DHLA-EG3-Man. One 
hundred twenty five L of each solution was then mixed with 125 L of phenol and 625 
L of H2SO4 as above to determine the amounts of unconjugated mannose ligand. The 
dilution factors were then corrected to calculate the total amount of unconjugated 
mannose ligand. Assuming the difference between the amounts of ligand added and 
unconjugated were those that have bound to the QD,207,208 the average number of 
mannose molecules conjugated to each QD was then calculated as 170±40 and 
330±70 for QD-PEG13-Man and QD-EG3-Man, respectively. A lower mannose valency 
in the former is likely due to a relatively long PEG chain that may sterically limit very 
high ligand packing on the QD surface, leading to a lower ligand density. 
8.2.2.4 Preparation of DHLA-ZW capped QDs 
TOPO capped hydrophobic QDs (1 nmole, 20 L in hexane) were first precipitated by 
adding 500 L of EtOH followed by centrifugation to remove any free TOPO ligands. 
The QD precipitate was then dissolved in 50 L of chloroform followed by addition of 20 
L of EtOH, resulting in QD solution. In a separate Eppendorf tube, LA-ZW (0.10 M, 2.0 
L in H2O) was reacted with TCEPHCl (0.10 M, 2.0 L in H2O) for 10 min to reduce 
the LA-ZW into DHLA-ZW. NaOH (0.10 M in EtOH, 12 L) was added to fully 
deprotonate the DHLA thiol-groups and to neutralise acid groups in TCEP. The 
resulting mixture was mixed with the previously-prepared QD solution, forming a 
homogenous solution. After a brief shaking by hand, the QDs were found to rise to the 
top aqueous layer within 1 min. The phase separation became clearer after addition of 
50 L of H2O, followed by a brief centrifugation. The QD was found to be completely 
transferred to the top aqueous phase, leaving the bottom organic layer colourless, 
indicating a full QD water-solubilisation. The top aqueous layer was then carefully 
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separated from the bottom chloroform layer and transferred to an Amicon ultra-
centrifugal tube equipped with a 30,000 MW cut-off (MWCO) filter membrane and 
centrifuged for 1 min at 3000 rpm. The residue was further washed with H2O (200 L) 
and followed by centrifugation. The process was repeated three times to remove any 
unbound ligands. This yielded a stable, water soluble QD stock solution. The stock QD 
concentration was determined from its UV-vis absorption at the first excitation peak and 
using the respective extinction coefficient as previously established.207,209 
8.2.2.5 Preparation of QD-PEG13-Man and QD-EG3-Man  
CdSe/ZnS core/shell QDs (EM = 560 nm, 1 nmol) in 0.2 mL of toluene were 
precipitated with EtOH (1 mL) and separated by centrifugation at 10 × kg for 3 
min.193,194 The resultant QDs were re-dissolved in chloroform (50 L). After being 
deprotonated by adding NaOH in EtOH (0.10 M, 600 nmol in total), previously prepared 
DHLA-PEG3-Man or DHLA-EG3-Man (500 nmol, in chloroform) was added to the QD 
solution together with some extra MeOH to make a homogenous solution 
(ChloroformMeOH 1:1, v/v). The reaction mixture was stirred at r.t. in the dark for 30 
min. Hexane was then added to the reaction mixture until the solution became cloudy. 
The resulting mixture was then centrifuged at 10 × kg for 5 min to obtain QD-PEG13-
Man/QD-EG3-Man pellet. After removal of clear supernatant (checked by UV to ensure 
no QD fluorescence), the pellet was dissolved in 100 L of H2O. The QD-conjugate-
solution was then transferred to a 30 KD MWCO spin column and washed with H2O (3 
× 100 L) to remove any unbound ligands. The QD stock concentration was 









Chapter 9: Appendix 
Appendix A: 1H - 1H COSY spectrum of trisaccharide 82  (600 MHz, CDCl3, 331 K) 
with the complete assignments of sugar proton resonances. N.B. Couplings from H-5 to 










Appendix B: 1H - 1H TOCSY spectrum of trisaccharide 82  (600 MHz, CDCl3, 331 K) 
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